Document:

EX-10.3

 Exhibit 10.3 
 EXECUTION VERSION 
  
  

 
 FIRST AMENDMENT TO THE CREDIT
AGREEMENT 
 $526,305,937.50 TRANCHE B TERM FACILITY 
 REVOLVING FACILITY 
 among 

TRUVEN HOLDING CORP. (formerly known as VCPH Holding Corp.), 
 as Holdings, 
 TRUVEN HEALTH ANALYTICS INC. (formerly known as Thomson Reuters
(Healthcare) Inc.), 
 as Borrower, 
 THE LENDERS PARTY HERETO, 
 JPMORGAN CHASE BANK, N.A., 

as Administrative Agent, 
 and 
 J.P. MORGAN SECURITIES LLC, MERRILL LYNCH, PIERCE, FENNER & SMITH

 INCORPORATED, MORGAN STANLEY SENIOR FUNDING, INC. AND UBS SECURITIES LLC, 

as Joint Arrangers and Bookrunners 
  

 
  

 FIRST AMENDMENT 
 FIRST AMENDMENT, dated as of October 3, 2012 (this “Amendment”), to the Credit Agreement, dated as of June 6, 2012 (the “Credit Agreement”), among Truven
Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation (“Holdings”), Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware corporation (the “Borrower”),
JPMorgan Chase Bank, N.A., as the administrative agent (the “Administrative Agent”), the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other
agents parties thereto. J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated, Morgan Stanley Senior Funding, Inc. and UBS Securities LLC are acting as the joint lead arrangers and joint bookrunners in connection
with this Amendment and the Amended Tranche B Term Facility referred to below. 
 W I T N E
S S E T H 
 WHEREAS, pursuant to the Credit Agreement, the Lenders have agreed to make, and
have made, certain loans and other extensions of credit to the Borrower. 
 WHEREAS, the Borrower has requested that the Credit
Agreement be amended to, among other things, amend the Tranche B Term Facility (as so amended, the “Amended Tranche B Term Facility”) by obtaining New Tranche B Term Commitments (as defined in Section 4 of this Amendment) and
having existing Tranche B Term Loans be continued as provided herein. 
 WHEREAS, the loans under the Amended Tranche B Term
Facility (the “New Tranche B Term Loans”) will replace and refinance the currently outstanding Tranche B Term Loans and, except as otherwise provided herein, the New Tranche B Term Loans will have the same terms as the Tranche B
Term Loans currently outstanding under the Credit Agreement. 
 WHEREAS, each existing Tranche B Term Lender that executes and
delivers a signature page to this Amendment (a “Lender Addendum”) and in connection therewith agrees to continue all of its outstanding Tranche B Term Loans (or such lesser amount thereof notified to such Lender by the
Administrative Agent prior the Amendment Effective Date (as defined below)) as New Tranche B Term Loans (such continued Tranche B Term Loans, the “Continued Tranche B Term Loans”, and such Lenders, collectively, the
“Continuing Tranche B Term Lenders”) will thereby (i) agree to the terms of this Amendment and (ii) agree to continue all of its existing Tranche B Term Loans (such existing Tranche B Term Loans, the “Existing
Tranche B Term Loans”, and the Lenders of such Existing Tranche B Term Loans, collectively, the “Existing Tranche B Term Lenders”) (or such lesser amount of such Existing Tranche B Term Loans notified to such Lender by the
Administrative Agent prior the Amendment Effective Date) outstanding on the Amendment Effective Date as New Tranche B Term Loans in a principal amount equal to the aggregate principal amount of such Existing Tranche B Term Loans so continued.
Existing Tranche B Term Lenders which do not become Continuing Tranche B Term Lenders as contemplated by this recital shall not otherwise be permitted to become Additional Tranche B Term Lenders (as defined below). 

WHEREAS, subject to the preceding recital, each Person (other than a Continuing Tranche B Term Lender in its capacity as such) that
executes and delivers a Lender Addendum and agrees in connection therewith to make New Tranche B Term Loans (collectively, the “Additional Tranche B Term Lenders”) will thereby (i) agree to the terms of this Amendment and
(ii) commit to make New Tranche B Term Loans to the Borrower on the Amendment Effective Date (the “Additional Tranche B Term Loans”) in such amount (not in excess of any such commitment) as is determined by the Administrative
Agent and notified to such Additional Tranche B Term Lender. The proceeds of the 

 
Additional Tranche B Term Loans will be used by the Borrower to repay in full the outstanding principal amount of the Existing Tranche B Term Loans that are not continued as New Tranche B Term
Loans by Continuing Tranche B Term Lenders. At the option of the Administrative Agent with the consent of the Borrower, the Additional Tranche B Term Loans may be made, to the extent of the amount thereof to be used to repay in full the Existing
Tranche B Term Loans that are not so continued, by the replacement of such Existing Tranche B Term Lenders pursuant to Section 2.22 of the Credit Agreement and the continuation of such Existing Tranche B Term Loans as Continued Tranche B Term
Loans by the replacement Lender. 
 WHEREAS, each Revolving Lender that executes and delivers a Lender Addendum solely in its
capacity as a Revolving Lender will thereby agree to the terms of this Amendment but will not thereby agree to have made any commitment to make New Tranche B Term Loans, and each Existing Tranche B Term Lender that executes and delivers a Lender
Addendum solely in its capacity as an Existing Tranche B Term Lender and not as a New Tranche B Term Lender or a Continuing Tranche B Term Lender will thereby agree to the terms of this Amendment but will not thereby agree to continue its Existing
Tranche B Term Loans as New Tranche B Term Loans or to have made any commitment to make New Tranche B Term Loans. 
 WHEREAS,
the Continuing Tranche B Term Lenders and the Additional Tranche B Term Lenders (collectively, the “New Tranche B Term Lenders”) are severally willing to continue their Existing Tranche B Term Loans as New Tranche B Term Loans
and/or to make New Tranche B Term Loans, as the case may be, subject to the terms and conditions set forth in this Amendment. 

WHEREAS, Section 10.1(h) of the Credit Agreement permits the Borrower to amend the Credit Agreement with the written consent of the
Administrative Agent and the New Tranche B Term Lenders and to prepay the Tranche B Term Loans with the proceeds of the New Tranche B Term Loans, which are Replacement Term Loans (as defined in such Section). 

WHEREAS, the Borrower has requested other amendments to the Credit Agreement. 

WHEREAS, Lenders and the Administrative Agent are willing to agree to this Amendment on the terms set forth herein. 

NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, the parties hereto agree as follows: 

SECTION 1. Defined Terms. Capitalized terms used but not defined herein shall have the meanings assigned to such terms in the
Credit Agreement. 
 SECTION 2. Amendments to Section 1. 

(a) Section 1.1 of the Credit Agreement is hereby amended as of the Amendment Effective Date by inserting, in its proper alphabetical
order, the following new definitions: 
 “First Amendment”: the First Amendment, dated the First Amendment
Effective Date, to this Agreement. 
 “First Amendment Effective Date”: October 3, 2012. 

  
 - 2 -

 (b) Section 1.1 of the Credit Agreement is hereby amended as of the Amendment Effective
Date by amending the definitions of “Applicable Margin” and “Applicable Pricing Grid” to read as set forth on Annex I. 
 (c) Section 1.1 of the Credit Agreement is hereby amended as of the Amendment Effective Date by amending the definition of “Loan Documents” by inserting “the First Amendment,”
immediately before the words “the Security Documents”. 
 (d) Section 1.1 of the Credit Agreement is hereby
amended as of the Amendment Effective Date by amending the definition of “Tranche B Term Loan” to read as follows: 

“Tranche B Term Loan”: as defined in Section 2.1, but shall include any Tranche B Term Loan made hereunder pursuant
to the First Amendment on the First Amendment Effective Date.” 
 SECTION 3. Amendments to Section 2.

 (a) Section 2.1 of the Credit Agreement is hereby amended as of the Amendment Effective Date by inserting the following
sentence immediately after the first sentence thereof: 
 On the First Amendment Effective Date, the New Tranche B Term Loans (as
defined in the First Amendment) shall constitute, on the terms provided in the First Amendment, Tranche B Term Loans and the Continuing Tranche B Term Loans (as defined in the First Amendment) shall be ratified and confirmed as Tranche B Term Loans
in all respects. 
 (b) Section 2.10(b) of the Credit Agreement is hereby amended as of the Amendment Effective Date by
deleting the words “Closing Date” and replacing them with “First Amendment Effective Date”. 
 SECTION 4.
New Tranche B Term Loans. (a) Subject to the terms and conditions set forth herein (i) each Continuing Tranche B Term Lender agrees to continue all of its Existing Tranche B Term Loans (or such lesser amount thereof as notified to
such Lender by the Administrative Agent prior to the Amendment Effective Date) as a New Tranche B Term Loan on the date requested by the Borrower to be the Amendment Effective Date (which date shall not be later than October 3, 2012) in a
principal amount equal to such Existing Tranche B Term Loans (or such lesser amount thereof as notified to such Lender by the Administrative Agent prior to the Amendment Effective Date) and (ii) each Additional Tranche B Term Lender agrees to
make a New Tranche B Term Loan on such date to the Borrower in a principal amount equal to such Additional Tranche B Term Lender’s New Tranche B Term Loan Commitment (as defined below). For purposes hereof, a Person may become a party to the
Credit Agreement as amended hereby and a New Tranche B Term Lender as of the Amendment Effective Date by executing and delivering to the Administrative Agent, on or prior to the Amendment Effective Date, a Lender Addendum in its capacity as a New
Tranche B Term Lender. The Borrower shall give notice to the Administrative Agent of the proposed Amendment Effective Date not later than one Business Day prior thereto, and the Administrative Agent shall notify each Tranche B Term Lender and each
Additional Tranche B Term Lender thereof. For the avoidance of doubt, the Existing Tranche B Term Loans of a Continuing Tranche B Term Lender must be continued in whole and may not be continued in part unless approved by the Administrative Agent.

  
 - 3 -

 (b) Each Additional Tranche B Term Lender will make its New Tranche B Term Loan on the
Amendment Effective Date by making available to the Administrative Agent, in the manner contemplated by Section 2.2 of the Credit Agreement, an amount equal to its New Tranche B Term Loan Commitment. The “New Tranche B Term Loan
Commitment” (i) of any Continuing Tranche B Term Lender will be the amount of its Existing Tranche B Term Loans to be continued as an equal amount (or such lesser amount as notified to such Lender by the Administrative Agent prior to
the Amendment Effective Date) of New Tranche B Term Loans and (ii) of any Additional Tranche B Term Lender (which Lender also may be a Continuing Tranche B Term Lender with respect to its Continued Tranche B Term Loans) will be such amount (not
exceeding any commitment offered by such Additional Tranche B Term Lender) allocated to it by the Administrative Agent and notified to it on or prior to the Amendment Effective Date. The commitments of the Additional Tranche B Term Lenders and the
continuation undertakings of the Continuing Tranche B Term Lenders are several and no such Lender will be responsible for any other such Lender’s failure to make or acquire by continuation its New Tranche B Term Loan. The New Tranche B Term
Loans may from time to time be Eurodollar Loans or ABR Loans, as determined by the Borrower and notified to the Administrative Agent as contemplated by Sections 2.2 and 2.12 of the Credit Agreement. The initial Interest Period for the Additional
Tranche B Term Loans shall begin on the Amendment Effective Date and end on the last day of the Interest Period then in effect for the Existing Tranche B Term Loans and upon the Amendment Effective Date, the interest rate applicable to the Continued
Tranche B Term Loans and the Additional Tranche B Term Loans for the remainder of the Interest Period then in effect shall be the interest rate, as modified by this Amendment, applicable to the Existing Tranche B Term Loans for such Interest Period.
The Borrower shall not be required to make any payments to Continuing Tranche B Term Lenders under Section 2.20 of the Credit Agreement in respect of the continuation of Existing Tranche B Term Loans on the Amendment Effective Date as New
Tranche B Term Loans. The Lenders that are replaced pursuant to Section 2.22 of the Credit Agreement in connection with the making of New Tranche B Term Loans shall be entitled to the benefits of Section 2.20 of the Credit Agreement with
respect thereto. 
 (c) The obligation of each New Tranche B Term Lender to make or acquire by continuation New Tranche B Term
Loans on the Amendment Effective Date is subject to the satisfaction of the conditions set forth in Section 6 of this Amendment. 
 (d) On and after the Amendment Effective Date, each reference in the Credit Agreement to “Tranche B Term Loans” shall be deemed a reference to the New Tranche B Term Loans contemplated hereby,
except as the context may otherwise require. Notwithstanding the foregoing, the provisions of the Credit Agreement with respect to indemnification, reimbursement of costs and expenses, increased costs and break funding payments shall continue in
full force and effect with respect to, and for the benefit of, each Existing Tranche B Term Lender in respect of such Lender’s Existing Tranche B Term Loans. 
 (e) The continuation of Continued Tranche B Term Loans and the making of Additional Tranche B Term Loans may be implemented pursuant to other procedures specified by the Administrative Agent, acting in
consultation with the Borrower, including by repayment of Continued Tranche B Term Loans of a Continuing Tranche B Term Lender followed by a subsequent assignment to it of New Tranche B Term Loans in the same amount (or such other amount (not
exceeding, in the case of any Additional Tranche B Term Lender, any commitment offered by such Additional Tranche B Term Lender) as notified to such Lender by the Administrative Agent prior to the Amendment Effective Date). 

(f) The Existing Tranche B Term Loans which are not continued as Continued Tranche B Term Loans will be repaid on the Amendment Effective
Date. 
 SECTION 5. Prepayment Fee. The Borrower will pay the 1.0% fee required under Section 2.10(b) of the Credit
Agreement to each Existing Tranche B Term Lender in respect of the repayment of such Lender’s Existing Tranche B Term Loans (or, as contemplated by the fifth recital of 

  
 - 4 -

 
this Amendment, in connection with any replacement of such Existing Tranche B Term Lender pursuant to Section 2.22 of the Credit Agreement). For the avoidance of doubt, the Lenders hereby
acknowledge and agree that, at the sole option of Administrative Agent, any Lender with Existing Tranche B Term Loans which are replaced as contemplated hereby shall, automatically upon receipt of the amount necessary to purchase such replaced
Lender’s Existing Tranche B Term Loans, at par, and pay all accrued interest thereon and the prepayment fee described herein, be deemed to have assigned such Loans pursuant to a form of Assignment and Assumption and, accordingly, no other
action by the Lenders, the Administrative Agent or the Loan Parties shall be required in connection therewith. The Lenders hereby agree to waive the notice requirements of Section 2.10 of the Credit Agreement in connection with the prepayment
or replacement of Existing Tranche B Term Loans contemplated hereby. 
 SECTION 6. Conditions to Effectiveness of
Amendment. This Amendment shall become effective on the date on which the following conditions precedent have been satisfied or waived (the “Amendment Effective Date”): 

(a) Amendment Documentation. The Administrative Agent shall have received (i) a counterpart of this Amendment, executed and
delivered by a duly authorized officer of Holdings and the Borrower and (ii) Lender Addenda, executed and delivered by the New Tranche B Term Lenders and the Revolving Lenders. 

(b) Collateral. The Borrower and the other Loan Parties shall have executed an instrument of acknowledgement and confirmation
reasonably satisfactory to the Administrative Agent with respect to the guarantees, security interests and liens created under the Security Documents. 
 (c) Fees and Expenses. All fees (including the fees set forth in Section 5 hereof) and expenses payable to the Administrative Agent and the Lenders in connection with this Amendment shall have
been received on or prior to the Amendment Effective Date. 
 Notwithstanding any other provisions of this Amendment to the contrary, the
Administrative Agent may appoint a fronting lender to act as the sole Additional Tranche B Term Lender for purposes of facilitating funding on the Amendment Effective Date. Accordingly, any Lender Addendum submitted by or on behalf of an Additional
Tranche B Term Lender other than such fronting lender will be deemed ineffective unless accepted by the Administrative Agent in its sole discretion. 
 SECTION 7. Representations and Warranties. The Borrower hereby represents and warrants that (a) each of the representations and warranties made by any Loan Party in or pursuant to the Loan
Documents shall be, after giving effect to this Amendment, true and correct in all material respects as if made on and as of the Amendment Effective Date, except to the extent such representations and warranties expressly relate to an earlier time,
in which case such representations and warranties were true and correct in all material respects as of such earlier time; provided that each reference to the Credit Agreement therein shall be deemed to be a reference to the Credit Agreement
after giving effect to this Amendment and (b) after giving effect to this Amendment, no Default or Event of Default shall have occurred and be continuing. 
 SECTION 8. Effects on Loan Documents. Except as specifically amended herein, all Loan Documents shall continue to be in full force and effect and are hereby in all respects ratified and confirmed.
Except as otherwise expressly provided herein, the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of any Lender or the Administrative Agent under any of the Loan Documents, nor
constitute a waiver of any provision of the Loan Documents. 

  
 - 5 -

 SECTION 9. GOVERNING LAW; WAIVER OF JURY TRIAL. THIS AMENDMENT AND THE RIGHTS AND
OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE CONSTRUED IN ACCORDANCE WITH AND BE GOVERNED BY THE LAW OF THE STATE OF NEW YORK. EACH PARTY HERETO HEREBY AGREES AS SET FORTH FURTHER IN SECTION 10.12 OF THE CREDIT AGREEMENT AS IF SUCH SECTION WAS SET
FORTH IN FULL HEREIN. 
 SECTION 10. Loan Document. This Amendment shall constitute a “Loan Document” for all
purposes of the Credit Agreement and the other Loan Documents. 
 SECTION 11. Amendments; Execution in Counterparts;
Notice. This Amendment shall not constitute an amendment of any other provision of the Credit Agreement not referred to herein and shall not be construed as a waiver or consent to any further or future action on the part of the Loan Parties that
would require a waiver or consent of the Required Lenders or the Administrative Agent. Except as expressly amended hereby, the provisions of the Credit Agreement are and shall remain in full force and effect. This Amendment may be executed in any
number of counterparts and by the different parties hereto on separate counterparts, including by means of facsimile or electronic transmission, each of which when so executed and delivered shall be an original, but all of which shall together
constitute one and the same instrument. 

  
 - 6 -

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and
delivered by their respective proper and duly authorized officers as of the day and year first above written. 
  

			
	TRUVEN HOLDING CORP.,
	    as Holdings
		
	By:	 	 /s/ Mike Boswood

	Name:	 	Mike Boswood
	Title:	 	President & CEO
	
	 TRUVEN HEALTH ANALYTICS INC.,
     as Borrower

		
	By:	 	 /s/ Mike Boswood

	Name:	 	Mike Boswood
	Title:	 	President & CEO

 [Signature Page to First Amendment] 

 
			
	 JPMORGAN CHASE BANK, N.A., as
 Administrative Agent

		
	By:	 	 /s/ Vanessa Chiu

	Name:	 	Vanessa Chiu
	Title:	 	Executive Director

 [Signature Page to First Amendment] 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Peerless Indemnity Insurance Company

  

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	 /s/ Sheila A. Finnerty

		 	Name:	 	Sheila A. Finnerty
		 	Title:	 	Authorized Signatory
	
	For any institution requiring a second signature line:
		
	    by	 	  

		 	Name:	 	
		 	Title:	 	

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Golden Eagle Insurance Corporation

  

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	 /s/ Sheila A. Finnerty

		 	Name:	 	Sheila A. Finnerty
		 	Title:	 	Authorized Signatory
	
	For any institution requiring a second signature line:
		
	    by	 	  

		 	Name:	 	
		 	Title:	 	

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Liberty Mutual Insurance Company

  

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	 /s/ Sheila A. Finnerty

		 	Name:	 	Sheila A. Finnerty
		 	Title:	 	Authorized Signatory
	
	For any institution requiring a second signature line:
		
	    by	 	  

		 	Name:	 	
		 	Title:	 	

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Liberty Mutual Retirement Plan Master Trust

  

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	 /s/ Sheila A. Finnerty

		 	Name:	 	Sheila A. Finnerty
		 	Title:	 	Authorized Signatory
	
	For any institution requiring a second signature line:
		
	    by	 	  

		 	Name:	 	
		 	Title:	 	

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

					
	Executing as a Continuing Tranche B Term Lender:
	
	Safety Insurance Company
	
	 By: Wellington Management Company, LLP as its
 Investment Adviser

		
	By:	 	 /s/ Steven M. Hoffman

	Name: Steven M. Hoffman
	Title:   Vice President and Counsel

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

					
	Executing as a Continuing Tranche B Term Lender:
	
	Stellar Performer Global Series W - Global Credit
	
	 By: Wellington Management Company, LLP as its
 Investment Adviser

		
	By:	 	 /s/ Steven M. Hoffman

	Name: Steven M. Hoffman
	Title:   Vice President and Counsel

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

					
	Executing as a Continuing Tranche B Term Lender:
	
	 SunAmerica Senior Floating Rate Fund, Inc.

	
	 By: Wellington Management Company, LLP as its
 Investment Adviser

		
	By:	 	 /s/ Steven M. Hoffman

	Name: Steven M. Hoffman
	Title:   Vice President and Counsel

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

					
	Executing as a Continuing Tranche B Term Lender:
	
	The Hartford Floating Rate Fund
	
	 By: Wellington Management Company, LLP as its
 Investment Adviser

		
	By:	 	 /s/ Steven M. Hoffman

	Name: Steven M. Hoffman
	Title:   Vice President and Counsel

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

					
	Executing as a Continuing Tranche B Term Lender:
	
	The Hartford Floating Rate High Income Fund
	
	 By: Wellington Management Company, LLP as its
 Investment Adviser

		
	By:	 	 /s/ Steven M. Hoffman

	Name: Steven M. Hoffman
	Title:	 	Vice President and Counsel

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

					
	Executing as a Continuing Tranche B Term Lender:
	
	The Hartford Inflation Plus Fund
	
	 By: Wellington Management Company, LLP as its
 Investment Adviser

		
	By:	 	 /s/ Steven M. Hoffman

	Name:	 		 	Steven M. Hoffman
	Title:	 		 	Vice President and Counsel

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

					
	Executing as a Continuing Tranche B Term Lender:
	
	The Hartford Strategic Income Fund
	
	 By: Wellington Management Company, LLP as its
 Investment Adviser

		
	By:	 	 /s/ Steven M. Hoffman

	Name:	 		 	Steven M. Hoffman
	Title:	 		 	Vice President and Counsel

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

					
	Executing as a Continuing Tranche B Term Lender:
	
	The Hartford Unconstrained Bond Fund
	
	 By: Wellington Management Company, LLP as its
 Investment Adviser

		
	By:	 	 /s/ Steven M. Hoffman

	Name:	 		 	Steven M. Hoffman
	Title:	 		 	Vice President and Counsel

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

					
	Executing as a Continuing Tranche B Term Lender:
	
	UMC Benefit Board, Inc.
	
	 By: Wellington Management Company, LLP as its
 Investment Adviser

		
	By:	 	 /s/ Steven M. Hoffman

	Name: Steven M. Hoffman
	Title: Vice President and Counsel

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

					
	Executing as a Continuing Tranche B Term Lender:
	
	Wellington Trust Company, National Association Multiple Common Trust Funds Trust-Opportunistic Fixed Income Allocation Portfolio
	
	 By: Wellington Management Company, LLP as its
 Investment Adviser

		
	By:	 	 /s/ Steven M. Hoffman

	Name: Steven M. Hoffman
	Title: Vice President and Counsel

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.),
a Delaware corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents
parties thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 

By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the
Amendment and the Credit Agreement as amended thereby and (B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser
amount as notified to such Lender by the Administrative Agent prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 

 

					
	Executing as a Continuing Tranche B Term Lender:
	
	Wellington Trust Company, NA Multiple Collective
	Investment Funds Trust II Real Total Return Portfolio
	
	 By: Wellington Management Company, LLP as its
 Investment Adviser

		
	By:	 	 /s/ Steven M. Hoffman

	Name: Steven M. Hoffman
	Title: Vice President and Counsel

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

	
	Name of Institution:    Franklin Templeton Series II Funds - Franklin Floating Rate II Fund

  

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	 /s/ Richard Hsu

		 	Name:	 	Richard Hsu
		 	Title:	 	Asst. Vice President
	
	For any institution requiring a second signature line:
		
	    by	 	  

		 	Name:	 	
		 	Title:	 	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

	
	Name of Institution:     Franklin Floating Rate Master Trust - Franklin Floating Rate Master Series

  

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by 	 	 /s/ Richard Hsu

		 	Name:	 	Richard Hsu
		 	Title:	 	Asst. Vice President
	
	For any institution requiring a second signature line:
		
	    by 	 	  

		 	Name:	 	
		 	Title:	 	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	 	    Franklin Investors Securities Trust - Franklin Floating Rate Daily Access Fund

  

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by  	 	/s/ Richard Hsu
		 	Name:	 	Richard Hsu
		 	Title:	 	Asst. Vice President
	
	For any institution requiring a second signature line:
		
	    by  	 	 
		 	Name:	 	
		 	Title:	 	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
		  	Schiller Park CLO Ltd.
		  	Burr Ridge CLO Plus Ltd.
	Name of Institution:	  	Bridgeport CLO II Ltd.
		
		  	By: Deerfield Capital Management LLC, its Collateral Manager

  

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by  	 	/s/ Robert Milton
		 	Name:	 	Robert Milton
		 	Title:	 	General Counsel
	
	For any institution requiring a second signature line:
		
	    by  	 	 
		 	Name:	 	
		 	Title:	 	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	 CIFC Funding 2006-IB, Ltd.

CIFC Funding 2006-II, Ltd.
 CIFC Funding 2007-II,
Ltd.
 CIFC Funding 2007-III, Ltd.

CIFC Funding 2012-I, Ltd.

		
		  	By: CIFC Asset Management LLC, its Collateral Manager

  

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by  	 	/s/ Robert Milton
		 	Name:	 	Robert Milton
		 	Title:	 	General Counsel
	
	For any institution requiring a second signature line:
		
	    by  	 	 
		 	Name:	 	
		 	Title:	 	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	ColumbusNova CLO IV Ltd. 2007-II
		
		  	By: Columbus Nova Credit Investments Management, LLC, its Collateral Manager

  

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by  	 	/s/ Robert Milton
		 	Name:	 	Robert Milton
		 	Title:	 	General Counsel
	
	For any institution requiring a second signature line:
		
	    by  	 	 
		 	Name:	 	
		 	Title:	 	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Primus CLO II, Ltd.
		
		  	By: CypressTree Investment Management, LLC, its Collateral Manager

  

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by  	 	/s/ Robert Milton
		 	Name:	 	Robert Milton
		 	Title:	 	General Counsel
	
	For any institution requiring a second signature line:
		
	    by  	 	 
		 	Name:	 	
		 	Title:	 	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	 	Golub Capital

  

					
	Executing as a Continuing Tranche B Term Lender:
	
	 By: Golub Capital Partners CLO 11, Ltd.
 GC Advisors LLC, its agent

		
		 	/s/ Chris Jamieson
		 	Name:	 	Chris Jamieson
		 	Title:	 	Portfolio Manager
	
	For any institution requiring a second signature line:
		
	    by  	 	 
		 	Name:	 	
		 	Title:	 	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 

			
	Name of Institution:	  	 

  

					
	 Executing as a Continuing Tranche B Term Lender:

	
	Baptist Health South Florida, Inc.
	By: Seix Investment Advisors LLC, as Advisor
	
	Blue Cross of Idaho Health Service, Inc.
	By: Seix Investment Advisors LLC, as Investment Manager
	
	RidgeWorth Funds – Seix Floating Rate High Income Fund
	By: Seix Investment Advisors LLC, as Subadviser
	
	RidgeWorth Funds – Total Return Bond Fund
	By: Seix Investment Advisors LLC, as Subadviser
	
	Rochdale Fixed Income Opportunities Portfolio
	By: Seix Investment Advisors LLC, as Subadviser
	
	as Lenders
		
	By:	 	/s/ George Goudelias
		 	Name:	 	George Goudelias
		 	Title:	 	Managing Director

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:    	 	 GCPH LOAN FUNDING 1, LLC
  

By: Citibank, N.A.

  

					
	Executing as a Continuing Tranche B Term Lender:
			
		 	by 	 	 /s/ Paul Plank

		 		 	Name: Paul Plank
		 		 	Title:   Director
	
	For any institution requiring a second signature line:
			
		 	by	 	  

		 		 	Name:
		 		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:    	 	 ASF1 Loan Funding LLC
  

By: Citibank, N.A.

  

					
	Executing as a Continuing Tranche B Term Lender:
			
		 	by 	 	 /s/ Lynette Thompson

		 		 	Name: Lynette Thompson
		 		 	Title:   Director
	
	For any institution requiring a second signature line:
			
		 	by	 	  

		 		 	Name:
		 		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:    	 	Delaware Group Advisor Funds- Delaware Diversified Income Fund

  

					
	Executing as a Continuing Tranche B Term Lender:
			
		 	by 	 	 /s/ Adam Brown

		 		 	Name: Adam Brown
		 		 	Title:   Vice President
	
	For any institution requiring a second signature line:
			
		 	by	 	  

		 		 	Name:
		 		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:    	 	Delaware VIP Trust - Delaware VIP Diversified Income Series

  

					
	Executing as a Continuing Tranche B Term Lender:
			
		 	by 	 	 /s/ Adam Brown

		 		 	Name: Adam Brown
		 		 	Title:   Vice President
	
	For any institution requiring a second signature line:
			
		 	by	 	  

		 		 	Name:
		 		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:    	 	Optimum Trust - Optimum Fixed Income Fund

  

					
	Executing as a Continuing Tranche B Term Lender:
			
		 	by 	 	 /s/ Adam Brown

		 		 	Name: Adam Brown
		 		 	Title: Vice President
	
	For any institution requiring a second signature line:
			
		 	by	 	  

		 		 	Name:
		 		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: Stichting Pensioenfonds voor Huisartsen 
  

					
	Executing as a Continuing Tranche B Term Lender:
			
		 	by 	 	 /s/ Adam Brown

		 		 	Name: Adam Brown
		 		 	Title:   Vice President
	
	For any institution requiring a second signature line:
			
		 	by	 	  

		 		 	Name:
		 		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: Delaware Diversified Income Trust 
  

			
	Executing as a Continuing Tranche B Term Lender:
		
	     by 
	 	/s/ Adam Brown
		 	Name: Adam Brown
		 	Title:   Vice President
	
	 For any institution requiring a second signature line:

		
	     by 
	 	 
		 	Name:
		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Delaware Group Income Funds-Delaware Diversified Floating Rate Fund

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	     by 
	 	/s/ Adam Brown
		 	Name: Adam Brown
		 	Title:   Vice President
	
	 For any institution requiring a second signature line:

		
	     by 
	 	 
		 	Name:
		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Eaton Vance CDO VII PLC
	 	  	By: Eaton Vance Management as Interim Investment Advisor

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	     by 
	 	/s/ Michael Botthof
		 	Name: Michael Botthof
		 	Title:   Vice President
	
	 For any institution requiring a second signature line:

		
	     by 
	 	 
		 	Name:
		 	Title:

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Eaton Vance Floating-Rate Income Trust
		
	 	  	By: Eaton Vance Management as Investment Advisor

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	     by 
	 	/s/ Michael Botthof
		 	Name: Michael Botthof
		 	Title:   Vice President
	
	 For any institution requiring a second signature line:

		
	     by 
	 	 
		 	Name:
		 	Title:

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Eaton Vance Institutional Senior Loan Fund
		
	 	  	By: Eaton Vance Management as Investment Advisor

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	     by 
	 	/s/ Michael Botthof
		 	Name: Michael Botthof
		 	Title:   Vice President
	
	 For any institution requiring a second signature line:

		
	     by 
	 	 
		 	Name:
		 	Title:

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Eaton Vance International (Cayman Islands) Floating-Rate Income Portfolio
		
	 	  	By: Eaton Vance Management as Investment Advisor

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	     by 
	 	/s/ Michael Botthof
		 	Name: Michael Botthof
		 	Title:   Vice President
	
	 For any institution requiring a second signature line:

		
	     by 
	 	 
		 	Name:
		 	Title:

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	 	Eaton Vance Limited Duration Income Fund
		
		 	By: Eaton Vance Management as Investment Advisor

  

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	 /s/ Michael Botthof

		 	Name:	 	Michael Botthof
		 	Title:	 	Vice President
	
	For any institution requiring a second signature line:
		
	    by	 	  

		 	Name:	 	
		 	Title:	 	

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	 	Eaton Vance Senior Floating-Rate Trust
		
		 	By: Eaton Vance Management as Investment Advisor

  

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	 /s/ Michael Botthof

		 	Name:	 	Michael Botthof
		 	Title:	 	Vice President
	
	For any institution requiring a second signature line:
		
	    by	 	  

		 	Name:	 	
		 	Title:	 	

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	 	Eaton Vance Senior Income Trust
		
		 	By: Eaton Vance Management as Investment Advisor

  

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	 /s/ Michael Botthof

		 	Name:	 	Michael Botthof
		 	Title:	 	Vice President
	
	For any institution requiring a second signature line:
		
	    by	 	  

		 	Name:	 	
		 	Title:	 	

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	 	Eaton Vance Short Duration Diversified Income Fund
		
		 	By: Eaton Vance Management as Investment Advisor

  

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	 /s/ Michael Botthof

		 	Name:	 	Michael Botthof
		 	Title:	 	Vice President
	
	For any institution requiring a second signature line:
		
	    by	 	  

		 	Name:	 	
		 	Title:	 	

  ̈ Check here if Lender
elects a cashless roll of its Continued Tranche B Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	 	Eaton Vance VT Floating-Rate Income Fund
		
		 	By: Eaton Vance Management as Investment Advisor

  

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	 /s/ Michael Botthof

		 	Name:	 	Michael Botthof
		 	Title:	 	Vice President
	
	For any institution requiring a second signature line:
		
	    by	 	  

		 	Name:	 	
		 	Title:	 	

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	 	Grayson & Co
		
		 	By: Boston Management and Research as Investment Advisor

  

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	 /s/ Michael Botthof

		 	Name:	 	Michael Botthof
		 	Title:	 	Vice President
	
	For any institution requiring a second signature line:
		
	    by	 	  

		 	Name:	 	
		 	Title:	 	

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	 	MET Investors Series Trust –Met/Eaton Vance Floating Rate Portfolio
		
		 	By: Eaton Vance Management as Investment Sub-Advisor

  

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	 /s/ Michael Botthof

		 	Name:	 	Michael Botthof
		 	Title:	 	Vice President
	
	For any institution requiring a second signature line:
		
	    by	 	  

		 	Name:	 	
		 	Title:	 	

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	 	Pacific Select Fund Floating Rate Loan Portfolio
		
		 	By: Eaton Vance Management as Investment Sub-Advisor

  

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	 /s/ Michael Botthof

		 	Name:	 	Michael Botthof
		 	Title:	 	Vice President
	
	For any institution requiring a second signature line:
		
	    by	 	  

		 	Name:	 	
		 	Title:	 	

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	 	Senior Debt Portfolio
		
		 	By: Boston Management and Research as Investment Advisor

  

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	 /s/ Michael Botthof

		 	Name:	 	Michael Botthof
		 	Title:	 	Vice President
	
	For any institution requiring a second signature line:
		
	    by	 	  

		 	Name:	 	
		 	Title:	 	

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	AXA Premier VIP Trust - Multimanager Multi-Sector Bond Portfolio

  

							
	Executing as a Continuing Tranche B Term Lender:	  	
		 	 by
	  	 /s/ Henry Chyung
	  	 Post Advisory Group, LLC, not in its individual capacity but solely as authorized agent for and on behalf of:

AXA Premier VIP Trust - Multimanager Multi-Sector Bond Portfolio

		 		  	Name: Henry Chyung	  	
		 		  	Title: Authorized Signor	  	
		
	For any institution requiring a second signature line:	  	
				
		 	 by
	  	 N/A
	  	
		 		  	Name:	  	
		 		  	Title:	  	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Stichting Blue Sky Active High Yield Fixed Income USA Fund

  

							
	Executing as a Continuing Tranche B Term Lender:	  	
		 	by	  	 /s/ Henry Chyung
	  	 Post Advisory Group, LLC, not in its individual capacity
 but solely as authorized agent for and on behalf of:
 Stichting Blue Sky Active High Yield Fixed
Income USA Fund

		 		  	Name: Henry Chyung	  	
		 		  	Title: Authorized Signor	  	
		
	For any institution requiring a second signature line:	  	
				
		 	by	  	 N/A
	  	
		 		  	Name:	  	
		 		  	Title:	  	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Fairfax County Employees Retirement System

  

							
	Executing as a Continuing Tranche B Term Lender:	  	
		 	by	  	 /s/ Henry Chyung
	  	 Post Advisory Group, LLC, not in its individual capacity but solely as authorized agent for and on behalf of:

Fairfax County Employees Retirement System

		 		  	Name: Henry Chyung	  	
		 		  	Title: Authorized Signor	  	
		
	For any institution requiring a second signature line:	  	
				
		 	by	  	 N/A
	  	
		 		  	Name:	  	
		 		  	Title:	  	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Post High Yield Plus Master Fund, L.P.

  

							
	Executing as a Continuing Tranche B Term Lender:	  	
		 	by	  	 /s/ Henry Chyung
	  	 Post Advisory Group, LLC, not in its individual capacity but solely as authorized agent for and on behalf of:

Post High Yield Plus Master Fund, L.P.

		 		  	Name: Henry Chyung	  	
		 		  	Title: Authorized Signor	  	
		
	For any institution requiring a second signature line:	  	
				
		 	by	  	 N/A
	  	
		 		  	Name:	  	
		 		  	Title:	  	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Post Intermediate Term High Yield, L.P.

  

							
	Executing as a Continuing Tranche B Term Lender:
		 	by	  	 /s/ Henry Chyung
	  	 Post Advisory Group, LLC, not in its individual capacity but solely as authorized agent for and on behalf of:

Post Intermediate Term High Yield, L.P.

		 		  	Name: Henry Chyung	  	
		 		  	Title: Authorized Signor	  	
	
	For any institution requiring a second signature line:
				
		 	by	  	 N/A
	  	
		 		  	Name:	  	
		 		  	Title:	  	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	W.M. Keck Foundation

  

							
	Executing as a Continuing Tranche B Term Lender:	  	
		 	by	  	 /s/ Henry Chyung
	  	 Post Advisory Group, LLC, not in its individual capacity but solely as authorized agent for and on behalf of:

W.M. Keck Foundation

		 		  	Name: Henry Chyung	  	
		 		  	Title: Authorized Signor	  	
		
	For any institution requiring a second signature line:	  	
				
		 	by	  	 N/A
	  	
		 		  	Name:	  	
		 		  	Title:	  	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Los Angeles County Employees Retirement Association

  

							
	Executing as a Continuing Tranche B Term Lender:	  	
		 	by	  	 /s/ Henry Chyung
	  	 Post Advisory Group, LLC, not in its individual capacity but solely as authorized agent for and on behalf of:

Los Angeles County Employees Retirement Association

		 		  	Name: Henry Chyung	  	
		 		  	Title: Authorized Signor	  	
		
	For any institution requiring a second signature line:	  	
				
		 	by	  	 N/A
	  	
		 		  	Name:	  	
		 		  	Title:	  	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	National Railroad Retirement System

  

							
	Executing as a Continuing Tranche B Term Lender:	  	
		 	by	  	 /s/ Henry Chyung
	  	 Post Advisory Group, LLC, not in its individual capacity but solely as authorized agent for and on behalf of:

National Railroad Retirement System

		 		  	Name: Henry Chyung	  	
		 		  	Title: Authorized Signor	  	
		
	For any institution requiring a second signature line:	  	
				
		 	by	  	 N/A
	  	
		 		  	Name:	  	
		 		  	Title:	  	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Public Employees Retirement System of Ohio

  

							
	Executing as a Continuing Tranche B Term Lender:	  	
		 	by	  	 /s/ Henry Chyung
	  	 Post Advisory Group, LLC, not in its individual capacity but solely as authorized agent for and on behalf of:

Public Employees Retirement System of Ohio

		 		  	Name: Henry Chyung	  	
		 		  	Title: Authorized Signor	  	
		
	For any institution requiring a second signature line:	  	
				
		 	by	  	 N/A
	  	
		 		  	Name:	  	
		 		  	Title:	  	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	South Carolina Retirement System

  

							
	Executing as a Continuing Tranche B Term Lender:	  	
		 	by	  	 /s/ Henry Chyung
	  	 Post Advisory Group, LLC, not in its individual capacity but solely as authorized agent for and on behalf of:

South Carolina Retirement System

		 		  	Name: Henry Chyung	  	
		 		  	Title: Authorized Signor	  	
		
	For any institution requiring a second signature line:	  	
				
		 	by	  	 N/A
	  	
		 		  	Name:	  	
		 		  	Title:	  	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	California State Teachers’ Retirement System

  

					
	Executing as a Continuing Tranche B Term Lender:	 	
			
	    by	 	/s/ Henry Chyung	 	 Post Advisory Group, LLC, not in its individual capacity but solely as authorized agent for and
on behalf of:
 California State Teachers’ Retirement System

		 	Name: Henry Chyung	 	
		 	Title: Authorized Signor	 	
		
	 For any institution requiring a second signature line:
	 	
			
	    by	 	N/A	 	
		 	 Name:
	 	
		 	 Title:
	 	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	The Timken Company Collective Investment Trust for Retirement Trusts

  

					
	Executing as a Continuing Tranche B Terra Lender:	 	
			
	    by	 	/s/ Henry Chyung	 	 Post Advisory Group, LLC, not in its individual capacity but solely as authorized agent for and
on behalf of:
 The Timken Company Collective Investment Trust for Retirement Trusts

		 	Name: Henry Chyung	 	
		 	Title: Authorized Signor	 	
		
	 For any institution requiring a second signature line:
	 	
			
	    by	 	N/A	 	
		 	 Name:
	 	
		 	 Title:
	 	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Post Traditional High Yield Fund, L.P.

  

					
	Executing as a Continuing Tranche B Term Lender:	 	
			
	    by	 	/s/ Henry Chyung	 	 Post Advisory Group, LLC, not in its individual capacity but solely as authorized agent for and on behalf
of:
 Post Traditional High Yield Fund, L.P.

		 	Name: Henry Chyung	 	
		 	Title: Authorized Signor	 	
		
	 For any institution requiring a second signature line:
	 	
			
	    by	 	N/A	 	
		 	 Name:
	 	
		 	 Title:
	 	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Texas County & District Retirement System

  

					
	Executing as a Continuing Tranche B Term Lender:	 	
			
	    by	 	/s/ Henry Chyung	 	 Post Advisory Group, LLC, not in its individual capacity but solely as authorized agent for and an behalf of:

Texas County & District Retirement System

		 	Name: Henry Chyung	 	
		 	Title: Authorized Signor	 	
		
	 For any institution requiring a second signature line:
	 	
			
	    by	 	N/A	 	
		 	 Name:
	 	
		 	 Title:
	 	

 x
Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Virginia Retirement System

  

					
	Executing as a Continuing Tranche B Term Lender:	 	
			
	    by	 	/s/ Henry Chyung	 	 Post Advisory Group, LLC, not in its individual capacity but solely as authorized agent for and on behalf of:

Virginia Retirement System

		 	Name: Henry Chyung	 	
		 	Title: Authorized Signor	 	
		
	 For any institution requiring a second signature line:
	 	
			
	    by	 	N/A	 	
		 	 Name:
	 	
		 	 Title:
	 	

 x Check
here if Lender elects a cashless roll of its Continued Tranche B Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	 	 ATLAS SENIOR LOAN FUND, LTD.
 By: Crescent Capital Group LP, its adviser

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Meric Topbas
		 	 Name: MERIC TOPBAS

		 	 Title: VICE PRESIDENT

	
	 For any institution requiring a second signature line:

		
	    by	 	 /s/ G. Wayne Hosang

		 	 Name: G. WAYNE HOSANG

		 	 Title: SENIOR VICE PRESIDENT

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	 BELL ATLANTIC MASTER TRUST
 By: Crescent Capital Group LP, its sub-adviser

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Meric Topbas
		 	 Name: MERIC TOPBAS

		 	 Title: VICE PRESIDENT

	
	 For any institution requiring a second signature line:

		
	    by	 	 /s/ G. Wayne Hosang

		 	 Name: G. WAYNE HOSANG

		 	 Title: SENIOR VICE PRESIDENT

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	 CRESCENT ALTERNATIVE CREDIT PARTNERS, L.P.
 By: Crescent Capital Group LP, its sub-adviser

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Meric Topbas
		 	 Name: MERIC TOPBAS

		 	 Title: VICE PRESIDENT

	
	For any institution requiring a second signature line:
		
	    by	 	 /s/ G. Wayne Hosang

		 	 Name: G. WAYNE HOSANG

		 	 Title: SENIOR VICE PRESIDENT

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	 Crescent Senior Secured Floating Rate Loan Fund, LLC
 By: Crescent Capital Group LP, its advisor

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Meric Topbas
		 	 Name: MERIC TOPBAS

		 	 Title: VICE PRESIDENT

	
	 For any institution requiring a second signature line:

		
	    by	 	 /s/ G. Wayne Hosang

		 	 Name: G. WAYNE HOSANG

		 	 Title: SENIOR VICE PRESIDENT

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	 FARAKER INVESTMENT PTE LTD.
 By: Crescent Capital Group LP, its sub-adviser

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Meric Topbas
		 	 Name: MERIC TOPBAS

		 	 Title: VICE PRESIDENT

	
	For any institution requiring a second signature line:
		
	    by	 	 /s/ G. Wayne Hosang

		 	 Name: G. WAYNE HOSANG

		 	 Title: SENIOR VICE PRESIDENT

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	 ILLINOIS STATE BOARD OF INVESTMENT
 By: Crescent Capital Group LP, its sub-adviser

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Meric Topbas
		 	 Name: MERIC TOPBAS

		 	 Title: VICE PRESIDENT

	
	For any institution requiring a second signature line:
		
	    by	 	 /s/ G. Wayne Hosang

		 	 Name: G. WAYNE HOSANG

		 	 Title: SENIOR VICE PRESIDENT

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	 MOMENTUM CAPITAL FUND, LTD.
 By: TCW-WLA JV Venture LLC, its sub-adviser

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Meric Topbas
		 	 Name: MERIC TOPBAS

		 	 Title: VICE PRESIDENT

	
	For any institution requiring a second signature line:
		
	    by	 	 /s/ G. Wayne Hosang

		 	 Name: G. WAYNE HOSANG

		 	 Title: SENIOR VICE PRESIDENT

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 

FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 
 DATED AS OF JUNE 6, 2012 

This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the
“Amendment”) to the Credit Agreement, dated as of June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc.
(formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto
(the “Lenders”), and the other agents parties thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 

By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the
Amendment and the Credit Agreement as amended thereby and (B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser
amount as notified to such Lender by the Administrative Agent prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 

 

			
	Name of Institution:	  	 RGA REINSURANCE COMPANY
 By: Crescent Capital Group LP, its sub-adviser

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Meric Topbas
		 	 Name: MERIC TOPBAS

		 	 Title: VICE PRESIDENT

	
	For any institution requiring a second signature line:
		
	    by	 	 /s/ G. Wayne Hosang

		 	 Name: G. WAYNE HOSANG

		 	 Title: SENIOR VICE PRESIDENT

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	 TCW SENIOR SECURED LOAN FUND, LP
 By: Crescent Capital Group LP, its sub-adviser

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Meric Topbas
		 	 Name: MERIC TOPBAS

		 	 Title: VICE PRESIDENT

	
	For any institution requiring a second signature line:
		
	    by	 	 /s/ G. Wayne Hosang

		 	 Name: G. WAYNE HOSANG

		 	 Title: SENIOR VICE PRESIDENT

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	 PALMETTO INVESTORS MASTER FUND, LLC.
 By: Crescent Capital Group LP, its sub-adviser

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Meric Topbas
		 	 Name: MERIC TOPBAS

		 	 Title: VICE PRESIDENT

	
	For any institution requiring a second signature line:
		
	    by	 	 /s/ G. Wayne Hosang

		 	 Name: G. WAYNE HOSANG

		 	 Title: SENIOR VICE PRESIDENT

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	 VITESSE CLO LTD.
 By:
TCW-WLA JV Venture LLC, its sub-adviser

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Meric Topbas
		 	 Name: MERIC TOPBAS

		 	 Title: VICE PRESIDENT

	
	For any institution requiring a second signature line:
		
	    by	 	 /s/ G. Wayne Hosang

		 	 Name: G. WAYNE HOSANG

		 	 Title: SENIOR VICE PRESIDENT

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	 WEST BEND MUTUAL INSURANCE COMPANY
 By: Crescent Capital Group LP, its sub-adviser

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Meric Topbas
		 	 Name: MERIC TOPBAS

		 	 Title: VICE PRESIDENT

	
	For any institution requiring a second signature line:
		
	    by	 	 /s/ G. Wayne Hosang

		 	 Name: G. WAYNE HOSANG

		 	 Title: SENIOR VICE PRESIDENT

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement,
dated as of June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a
Delaware corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents
parties thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 

By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the
Amendment and the Credit Agreement as amended thereby and (B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser
amount as notified to such Lender by the Administrative Agent prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 

 

			
	Name of Institution:	  	UBS AG, Stamford Branch

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Irja R. Otsa
		 	 Name: Irja R. Otsa

		 	 Title: Associate Director

	
	For any institution requiring a second signature line:
		
	    by	 	 /s/ Joselin Fernandes

		 	 Name: Joselin Fernandes

		 	 Title: Associate Director

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 This consent is made by the following Lender, acting through the undersigned investment advisor: 
  

			
	Name of Institution:        	  	ACE Tempest Reinsurance Limited
		
		  	 By: T. Rowe Price Associates, Inc. as investment manager
 Re: TRP A/C #5232

  

							
	Executing as a Continuing Tranche B Term Lender:	  	
				
		  	by	  	 /s/ Brian Burns
	  	
		  		  	Name: Brian Burns	  	
		  		  	Title: Vice President	  	
		
	For any institution requiring a second signature line:	  	Once the amendment is complete, we expect our position to remain unchanged at 925,000.
				
		  	by	  	  
	  	
		  		  	Name:	  	
		  		  	Title:	  	
	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 This consent is made by the following Lender, acting through the undersigned investment advisor: 
  

			
	Name of Institution:            	  	ACE American Insurance Company
		
		  	By: T. Rowe Price Associates, Inc. as investment advisor

  

							
	Executing as a Continuing Tranche B Term Lender:	  	
				
		  	by	  	 /s/ Brian Burns
	  	
		  		  	Name: Brian Burns	  	
		  		  	Title: Vice President	  	
		
	For any institution requiring a second signature line:	  	Once the amendment is complete, we expect our position to remain unchanged at 1,475,000.
				
		  	by	  	  
	  	
		  		  	Name:	  	
		  		  	Title:	  	
	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 This consent is made by the following Lender, acting through the undersigned investment advisor: 
  

			
	Name of Institution:        	  	ACE Tempest Life Reinsurance Limited
		
		  	By: T. Rowe Price Associates, Inc. as investment advisor

  

							
	Executing as a Continuing Tranche B Term Lender:
				
		  	by	  	 /s/ Brian Burns
	  	
		  		  	Name: Brian Burns	  	
		  		  	Title: Vice President	  	
		
	For any institution requiring a second signature line:	  	Once the amendment is complete, we expect our position to remain unchanged at 775,000.
				
		  	by	  	  
	  	
		  		  	Name:	  	
		  		  	Title:	  	
	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 This consent is made by the following Lender, acting through the undersigned investment advisor: 
  

			
	Name of Institution:        	  	ACE Tempest Reinsurance Limited
		
		  	 By: T. Rowe Price Associates, Inc. as investment advisor
 Re: TRP A/C #4965

  

							
	Executing as a Continuing Tranche B Term Lender:	  	
				
		  	by	  	 /s/ Brian Burns
	  	
		  		  	Name: Brian Burns	  	
		  		  	Title: Vice President	  	
		
	For any institution requiring a second signature line:	  	Once the amendment is complete, we expect our position to remain unchanged at 625,000.
		  	by	  	  
	  	
		  		  	Name:	  	
		  		  	Title:	  	
	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 This consent is made by the following Lender, acting through the undersigned investment advisor: 
  

			
	Name of Institution:        	  	T. Rowe Price Floating Rate Fund, Inc.

  

							
	Executing as a Continuing Tranche B Term Lender:	  	
				
		  	by	  	 /s/ Brian Burns
	  	
		  		  	Name: Brian Burns	  	
		  		  	Title: Vice President	  	
		
	For any institution requiring a second signature line:	  	Once the amendment is complete, we expect our position to remain unchanged at 250,000.
		  	by	  	  
	  	
		  		  	Name:	  	
		  		  	Title:	  	
	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 This consent is made by the following Lender, acting through the undersigned investment advisor: 
  

			
	Name of Institution:        	  	T. Rowe Price Floating Rate Multi-Sector Account Portfolio

  

							
	Executing as a Continuing Tranche B Term Lender:	  	
				
		  	by	  	 /s/ Brian Burns
	  	
		  		  	Name: Brian Burns	  	
		  		  	Title: Vice President	  	
		
	For any institution requiring a second signature line:	  	Once the amendment is complete, we expect our position to remain unchanged at 100,000.
		  	by	  	  
	  	
		  		  	Name:	  	
		  		  	Title:	  	
	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 This consent is made by the following Lender, acting through the undersigned investment advisor: 
  

			
	Name of Institution:        	  	T. Rowe Price Institutional Floating Rate Fund

  

							
	Executing as a Continuing Tranche B Term Lender:	  	
				
		  	by	  	 /s/ Brian Burns
	  	
		  		  	Name: Brian Burns	  	
		  		  	Title: Vice President	  	
		
	For any institution requiring a second signature line:	  	Once the amendment is complete, we expect our position to remain unchanged at 6,625,000.
		  	by	  	  
	  	
		  		  	Name:	  	
		  		  	Title:	  	

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:        	  	Dryden XXII Senior Loan Fund
		  	By: Prudential Investment Management, Inc., as Collateral Manager

  

					
	Executing as a Continuing Tranche B Term Lender:
			
		 	by	 	 /s/ Joseph Lemanowicz

		 		 	Name: Joseph Lemanowicz
		 		 	Title: Vice President

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:        	  	Prudential Investment Portfolios, Inc. 14 - Prudential Floating Rate Income Fund
		  	By: Prudential Investment Management, Inc., as Investment Advisor

  

					
	Executing as a Continuing Tranche B Term Lender:
			
		 	by	 	 /s/ Joseph Lemanowicz

		 		 	Name: Joseph Lemanowicz
		 		 	Title: Vice President

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:        	  	Prudential Bank Loan Fund of the Prudential Trust Company Collective Trust
		  	By: Prudential Investment Management, Inc. As Investment Advisor

  

					
	Executing as a Continuing Tranche B Term Lender:
			
		 	by	 	 /s/ Joseph Lemanowicz

		 		 	Name: Joseph Lemanowicz
		 		 	Title: Vice President

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:        	  	Gateway CLO Limited
		  	By: Prudential Investment Management, Inc., as Collateral Manager

  

					
	Executing as a Continuing Tranche B Term Lender:
			
		 	by	 	 /s/ Joseph Lemanowicz

		 		 	Name: Joseph Lemanowicz
		 		 	Title: Vice President

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Dryden XXI Leveraged Loan CDO LLC
		  	By: Prudential Investment Management, Inc., as Collateral Manager

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by 	 	/s/ Joseph Lemanowicz
		 	Name: Joseph Lemanowicz
		 	Title:   Vice President

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Pioneer Floating Rate Trust

  

			
	Executing as a Continuing Tranche B Term Lender:
	
	By: Pioneer Investment Management, Inc. Its adviser
		
	    by 	 	/s/ Margaret C. Begley
		 	Name: Margaret C. Begley
		 	Title:   Secretary and Assoc. Gen. Counsel
	
	For any institution requiring a second signature line:
		
	    by 	 	 
		 	Name:
		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Pioneer Multi-Asset Ultrashort Income Fund

  

			
	Executing as a Continuing Tranche B Term Lender:
	
	By: Pioneer Investment Management, Inc. Its adviser
		
	    by 	 	/s/ Margaret C. Begley
		 	Name: Margaret C. Begley
		 	Title:   Secretary and Assoc. Gen. Counsel
	
	For any institution requiring a second signature line:
		
	    by 	 	 
		 	Name:
		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Pioneer Strategic Income Fund

  

			
	Executing as a Continuing Tranche B Term Lender:
	
	By: Pioneer Investment Management, Inc. Its adviser
		
	    by 	 	/s/ Margaret C. Begley
		 	Name: Margaret C. Begley
		 	Title:   Secretary and Assoc. Gen. Counsel
	
	For any institution requiring a second signature line:
		
	    by 	 	 
		 	Name:
		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Pioneer Institutional Solutions – Credit Opportunities

  

			
	Executing as a Continuing Tranche B Term Lender:
	
	By: Pioneer Investment Management, Inc. Its adviser
		
	    by 	 	/s/ Margaret C. Begley
		 	Name: Margaret C. Begley
		 	Title:   Secretary and Assoc. Gen. Counsel
	
	For any institution requiring a second signature line:
		
	    by 	 	 
		 	Name:
		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Met Investors Series Trust – Pioneer Strategic Income Portfolio

  

			
	Executing as a Continuing Tranche B Term Lender:
	
	 By: Pioneer Investment Management, Inc.
             Its adviser

		
	    by 	 	/s/ Margaret C. Begley
		 	Name: Margaret C. Begley
		 	Title:   Secretary and Assoc. Gen. Counsel
	
	For any institution requiring a second signature line:
		
	    by 	 	 
		 	Name:
		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Cole Brook CBNA Loan Funding LLC

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by 	 	/s/ Adam Kaiser
		 	Name: Adam Kaiser
		 	Title:   ATTORNEY-IN-FACT
	
	For any institution requiring a second signature line:
		
	    by 	 	N/A
		 	Name:
		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	First Trust Senior Floating Rate Income Fund II
		
		  	By: First Trust Advisors L.P., its investment manager

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by 	 	/s/ William Housey
		 	Name: William Housey
		 	Title: Senior Portfolio Manager
	
	For any institution requiring a second signature line:
		
	    by 	 	 
		 	Name:
		 	Title:

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Golden Knight II CLO, Ltd.

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by 	 	/s/ Christopher Towle
		 	Name: Christopher Towle
		 	Title:   Portfolio Manager
	
	For any institution requiring a second signature line:
		
	    by 	 	 
		 	Name:
		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Lord Abbett Investment Trust – Lord Abbett Floating Rate Fund

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Christopher Towle
		 	 Name: Christopher Towle

		 	 Title: Portfolio Manager

	
	For any institution requiring a second signature line:
		
	    by	 	 
		 	 Name:

		 	 Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Lord Abbett Investment Trust – Lord Abbett Inflation Focused Fund

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Christopher Towle
		 	 Name: Christopher Towle

		 	 Title: Portfolio Manager

	
	For any institution requiring a second signature line:
		
	    by	 	 
		 	 Name:

		 	 Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Lord Abbett Investment Trust – Lord Abbett Short Duration Income Fund

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Christopher Towle
		 	 Name: Christopher Towle

		 	 Title: Portfolio Manager

	
	For any institution requiring a second signature line:
		
	    by	 	 
		 	 Name:

		 	 Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT DATED AS OF
JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to,
the First Amendment (the “Amendment”) to the Credit Agreement, dated as of June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation,
Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from
time to time parties thereto (the “Lenders”), and the other agents parties thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as
applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees
(A) to the terms of the Amendment and the Credit Agreement as amended thereby and (B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B
Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment.

  

			
	Name of Institution:	  	Lord Abbett Investment Trust – Lord Abbett Income Fund

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Christopher Towle
		 	 Name: Christopher Towle

		 	 Title: Portfolio Manager

	
	For any institution requiring a second signature line:
		
	    by	 	 
		 	 Name:

		 	 Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT DATED AS OF
JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to,
the First Amendment (the “Amendment”) to the Credit Agreement, dated as of June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation,
Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from
time to time parties thereto (the “Lenders”), and the other agents parties thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as
applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees
(A) to the terms of the Amendment and the Credit Agreement as amended thereby and (B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B
Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment.

  

			
	Name of Institution:	  	KVK CLO 2012-1 LTD.

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ David Cifonelli
		 	 Name: David Cifonelli

		 	 Title: Vice President

	
	For any institution requiring a second signature line:
		
	    by	 	 
		 	 Name:

		 	 Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”) among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	GSC Investment Corp. CLO 2007, LTD.

  

			
	Executing as a Continuing Tranche B Term Lender:
	GSC Investment Corp. CLO 2007, LTD.
	
	By: Saratoga Investment Corp., As Collateral Manager
	
	By: Saratoga Investment Advisors, LLC, Its Investment Advisor
		
	    by	 	/s/ Thomas Inglesby
		 	 Name: Thomas Inglesby

		 	 Title: Managing Director

	
	For any institution requiring a second signature line:
		
	    by	 	 
		 	 Name:

		 	 Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	GE Capital Bank (formerly Known as GE Capital Finance Inc.)

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Keith Bird
		 	 Name: Keith Bird

		 	 Title: Duly Authorized Signatory

	
	For any institution requiring a second signature line:
		
	    by	 	 
		 	 Name:

		 	 Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum (i) as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans as New Tranche B Term Loans on the Amendment Effective Date in the amount of
its New Tranche B Term Loan Commitment, and (ii) as an existing Lender that is not Continuing Tranche B Term Lender or an Additional Tranche B Term Lender (any such Lender, a “Non-Continuing Lender”), the undersigned institution
agrees to the terms of the Amendment and the Credit Agreement as amended thereby, but not to have its Existing Tranche B Term Loans continued or make and fund New Tranche B Term Loans on the Amendment Effective Date. 

 

			
	Name of Institution:	  	MARATHON CLO IV LTD.

 

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Jake Hyde
		 	 Name: Jake Hyde

		 	 Title: Authorized Signatory

	
	For any institution requiring a second signature line:
		
	    by	 	 
		 	 Name:

		 	 Title:

	
	x Check here if Lender elects a cashless roll of its Tranche B Term Loans

 

			
	Executing solely as a Non-Continuing Lender:
		
	    by	 	 
		 	 Name:

		 	 Title:

	
	For any institution requiring a second signature line:
		
	    by	 	 
		 	 Name:

		 	 Title:

 
 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

							
		 	 APOSTLE LOOMIS SAYLES
 CREDIT OPPORTUNITIES FUND,
 As Lender
	  	
				
	Name of Institution:	 	By:	  	 Loomis, Sayles & Company, L.P.,
 Its Investment Manager
	  	
				
		 	By:	  	 Loomis, Sayles & Company, Incorporated,
 Its General Partner
	  	

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Mary McCarthy
		 	 Name: Mary McCarthy

		 	 Title: Vice President

	
	 ̈ Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment’’) to the Credit Agreement, dated as
of June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

							
		 	 APOSTLE LOOMIS SAYLES
 SENIOR LOAN FUND,
 As Lender
	  	
				
	Name of Institution:	 	By:	  	 Loomis, Sayles & Company, L.P.,
 Its Investment Manager
	  	
				
		 	By:	  	 Loomis, Sayles & Company, Incorporated,
 Its General Partner
	  	

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Mary McCarthy
		 	 Name: Mary McCarthy

		 	 Title: Vice President

	
	 ̈ Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUYEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

							
		 	 GUIDEMARK OPPORTUNISTIC
 FIXED INCOME FUND,
 As Lender
	  	
				
	Name of Institution:	 	By:	  	 Loomis, Sayles & Company, L.P.,
 Sub-Advisor
	  	
				
		 	By:	  	 Loomis, Sayles & Company, Incorporated,
 Its General Partner
	  	

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Mary McCarthy
		 	 Name: Mary McCarthy

		 	 Title: Vice President

	
	 ̈ Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

							
		 	INDIANA UNIVERSITY
 As Lender
	  	
				
	Name of Institution:	 	By:	  	 Loomis, Sayles & Company, L.P.,
 Its Investment Adviser
	  	
				
		 	By:	  	 Loomis, Sayles & Company, Incorporated,
 Its General Partner
	  	

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Mary McCarthy
		 	 Name: Mary McCarthy

		 	 Title: Vice President

	
	 ̈ Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

  

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

 

							
		 	 LITMAN GREGORY
 MASTERS ALTERNATIVE STRATEGIES FUND,
 As Lender
	  	
				
	Name of Institution:	 	By:	  	 Loomis, Sayles & Company, L.P.,
 As Sub-advisor for Litman Gregory
 Fund Advisors, LLC
	  	

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Mary McCarthy
		 	 Name: Mary McCarthy

		 	 Title: Vice President

	
	 ̈ Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

							
		 	LOOMIS SAYLES
 ABSOLUTE STRATEGIES
FUND,
 As Lender
	  	
				
	Name of Institution:	 	By:	  	 Loomis, Sayles & Company, L.P.,
 Its Investment Manager
	  	
				
		 	By:	  	 Loomis, Sayles & Company, Incorporated,
 Its General Partner
	  	

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Mary McCarthy
		 	 Name: Mary McCarthy

		 	 Title: Vice President

	
	 ̈ Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

							
		 	 LOOMIS SAYLES

ABSOLUTE STRATEGIES TRUST,
 As
Lender
	  	
				
	Name of Institution:	 	By:	  	 Loomis Sayles Trust Company, LLC,
 as Trustee of
 Loomis Sayles Absolute Strategies Trust
	  	

  
  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Mary McCarthy
		 	 Name: Mary McCarthy

		 	 Title:Vice President

	
	 ̈ Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

							
		 	LOOMIS SAYLES CREDIT
 ALPHA MASTER FUND,
LTD.,
 As Lender
	  	
				
	Name of Institution:	 	By:	  	 Loomis, Sayles & Company, L.P.,
 Its Investment Manager
	  	
				
		 	By:	  	 Loomis, Sayles & Company, Incorporated,
 Its General Partner
	  	

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Mary McCarthy
		 	 Name: Mary McCarthy

		 	 Title:Vice President

	
	 ̈ Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

  

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

							
		 	LOOMIS SAYLES CREDIT ASSET TRUST, 
 As
Lender
	  	
				
	Name of Institution:	 	By:	  	 Loomis Sayles Trust Company, LLC,
 As Trustee of Loomis Sayles Credit Asset Trust
	  	

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Mary McCarthy
		 	 Name: Mary McCarthy

		 	 Title: Vice President

	
	 ̈ Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

  

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

							
		 	THE LOOMIS SAYLES
 SENIOR LOAN FUND,
LLC,
 As Lender
	  	
				
	Name of Institution:	 	By:	  	 Loomis, Sayles & Company, L.P.,
 Its Managing Member
	  	
				
		 	By:	  	 Loomis, Sayles & Company, Incorporated,
 Its General Partner
	  	

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Mary McCarthy
		 	 Name: Mary McCarthy

		 	 Title: Vice President

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

							
		 	LOOMIS SAYLES SENIOR
 FLOATING RATE &
FIXED INCOME FUND,
 As Lender
	  	
				
	Name of Institution:	 	By:	  	 Loomis, Sayles & Company, L.P.,
 Its Investment Adviser
	  	
				
		 	By:	  	 Loomis, Sayles & Company, Incorporated,
 Its General Partner
	  	

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Mary McCarthy
		 	 Name: Mary McCarthy

		 	 Title: Vice President

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

							
		 	 MONTPELIER REINSURANCE LTD.,
 As Lender
	  	
				
	Name of Institution:	 	By:	  	 Loomis, Sayles & Company, L.P.,
 Its Investment Manager
	  	
				
		 	By:	  	 Loomis, Sayles & Company, Incorporated,
 Its General Partner
	  	

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by	 	/s/ Mary McCarthy
		 	 Name: Mary McCarthy

		 	 Title: Vice President

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
		  	 NATIXIS LOOMIS SAYLES
 SENIOR LOAN FUND,
 As Lender

		
	Name of Institution:	  	 By:   Loomis, Sayles & Company, L.P.,

         Its Investment Manager

		
		  	 By:   Loomis, Sayles & Company, Incorporated,

         Its General Partner

  

			
	 Executing as a Continuing Tranche B Term
 Lender:

		
	    by	 	/s/ Mary McCarthy
		 	Name: Mary McCarthy
		 	Title: Vice President

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
		  	 PRINCIPAL FUNDS, INC -

GLOBAL MULTI STRATEGY FUND,
 As
Lender

		
	Name of Institution:	  	 By:   Loomis, Sayles & Company, L.P.,

        Its Sub-Advisor 

		
		  	 By:   Loomis, Sayles & Company, Incorporated,

         Its General Partner

  

			
	 Executing as a Continuing Tranche B Term
 Lender:

		
	    by	 	/s/ Mary McCarthy
		 	Name: Mary McCarthy
		 	Title: Vice President

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
		  	 SEARS HOLDING PENSION PLAN,
 As Lender

		
	Name of Institution:	  	 By:   Loomis, Sayles & Company, L.P.,

        Its Investment Adviser 

		
		  	 By:   Loomis, Sayles & Company, Incorporated,

         Its General Partner

  

			
	 Executing as a Continuing Tranche B Term
 Lender:

		
	    by	 	/s/ Mary McCarthy
		 	Name: Mary McCarthy
		 	Title: Vice President

  ̈ Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	 	JPMORGAN CHASE BANK, N.A.

  

			
	 Executing as a Continuing Tranche B Term
 Lender:

		
	    by	 	/s/ Andrew C. Faherty
		 	Name: Andrew C. Faherty
		 	Title: Authorized Signatory

 x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	Oberhausen S.a.r.l., A Societe A Responsabilite Limitee De Titrisation

  

			
	 Executing as a Continuing Tranche B Term
 Lender:

	
	 By: Highbridge Leveraged Loan Partners
 2010 Master Fund, L.P. as Portfolio Manager
 By: Highbridge Principal Strategies, LLC as Trading
Manager

		
		 	/s/ Daniel Klein
		 	Name: Daniel Klein
		 	Title: Managing Director

 x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	
	
	 BlackRock Senior High Income Fund, Inc.

  

			
	 Executing as a Continuing Tranche B Term
 Lender:

		
	    by	 	/s/ C. Adrian Marshall
		 	Name: C. Adrian Marshall
		 	Title: Authorized Signatory
	
	 For any institution requiring a second signature
 line:

		
	    by	 	 
		 	Name:
		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	
	
	Allied World Assurance Company, Ltd

  

			
	 Executing as a Continuing Tranche B Term
 Lender:

		
	    by	 	/s/ C. Adrian Marshall
		 	Name: C. Adrian Marshall
		 	Title: Authorized Signatory
	
	 For any institution requiring a second signature
 line:

		
	    by	 	 
		 	Name:
		 	Title:
	
	x Check here if Lender elects a cashless roll of
	its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	
	
	JPMBI re Blackrock BankLoan Fund

  

			
	 Executing as a Continuing Tranche B Term
 Lender:

		
	    by	 	/s/ C. Adrian Marshall
		 	Name: C. Adrian Marshall
		 	Title: Authorized Signatory
	
	 For any institution requiring a second signature
 line:

		
	    by	 	 
		 	Name:
		 	Title:
	
	x Check here if Lender elects a cashless roll of
	its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	
	
	BlackRock Floating Rate Income Trust

  

			
	 Executing as a Continuing Tranche B Term
 Lender:

		
	    by	 	/s/ C. Adrian Marshall
		 	Name: C. Adrian Marshall
		 	Title: Authorized Signatory
	
	 For any institution requiring a second signature

line:

		
	    by	 	 
		 	Name:
		 	Title:
	
	x Check here if Lender elects a cashless roll of
	its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	
	
	BlackRock Strategic Bond Trust

  

			
	 Executing as a Continuing Tranche B Term
 Lender:

		
	    by	 	/s/ C. Adrian Marshall
		 	Name: C. Adrian Marshall
		 	Title: Authorized Signatory
	
	 For any institution requiring a second signature
 line:

		
	    by	 	 
		 	Name:
		 	Title:
	
	x Check here if Lender elects a cashless roll of
	its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 BlackRock Defined Opportunity Credit Trust 

Executing as a Continuing Tranche B Term Lender: 
  

					
		 	by	 	/s/ C. Adrian Marshall
		 		 	Name: C. Adrian Marshall
		 		 	Title: Authorized Signatory

 For any institution requiring a second signature line: 

 

					
		 	by	 	 
		 		 	Name:
		 		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 BlackRock High Yield Trust 

Executing as a Continuing Tranche B Term Lender: 
  

					
		 	by	 	/s/ C. Adrian Marshall
		 		 	Name: C. Adrian Marshall
		 		 	Title: Authorized Signatory

 For any institution requiring a second signature line: 

 

					
		 	by	 	 
		 		 	Name:
		 		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 BlackRock Limited Duration Income Trust 

Executing as a Continuing Tranche B Term Lender: 
  

					
		 	by	 	/s/ C. Adrian Marshall
		 		 	Name: C. Adrian Marshall
		 		 	Title: Authorized Signatory

 For any institution requiring a second signature line: 

 

					
		 	by	 	 
		 		 	Name:
		 		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 BMI-CLO-I 
 Executing as a Continuing Tranche B Term Lender: 
  

					
		 	by	 	/s/ C. Adrian Marshall
		 		 	Name: C. Adrian Marshall
		 		 	Title: Authorized Signatory

 For any institution requiring a second signature line: 

 

					
		 	by	 	 
		 		 	Name:
		 		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 BlackRock Funds II BlackRock Floating Rate Income Portfolio

 Executing as a Continuing Tranche B Term Lender: 

 

					
		 	by	 	/s/ C. Adrian Marshall
		 		 	Name: C. Adrian Marshall
		 		 	Title: Authorized Signatory

 For any institution requiring a second signature line: 

 

					
		 	by	 	 
		 		 	Name:
		 		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 BlackRock Funds II – BlackRock High Yield Bond Portfolio

 Executing as a Continuing Tranche B Term Lender: 

 

					
		 	by	 	/s/ C. Adrian Marshall
		 		 	Name: C. Adrian Marshall
		 		 	Title: Authorized Signatory

 For any institution requiring a second signature line: 

 

					
		 	by	 	 
		 		 	Name:
		 		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	

 BlackRock Funds II, BlackRock Multi-Asset Income Portfolio 

 

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by  	 	/s/ C. Adrian Marshall
		 	Name:	 	C. Adrian Marshall
		 	Title:	 	Authorized Signatory
	
	For any institution requiring a second signature line:
		
	    by  	 	 
		 	Name:	 	
		 	Title:	 	
	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	

 BlackRock Senior Income Series V Limited 

 

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by  	 	/s/ C. Adrian Marshall
		 	Name:	 	C. Adrian Marshall
		 	Title:	 	Authorized Signatory
	
	For any institution requiring a second signature line:
		
	    by  	 	 
		 	Name:	 	
		 	Title:	 	
	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	

 BlackRock High Yield Portfolio of BlackRock Series Fund, Inc. 

 

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by  	 	/s/ C. Adrian Marshall
		 	Name:	 	C. Adrian Marshall
		 	Title:	 	Authorized Signatory
	
	For any institution requiring a second signature line:
		
	    by  	 	 
		 	Name:	 	
		 	Title:	 	
	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	

 BlackRock High Income V.I. Fund of BlackRock Variable Series Funds, Inc. 

 

					
	Executing as a Continuing Tranche B Term Lender:
		
	    by  	 	/s/ C. Adrian Marshall
		 	Name:	 	C. Adrian Marshall
		 	Title:	 	Authorized Signatory
	
	For any institution requiring a second signature line:
		
	    by  	 	 
		 	Name:	 	
		 	Title:	 	
	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 BlackRock Corporate High Yield Fund, Inc. 

 

			
	Executing as a Continuing Tranche B Term Lender: 
		
	    by 	 	/s/ C. Adrian Marshall
		 	Name: C. Adrian Marshall
		 	Title:   Authorized Signatory
	
	For any institution requiring a second signature line:
		
	    by 	 	 
		 	Name:
		 	Title:
	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 BlackRock Corporate High Yield Fund III, Inc. 

 

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by 	 	/s/ C. Adrian Marshall
		 	 Name: C. Adrian Marshall

Title:   Authorized Signatory

	
	For any institution requiring a second signature line:
		
	    by 	 	 
		 	 Name:

Title:

	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 BlackRock Debt Strategies Fund, Inc. 

 

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by 	 	/s/ C. Adrian Marshall
		 	 Name: C. Adrian Marshall

Title:   Authorized Signatory

	
	For any institution requiring a second signature line:
		
	    by 	 	 
		 	Name:
		 	Title:
	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 BlackRock Diversified Income Strategies Fund, Inc. 

 

			
	Executing as a Continuing Tranche B Term Lender:
		
	    by 	 	/s/ C. Adrian Marshall
		 	 Name: C. Adrian Marshall

Title:   Authorized Signatory

	
	For any institution requiring a second signature line:
		
	    by 	 	 
		 	 Name:

Title:

	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 BlackRock Floating Rate Income Strategies Fund, Inc. 

 

			
	Executing as a Continuing Tranche B Term Lender:
		
	by	 	/s/ C. Adrian Marshall
		 	Name: C. Adrian Marshall
		 	Title: Authorized Signatory
	
	For any institution requiring a second signature line:
		
	by	 	 
		 	Name:
		 	Title:
	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 BlackRock Floating Rate Income Strategies Fund II, Inc. 

 

			
	Executing as a Continuing Tranche B Term Lender:
		
	by	 	/s/ C. Adrian Marshall
		 	Name: C. Adrian Marshall
		 	Title: Authorized Signatory
	
	For any institution requiring a second signature line:
		
	by	 	 
		 	Name:
		 	Title:
	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 BlackRock Global Investment Series: Income Strategies Portfolio

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	by	 	/s/ C. Adrian Marshall
		 	Name: C. Adrian Marshall
		 	Title: Authorized Signatory
	
	For any institution requiring a second signature line:
		
	by	 	 
		 	Name:
		 	Title:
	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 Houston Casualty Company 

 

			
	Executing as a Continuing Tranche B Term Lender:
		
	by	 	/s/ C. Adrian Marshall
		 	Name: C. Adrian Marshall
		 	Title: Authorized Signatory
	
	For any institution requiring a second signature line:
		
	by	 	 
		 	Name:
		 	Title:
	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 US Specialty Insurance Company 

 

			
	Executing as a Continuing Tranche B Term Lender:
		
	by	 	/s/ C. Adrian Marshall
		 	Name: C. Adrian Marshall
		 	Title: Authorized Signatory
	
	For any institution requiring a second signature line:
		
	by	 	 
		 	Name:
		 	Title:
	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 BlackRock High Income Shares 

 

			
	Executing as a Continuing Tranche B Term Lender:
		
	by	 	 /s/ C. Adrian Marshall

		 	Name: C. Adrian Marshall
		 	Title: Authorized Signatory
	
	For any institution requiring a second signature line:
		
	by	 	 
		 	Name:
		 	Title:
	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 Alterra Bermuda Limited 

 

			
	Executing as a Continuing Tranche B Term Lender:
		
	by	 	/s/ C. Adrian Marshall
		 	Name: C. Adrian Marshall
		 	Title: Authorized Signatory
	
	For any institution requiring a second signature line:
		
	by	 	 
		 	Name:
		 	Title:
	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 BlackRock Corporate High Yield Fund VI, Inc. 

 

			
	Executing as a Continuing Tranche B Term Lender:
		
	by	 	/s/ C. Adrian Marshall
		 	Name: C. Adrian Marshall
		 	Title: Authorized Signatory
	
	For any institution requiring a second signature line:
		
	by	 	 
		 	Name:
		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 BlackRock Corporate High Yield Fund V, Inc. 

 

			
	Executing as a Continuing Tranche B Term Lender:
		
	by	 	/s/ C. Adrian Marshall
		 	Name: C. Adrian Marshall
		 	Title: Authorized Signatory
	
	For any institution requiring a second signature line:
		
	by	 	 
		 	Name:
		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 Ironshore Inc. 

 

			
	Executing as a Continuing Tranche B Term Lender:
		
	by	 	/s/ C. Adrian Marshall
		 	Name: C. Adrian Marshall
		 	Title: Authorized Signatory
	
	For any institution requiring a second signature line:
		
	by	 	 
		 	Name:
		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 Magnetite VI, Limited 

 

			
	Executing as a Continuing Tranche B Term Lender:
		
	by	 	/s/ C. Adrian Marshall
		 	Name: C. Adrian Marshall
		 	Title: Authorized Signatory
	
	For any institution requiring a second signature line:
		
	by	 	 
		 	Name:
		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 MET Investors Series Trust - BlackRock High Yield Portfolio

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	by	 	/s/ C. Adrian Marshall
		 	Name: C. Adrian Marshall
		 	Title: Authorized Signatory
	
	For any institution requiring a second signature line:
		
	by	 	 
		 	Name:
		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 Advanced Series Trust - AST BlackRock Global Strategies Portfolio

  

			
	Executing as a Continuing Tranche B Term Lender:
		
	by	 	 /s/ C. Adrian Marshall

		 	Name: C. Adrian Marshall
		 	Title: Authorized Signatory
	
	For any institution requiring a second signature line:
		
	by	 	  

		 	Name:
		 	Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
 Name of Institution: 
 BlackRock Senior Floating Rate Portfolio 

 

			
	Executing as a Continuing Tranche B Term Lender:
		
	by	 	 /s/ C. Adrian Marshall

		 	Name: C. Adrian Marshall
		 	Title: Authorized Signatory
	
	For any institution requiring a second signature line:
		
	by	 	 
		 	Name:
		 	Title:
	
	x Check here if Lender elects a cashless roll of its Continued Tranche B Term Loans

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	 Name of

Institution:
	  	BLACKSTONE / GSO LONG-SHORT CREDIT INCOME FUND
	  	By: GSO / Blackstone Debt Funds Management LLC
	  	as Investment Advisor

 Executing as a Continuing Tranche B Term Lender: 

 

					
		 	 by
	 	/s/ Daniel H. Smith
		 		 	 Name: Daniel H. Smith

		 		 	 Title: Authorized Signatory

 For any institution requiring a second signature line: 

 

					
		 	 by
	 	 
		 		 	 Name:

		 		 	 Title:

 x Check here if Lender elects a cashless
roll of its Continued Tranche B Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	 Name of

Institution:
	  	BLACKSTONE / GSO SECURED TRUST LTD
	  	By: GSO / Blackstone Debt Funds Management LLC
	  	as Investment Manager

 Executing as a Continuing Tranche B Term Lender: 

 

					
		 	 by
	 	/s/ Daniel H. Smith
		 		 	 Name: Daniel H. Smith

		 		 	 Title: Authorized Signatory

 For any institution requiring a second signature line: 

 

					
		 	 by
	 	 
		 		 	 Name:

		 		 	 Title:

 x Check here if Lender elects a cashless
roll of its Continued Tranche B Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	BLACKSTONE / GSO SENIOR FLOATING RATE TERM FUND
		  	By: GSO / Blackstone Debt Funds Management LLC
		  	as Investment Advisor

 Executing as a Continuing Tranche B Term Lender: 

 

					
		 	 by
	 	/s/ Daniel H. Smith
		 		 	 Name: Daniel H. Smith

		 		 	 Title: Authorized Signatory

 For any institution requiring a second signature line: 

 

					
		 	 by
	 	 
		 		 	 Name:

		 		 	 Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	 CENTRAL PARK CLO, LTD.

By: GSO / Blackstone Debt Funds Management LLC

as Collateral Manager

 Executing as a Continuing Tranche B Term Lender: 

 

					
		 	 by
	 	/s/ Daniel H. Smith
		 		 	 Name: Daniel H. Smith

		 		 	 Title: Authorized Signatory

 For any institution requiring a second signature line: 

 

					
		 	 by
	 	 
		 		 	 Name:

		 		 	 Title:

 x Check here if Lender elects a cashless
roll of its Continued Tranche B Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	 GALE FORCE 3 CLO, LTD.

By: GSO/BLACKSTONE Debt Funds Management LLC
 as
Collateral Manager

 Executing as a Continuing Tranche B Term Lender: 

 

					
		 	 by
	 	/s/ Daniel H. Smith
		 		 	 Name: Daniel H. Smith

		 		 	 Title: Authorized Signatory

 For any institution requiring a second signature line: 

 

					
		 	 by
	 	 
		 		 	 Name:

		 		 	 Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	 INWOOD PARK CDO LTD.

By: Blackstone Debt Advisors L.P.
 as Collateral
Manager

 Executing as a Continuing Tranche B Term Lender: 

 

					
		 	 by
	 	/s/ Daniel H. Smith
		 		 	 Name: Daniel H. Smith

		 		 	 Title: Authorized Signatory

 For any institution requiring a second signature line: 

 

					
		 	 by
	 	 
		 		 	 Name:

		 		 	 Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	 MAPS CLO FUND II, LTD.

By: GSO / Blackstone Debt Funds Management LLC

as Collateral Manager

 Executing as a Continuing Tranche B Term Lender: 

 

					
		 	 by
	 	/s/ Daniel H. Smith
		 		 	 Name: Daniel H. Smith

		 		 	 Title: Authorized Signatory

 For any institution requiring a second signature line: 

 

					
		 	 by
	 	 
		 		 	 Name:

		 		 	 Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	 PROSPECT PARK CDO LTD.

By: Blackstone Debt Advisors L.P.
 as Collateral
Manager

 Executing as a Continuing Tranche B Term Lender: 

 

					
		 	 by
	 	/s/ Daniel H. Smith
		 		 	 Name: Daniel H. Smith

		 		 	 Title: Authorized Signatory

 For any institution requiring a second signature line: 

 

					
		 	 by
	 	 
		 		 	 Name:

		 		 	 Title:

 x Check here if Lender elects a cashless
roll of its Continued Tranche B Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Continuing Tranche B Term Lender, the undersigned institution agrees (A) to the terms of the Amendment and the Credit Agreement as amended thereby and
(B) on the terms and subject to the conditions set forth in the Amendment and the Credit Agreement as amended thereby, to continue its Existing Tranche B Term Loans (or such lesser amount as notified to such Lender by the Administrative Agent
prior to the Amendment Effective Date) as New Tranche B Term Loans on the Amendment Effective Date in the amount of its New Tranche B Term Loan Commitment. 
  

			
	Name of Institution:	  	 RIVERSIDE PARK CLO LTD.

By: GSO/BLACKSTONE Debt Funds Management LLC
 as
Collateral Manager

 Executing as a Continuing Tranche B Term Lender: 

 

					
		 	 by
	 	/s/ Daniel H. Smith
		 		 	 Name: Daniel H. Smith

		 		 	 Title: Authorized Signatory

 For any institution requiring a second signature line: 

 

					
		 	 by
	 	 
		 		 	 Name:

		 		 	 Title:

 x Check here if Lender elects a cashless roll of its Continued Tranche B
Term Loans 

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Revolving Lender, the undersigned institution agrees to the terms of the Amendment and the Credit Agreement as amended thereby. 

 

			
	 Name of Institution:
	 	JPMorgan Chase Bank, N.A.

  

					
	    Executing as a Revolving Lender:
			
		 	    by	 	/s/ Vanessa Chiu
		 		 	Name: Vanessa Chiu
		 		 	Title: Executive Director
	
	    For any institution requiring a second signature line:
			
		 	    by	 	 
		 		 	Name:
		 		 	Title:

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Revolving Lender, the undersigned institution agrees to the terms of the Amendment and the Credit Agreement as amended thereby. 

 

			
	Name of Institution:	  	Morgan Stanley Bank, N.A.

  

					
	    Executing as a Revolving Lender: 
			
		 	by	 	/s/ Kelly Chin
		 		 	 Name: Kelly Chin
 Title:
Authorized Signatory

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Revolving Lender, the undersigned institution agrees to the terms of the Amendment and the Credit Agreement as amended thereby. 

 

			
	Name of Institution:	  	Bank of America, N.A.

  

					
	    Executing as a Revolving Lender:
			
		 	by	 	/s/ Greg Roetting
		 		 	 Name: Greg Roetting
 Title:
VP

	
	    For any institution requiring a second signature line:
			
		 	by	 	 
		 		 	Name:
		 		 	Title:

 LENDER ADDENDUM TO THE 
 FIRST AMENDMENT TO THE TRUVEN HEALTH ANALYTICS INC. 
 CREDIT AGREEMENT 

DATED AS OF JUNE 6, 2012 
 This Lender Addendum (this “Lender Addendum”) is referred to in, and is a signature page to, the First Amendment (the “Amendment”) to the Credit Agreement, dated as of
June 6, 2012 (the “Credit Agreement”), among Truven Holding Corp. (formerly known as VCPH Holding Corp.), a Delaware corporation, Truven Health Analytics Inc. (formerly known as Thomson Reuters (Healthcare) Inc.), a Delaware
corporation, as the borrower, JPMorgan Chase Bank, N.A., as the administrative agent, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”), and the other agents parties
thereto. Capitalized terms used but not defined in this Lender Addendum have the meanings assigned to such terms in the Amendment or the Credit Agreement, as applicable. 
 By executing this Lender Addendum as a Revolving Lender, the undersigned institution agrees to the terms of the Amendment and the Credit Agreement as amended thereby. 

 

			
	Name of Institution:	  	UBS Loan Finance LLC

  

					
	    Executing as a Revolving Lender:
			
		 	by	 	/s/ Irja R. Otsa
		 		 	 Name: Irja R. Otsa
 Title:
Associate Director Banking Products Services, US

	
	    For any institution requiring a second signature line:
			
		 	by	 	/s/ Joselin Fernandes
		 		 	 Name: Joselin Fernandes
 Title: Associate Director Banking Products Services, US

 Annex I 
 “Applicable Margin”: (a) (i) for Revolving Loans that are Eurodollar Loans, 4.50% per annum, (ii) for Revolving Loans that are ABR Loans and Swingline Loans,
3.50% per annum and (iii) for the Commitment Fee, 0.50% per annum; provided, that on and after the first Adjustment Date occurring after the completion of the first full fiscal quarter of the Borrower after the First Amendment
Effective Date, the Applicable Margin with respect to Revolving Loans and Swingline Loans and the Commitment Fee will be determined pursuant to the Applicable Pricing Grid; 
 (b) (i) for Tranche B Term Loans that are Eurodollar Loans, 4.50% per annum and (ii) for Tranche B Term Loans that are ABR Loans, 3.50% per annum; and 

(c) for Incremental Term Loans, such per annum rates as shall be agreed to by the Borrower and the applicable Incremental Term Lenders as
shown in the applicable Increased Facility Activation Notice. 
 “Applicable Pricing Grid”: the table set forth
below: 
  

							
	 Consolidated Senior
 Secured Leverage
 Ratio
	  	Applicable Margin for
Revolving Loans 
that
are Eurodollar Loans	 	Applicable Margin for
Revolving Loans 
and
Swingline Loans that
are ABR Loans	 	Commitment Fee
	 > 3.00:1.00
	  	4.50%	 	3.50%	 	0.50%
	 < 3.00:1.00 and

> 2.00:1.00
	  	4.25%	 	3.25%	 	0.50%
	 < 2.00:1.00
	  	4.00%	 	3.00%	 	0.375%

 For the purposes of the Applicable Pricing Grid, changes in the Applicable Margin resulting from changes
in the Consolidated Senior Secured Leverage Ratio shall become effective on the date (the “Adjustment Date”) that is three Business Days after the date on which financial statements are delivered to the Lenders pursuant to
Section 6.1(a) or (b), as applicable, and shall remain in effect until the next change to be effected pursuant to this paragraph. If any financial statements referred to above are not delivered within the time periods specified in
Section 6.1, then, until the date that is three Business Days after the date on which such financial statements are delivered, the highest rate set forth in each column of the Applicable Pricing Grid shall apply. In addition, at all times while
an Event of Default shall have occurred and be continuing, the highest rate set forth in each column of the Applicable Pricing Grid shall apply. Each determination of the Consolidated Senior Secured Leverage Ratio pursuant to the Applicable Pricing
Grid shall be made in a manner consistent with the determination thereof pursuant to Section 7.1.EX-10.4

 Exhibit 10.4 
 EXECUTION VERSION 
  
  

 
 GUARANTEE AND COLLATERAL
AGREEMENT 
 made by 
 VCPH HOLDING CORP. 
 WOLVERINE HEALTHCARE ANALYTICS, INC. 

and certain of their Subsidiaries 
 in favor of 
 JPMORGAN CHASE BANK, N.A., 

as Administrative Agent 
 Dated as of June 6, 2012 
  

 
  

 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 SECTION 1.
	 	DEFINED TERMS	  	 	1	  
	 1.1
	 	Definitions	  	 	1	  
	 1.2
	 	Other Definitional Provisions	  	 	5	  
			
	 SECTION 2.
	 	GUARANTEE	  	 	5	  
	 2.1
	 	Guarantee	  	 	5	  
	 2.2
	 	Right of Contribution	  	 	6	  
	 2.3
	 	No Subrogation	  	 	6	  
	 2.4
	 	Amendments, etc. with respect to the Borrower Obligations	  	 	6	  
	 2.5
	 	Guarantee Absolute and Unconditional	  	 	6	  
	 2.6
	 	Reinstatement	  	 	7	  
	 2.7
	 	Payments	  	 	7	  
			
	 SECTION 3.
	 	GRANT OF SECURITY INTEREST	  	 	7	  
			
	 SECTION 4.
	 	REPRESENTATIONS AND WARRANTIES	  	 	9	  
	 4.1
	 	Title; No Other Liens	  	 	9	  
	 4.2
	 	Perfected First Priority Liens	  	 	10	  
	 4.3
	 	Jurisdiction of Organization; Chief Executive Office	  	 	10	  
	 4.4
	 	Inventory and Equipment	  	 	10	  
	 4.5
	 	Farm Products	  	 	10	  
	 4.6
	 	Investment Property	  	 	10	  
	 4.7
	 	Receivables	  	 	11	  
	 4.8
	 	Material Government Contracts	  	 	11	  
	 4.9
	 	Intellectual Property	  	 	11	  
	 4.10
	 	Commercial Tort Claims	  	 	12	  
			
	 SECTION 5.
	 	COVENANTS	  	 	12	  
	 5.1
	 	Delivery of Instruments, Certificated Securities and Chattel Paper	  	 	12	  
	 5.2
	 	Maintenance of Insurance	  	 	12	  
	 5.3
	 	Maintenance of Perfected Security Interest; Further Documentation	  	 	12	  
	 5.4
	 	Changes in Name, etc.	  	 	13	  
	 5.5
	 	Notices	  	 	13	  
	 5.6
	 	Investment Property	  	 	13	  
	 5.7
	 	Material Government Contracts	  	 	14	  
	 5.8
	 	Intellectual Property	  	 	15	  
	 5.9
	 	Commercial Tort Claims	  	 	16	  
	 5.10
	 	Receivables	  	 	16	  
	 5.11
	 	Perfection of Assets Covered by Certificates of Title	  	 	16	  
			
	 SECTION 6.
	 	REMEDIAL PROVISIONS	  	 	17	  
	 6.1
	 	Certain Matters Relating to Receivables	  	 	17	  
	 6.2
	 	Communications with Obligors; Grantors Remain Liable	  	 	17	  
	 6.3
	 	Pledged Stock and Pledged Notes	  	 	18	  
	 6.4
	 	Proceeds to be Turned Over To Administrative Agent	  	 	18	  
	 6.5
	 	Application of Proceeds	  	 	19	  

  
 i 

							
	 6.6
	 	Code and Other Remedies	  	 	19	  
	 6.7
	 	Registration Rights	  	 	20	  
	 6.8
	 	Subordination	  	 	21	  
	 6.9
	 	Deficiency	  	 	21	  
	 6.10
	 	Grant of Intellectual Property License	  	 	21	  
			
	 SECTION 7.
	 	THE ADMINISTRATIVE AGENT	  	 	21	  
	 7.1
	 	Administrative Agent’s Appointment as Attorney-in-Fact, etc.	  	 	21	  
	 7.2
	 	Duty of Administrative Agent	  	 	23	  
	 7.3
	 	Execution of Financing Statements	  	 	23	  
	 7.4
	 	Authority of Administrative Agent	  	 	23	  
			
	 SECTION 8.
	 	MISCELLANEOUS	  	 	24	  
	 8.1
	 	Amendments in Writing	  	 	24	  
	 8.2
	 	Notices	  	 	24	  
	 8.3
	 	No Waiver by Course of Conduct; Cumulative Remedies	  	 	24	  
	 8.4
	 	Enforcement Expenses; Indemnification	  	 	24	  
	 8.5
	 	Successors and Assigns	  	 	24	  
	 8.6
	 	Set-Off	  	 	24	  
	 8.7
	 	Counterparts	  	 	25	  
	 8.8
	 	Severability	  	 	25	  
	 8.9
	 	Section Headings	  	 	25	  
	 8.10
	 	Integration	  	 	25	  
	 8.11
	 	GOVERNING LAW	  	 	25	  
	 8.12
	 	Submission To Jurisdiction; Waivers	  	 	25	  
	 8.13
	 	Acknowledgements	  	 	25	  
	 8.14
	 	Additional Grantors	  	 	26	  
	 8.15
	 	Rights Relating to the Collateral	  	 	26	  
	 8.16
	 	Releases	  	 	26	  
	 8.17
	 	WAIVER OF JURY TRIAL	  	 	26	  

  

			
	SCHEDULES	  	
		
	Schedule 1	  	Notice Addresses
	Schedule 2	  	Investment Property
	Schedule 3	  	Perfection Matters
	Schedule 4	  	Jurisdictions of Organization and Chief Executive Offices
	Schedule 5	  	Inventory and Equipment Locations
	Schedule 6	  	Intellectual Property
	Schedule 7	  	Material Government Contracts

  
 ii 

 GUARANTEE AND COLLATERAL AGREEMENT 

GUARANTEE AND COLLATERAL AGREEMENT, dated as of June 6, 2012, made by each of the signatories hereto (together
with any other entity that may become a party hereto as provided herein, the “Grantors”), in favor of JPMorgan Chase Bank, N.A., as Administrative Agent (in such capacity, the “Administrative Agent”) for the banks
and other financial institutions or entities (the “Lenders”) from time to time parties to the Credit Agreement, dated as of June 6, 2012 (as amended, restated, replaced, supplemented or otherwise modified from time to time, the
“Credit Agreement”), among VCPH Holding Corp. (“Holdings”) Wolverine Healthcare Analytics, Inc. (the “Borrower”) (subject to the contemplated merger of the Borrower with and into Thomson Reuters (Healthcare) Inc. (“TRHI”) with
TRHI surviving the merger as a wholly owned subsidiary of Holdings, whereupon TRHI will accede to this Agreement), Morgan Stanley Senior Funding, Inc. and UBS Securities LLC, as co-documentation agents, Merrill Lynch, Pierce, Fenner & Smith
Incorporated, as syndication agent, the Lenders and the Administrative Agent. 
 W I T N E
S S E T H: 
 WHEREAS, pursuant to the Credit Agreement, the Lenders have severally agreed to
make extensions of credit to the Borrower upon the terms and subject to the conditions set forth therein; 
 WHEREAS, the
Borrower is a direct wholly owned Subsidiary of Holdings; 
 WHEREAS, the proceeds of the extensions of credit under the Credit
Agreement will be used in part to finance the Acquisition, and otherwise for general corporate purposes of the Borrower, including the operation of the businesses of the Borrower and the Grantors; 

WHEREAS, each Grantor will derive substantial direct and indirect benefit from the making of the extensions of credit under the Credit
Agreement; and 
 WHEREAS, it is a condition precedent to the obligation of the Lenders to make their respective extensions of
credit to the Borrower under the Credit Agreement that each Grantor shall have executed and delivered this Agreement to the Administrative Agent for the ratable benefit of the Secured Parties; 

NOW, THEREFORE, in consideration of the premises and to induce the Administrative Agent and the Lenders to enter into the Credit
Agreement and to induce the Lenders to make their respective extensions of credit to the Borrower thereunder, each Grantor hereby agrees with the Administrative Agent, for the ratable benefit of the Secured Parties, as follows: 

SECTION 1. DEFINED TERMS 
 1.1 Definitions. (a) Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement, and the following
terms are used herein as defined in Article 8 or 9 of the New York UCC: Accounts, Certificated Security, Chattel Paper, Commercial Tort Claims, Documents, Equipment, Farm Products, Fixtures, General Intangibles, Goods, Instruments, Inventory,
Letter-of-Credit Rights, Records and Supporting Obligations. 

 (b) The following terms shall have the following meanings: 

“Actual Knowledge”: with respect to a Grantor, the actual knowledge of the chief executive officer, president, chief
financial officer, treasurer, comptroller or general counsel of the Borrower or such Grantor. 
 “Agreement”:
this Guarantee and Collateral Agreement, as the same may be amended, restated, replaced, supplemented or otherwise modified from time to time. 
 “Borrower Obligations”: the collective reference to the unpaid principal of and interest on the Loans and Reimbursement Obligations and all other obligations and liabilities of the
Borrower (including, without limitation, interest accruing at the then applicable rate provided in the Credit Agreement after the maturity of the Loans and Reimbursement Obligations and interest accruing at the then applicable rate provided in the
Credit Agreement after the filing of any petition in bankruptcy, or the commencement of any insolvency, reorganization or like proceeding, relating to the Borrower, whether or not a claim for post-filing or post-petition interest is allowed in such
proceeding) to the Administrative Agent or any Lender (or, in the case of any Specified Swap Agreement or Specified Cash Management Agreement, any Affiliate of any Lender), whether direct or indirect, absolute or contingent, due or to become due, or
now existing or hereafter incurred, which may arise under, out of, or in connection with, the Credit Agreement, this Agreement, the other Loan Documents, any Letter of Credit, any Specified Swap Agreement or any Specified Cash Management Agreement,
in each case whether on account of principal, interest, reimbursement obligations, fees, indemnities, costs, expenses or otherwise (including, without limitation, all reasonable and documented fees and disbursements of counsel to the Administrative
Agent or to the Lenders that are required to be paid by the Borrower pursuant to the terms of any of the Loan Documents). 

“Collateral”: as defined in Section 3. 
 “Collateral Account”: any collateral account established by the Administrative Agent as provided in Section 6.1 or 6.4. 

“Contract”: any written agreement, contract, subcontract, purchase order, arrangement, obligation or commitment to which
a party is bound. 
 “Copyrights”: all copyrights, published and unpublished original works of authorship
(including software to the extent it constitutes an original work of authorship) fixed in any tangible media (including, without limitation, those registered copyrights listed in Schedule 6 as such schedule may be amended or supplemented from
time to time), and registrations and applications therefor, and all renewals, extensions, restorations, and reversions thereof. 

“Deposit Account”: as defined in the Uniform Commercial Code of any applicable jurisdiction and, in any event,
including, without limitation, any demand, time, savings, passbook or like account maintained with a depositary institution. 

“Government Contract”: any Contract to which a Grantor is a party and a counterparty is the United States Government to
the extent such Contract involves the performance of services or delivery of Goods by or on behalf of such Loan Party to the United States Government. 
 “Guarantor Obligations”: with respect to any Guarantor, all obligations and liabilities of such Guarantor which may arise under or in connection with this Agreement (including, without
limitation, Section 2) or any other Loan Document, any Specified Swap Agreement or any Specified Cash Management Agreement to which such Guarantor is a party, in each case whether on account of guarantee obligations, reimbursement obligations,
fees, indemnities, costs, expenses or otherwise (including, without limitation, all reasonable and documented fees and disbursements of counsel to the Administrative Agent or to the Lenders that are required to be paid by such Guarantor pursuant to
the terms of this Agreement or any other Loan Document). 

  
 2 

 “Guarantors”: the collective reference to each Grantor other than the
Borrower. 
 “Intellectual Property”: the collective reference to all intellectual property, whether arising
under United States, multinational or foreign laws or otherwise, including, without limitation, the Copyrights, the Patents, the Trademarks and the Trade Secrets, and all rights to sue at law or in equity for any infringement or other impairment
thereof, including the right to receive all proceeds and damages therefrom. 
 “Intercompany Note”: any
promissory note evidencing loans made by any Grantor to Holdings or any of its Subsidiaries. 
 “Investment
Property”: the collective reference to (i) all “investment property” as such term is defined in Section 9-102(a)(49) of the New York UCC (other than any stock excluded from the definition of “Pledged Stock”)
and (ii) whether or not constituting “investment property” as so defined, all Pledged Notes and all Pledged Stock. 
 “Issuers”: the collective reference to each issuer of any Investment Property. 
 “Material Government Contracts”: each Government Contract: 
  

	 	(i)	having a duration of one year or greater, 

  

	 	(ii)	involving aggregate consideration payable (or expected gross revenue) by the applicable governmental entity to the applicable Grantor of $5,000,000 or more per annum,
including base period plus priced options (or a lesser amount to the extent necessary to ensure that Material Government Contracts include Government Contracts that yield, in aggregate, at least 90% of the consolidated gross revenue of the Borrower
and its Subsidiaries per annum); and 

  

	 	(iii)	which are not subject to the provisions of Federal Acquisition Regulation 52.232-24 or any successor provision; 

provided that “Material Government Contracts” shall not include any contract the existence of which may not be disclosed to the Secured
Parties under applicable law, rule or regulations. The Material Government Contracts existing on the Closing Date are listed on Schedule 7. 
 “New York UCC”: the Uniform Commercial Code as from time to time in effect in the State of New York. 
 “Obligations”: (i) in the case of the Borrower, the Borrower Obligations, and (ii) in the case of each Guarantor, its Guarantor Obligations. 

“paid in full” or “payment in full” or “pay such amounts in full”: the payment in full
in cash of the Obligations, including the unpaid principal of and accrued interest (including interest accruing at the then applicable rate provided in the Credit Agreement after the filing of any petition in bankruptcy, or the commencement of any
insolvency, reorganization or like proceeding, relating to the Borrower, whether or not a claim for post-filing or post-petition interest is allowed in such proceeding) on all 

  
 3 

 Obligations, and, with respect to Letters of Credit outstanding, delivery of cash collateral in an amount
not less than 105% of the aggregate undrawn face amount thereof or backstop letters of credit from issuing lenders satisfactory to the Administrative Agent in respect thereof in an amount not less than 105% of the aggregate undrawn face amount
thereof in compliance with the Loan Documents, after or concurrently with termination of all Commitments and payment in full in cash of all fees, expenses and other amounts constituting Obligations. 

“Patents”: all technology, inventions and discoveries, whether patentable or not (including, without limitation, those
listed on Schedule 6 as such schedule may be amended or supplemented from time to time), and all patents and applications therefor, including divisionals, continuations, continuations-in-part, renewals, extensions, reissues and
reexaminations. 
 “Pledged Notes”: all promissory notes listed on Schedule 2 (as such schedule may be
amended or supplemented from time to time), all Intercompany Notes at any time issued to any Grantor and all other promissory notes issued to or held by any Grantor (other than promissory notes issued in connection with extensions of trade credit by
any Grantor in the ordinary course of business). 
 “Pledged Stock”: the shares of Capital Stock listed on
Schedule 2 (as such schedule may be amended or supplemented from time to time), together with any other shares, stock certificates, options, interests or rights of any nature whatsoever in respect of the Capital Stock of any Person that may
be issued or granted to, or held by, any Grantor while this Agreement is in effect; provided that in no event shall stock of a (x) CFC, (y) Domestic Subsidiary of a CFC or (z) CFC Holdco constitute Pledged Stock (except, in
each case, non-voting stock and 66% of the total outstanding voting Capital Stock thereof held directly by a Grantor). 

“Proceeds”: all “proceeds” as such term is defined in Section 9-102(a)(64) of the New York UCC and, in
any event, shall include, without limitation, all dividends or other income from the Investment Property, collections thereon or distributions or payments with respect thereto. 

“Receivable”: any right to payment for goods sold or leased or for services rendered, whether or not such right is
evidenced by an Instrument or Chattel Paper and whether or not it has been earned by performance (including, without limitation, any Account). 
 “Registered”: issued by, registered with, renewed by or the subject of a pending application before any governmental entity or Internet domain name registrar. 

“Secured Parties”: the collective reference to the Administrative Agent, the Lenders and any affiliate of any Lender to
which Borrower Obligations or Guarantor Obligations, as applicable, are owed. 
 “Securities Act”: the
Securities Act of 1933, as amended. 
 “Trademarks”: all trademarks, trade names, logos, service marks, and
other indicia of origin, all registrations and applications for any of the foregoing, and all goodwill associated therewith and symbolized thereby (including, without limitation, those registered trademarks listed on Schedule 6 as such
schedule may be amended or supplemented from time to time), including all renewals of same. 
 “Trade Secrets”:
all know-how and proprietary or confidential information that qualify as protectable trade secrets under applicable law. 

  
 4 

 “United States Government”: the federal government of the United States and
any agencies, instrumentalities and departments thereof. 
 “Vehicles”: all cars, trucks, trailers,
construction and earth moving equipment and other vehicles covered by a certificate of title law of any state and appurtenances to any of the foregoing. 
 1.2 Other Definitional Provisions. (a) The words “hereof,” “herein”, “hereto” and “hereunder” and words of similar import when used in this Agreement
shall refer to this Agreement as a whole and not to any particular provision of this Agreement, and Section and Schedule references are to this Agreement unless otherwise specified. 

(b) The meanings given to terms defined herein shall be equally applicable to both the singular and plural forms of such terms.

 (c) Where the context requires, terms relating to the Collateral or any part thereof, when used in relation to a Grantor,
shall refer to such Grantor’s Collateral or the relevant part thereof. 
 SECTION 2. GUARANTEE 

2.1 Guarantee. (a) Each of the Guarantors hereby, jointly and severally, unconditionally and irrevocably, guarantees to the
Administrative Agent, for the ratable benefit of the Secured Parties and their respective successors, indorsees, transferees and assigns, the prompt and complete payment and performance by the Borrower when due (whether at the stated maturity, by
acceleration or otherwise) of the Borrower Obligations. 
 (b) Anything herein or in any other Loan Document to the contrary
notwithstanding, the maximum liability of each Guarantor hereunder and under the other Loan Documents shall in no event exceed the amount which can be guaranteed by such Guarantor under applicable federal and state laws relating to fraudulent
conveyances or transfers or the insolvency of debtors (after giving effect to the right of contribution established in Section 2.2). 
 (c) Each Guarantor agrees that the Borrower Obligations may at any time and from time to time exceed the amount of the liability of such Guarantor hereunder without impairing the guarantee of such Grantor
contained in this Section 2 or affecting the rights and remedies of the Administrative Agent or any Lender hereunder. 

(d) The guarantee contained in this Section 2 shall remain in full force and effect until all the Borrower Obligations and the
obligations of each Guarantor under the guarantee contained in this Section 2 shall have been satisfied by payment in full, notwithstanding that from time to time during the term of the Credit Agreement the Borrower may be free from any
Borrower Obligations, subject to the right of a Guarantor to be released from its obligations under this Agreement pursuant to Section 8.15(b). 
 (e) No payment made by the Borrower, any of the Guarantors, any other guarantor or any other Person or received or collected by the Administrative Agent or any Lender from the Borrower, any of the
Guarantors, any other guarantor or any other Person by virtue of any action or proceeding or any set-off or appropriation or application at any time or from time to time in reduction of or in payment of the Borrower Obligations shall be deemed to
modify, reduce, release or otherwise affect the liability of any Guarantor hereunder which shall, notwithstanding any such payment (other than any payment made by such Guarantor in respect of the Borrower Obligations or any payment received or
collected from such Guarantor in respect of the Borrower Obligations), remain liable for the Borrower Obligations up to the maximum liability of such Guarantor hereunder until the Borrower Obligations are paid in full. 

  
 5 

 2.2 Right of Contribution. Each Subsidiary Guarantor hereby agrees that to the extent
that a Subsidiary Guarantor shall have paid more than its proportionate share of any payment made hereunder, such Subsidiary Guarantor shall be entitled to seek and receive contribution from and against any other Subsidiary Guarantor hereunder which
has not paid its proportionate share of such payment. Each Subsidiary Guarantor’s right of contribution shall be subject to the terms and conditions of Section 2.3. The provisions of this Section 2.2 shall in no respect limit the
obligations and liabilities of any Subsidiary Guarantor to the Administrative Agent and the Lenders, and each Subsidiary Guarantor shall remain liable to the Administrative Agent and the Lenders for the full amount guaranteed by such Subsidiary
Guarantor hereunder. 
 2.3 No Subrogation. Notwithstanding any payment made by any Guarantor hereunder or any set-off or
application of funds of any Guarantor by the Administrative Agent or any Lender, no Guarantor shall be entitled to be subrogated to any of the rights of the Administrative Agent or any Lender against the Borrower or any other Guarantor or any
collateral security or guarantee or right of offset held by the Administrative Agent or any Lender for the payment of the Borrower Obligations, nor shall any Guarantor seek or be entitled to seek any contribution or reimbursement from the Borrower
or any other Guarantor in respect of payments made by such Guarantor hereunder, until all amounts owing to the Administrative Agent and the Lenders by the Borrower on account of the Borrower Obligations are paid in full. If any amount shall be paid
to any Guarantor on account of such subrogation rights at any time when all of the Borrower Obligations shall not have been paid in full, such amount shall be held by such Guarantor in trust for the Administrative Agent and the Lenders, segregated
from other funds of such Guarantor, and shall, forthwith upon receipt by such Guarantor, be turned over to the Administrative Agent in the exact form received by such Guarantor (duly indorsed by such Guarantor to the Administrative Agent, if
required), to be applied against the Borrower Obligations, whether matured or unmatured, in accordance with the Loan Documents. 

2.4 Amendments, etc. with respect to the Borrower Obligations. Each Guarantor shall remain obligated hereunder notwithstanding
that, without any reservation of rights against any Guarantor and without notice to or further assent by any Guarantor, any demand for payment of any of the Borrower Obligations made by the Administrative Agent or any Lender may be rescinded by the
Administrative Agent or such Lender and any of the Borrower Obligations continued, and the Borrower Obligations, or the liability of any other Person upon or for any part thereof, or any collateral security or guarantee therefor or right of offset
with respect thereto, may, from time to time, in whole or in part, be renewed, extended, amended, modified, accelerated, compromised, waived, surrendered or released by the Administrative Agent or any Lender, and the Credit Agreement and the other
Loan Documents and any other documents executed and delivered in connection therewith may be amended, modified, supplemented, replaced or terminated, in whole or in part, as the Administrative Agent (or the Required Lenders, Majority Facility
Lenders or all Lenders, as the case may be) may deem advisable from time to time, and any collateral security, guarantee or right of offset at any time held by the Administrative Agent or any Lender for the payment of the Borrower Obligations may be
sold, exchanged, waived, surrendered or released. Neither the Administrative Agent nor any Lender shall have any obligation to protect, secure, perfect or insure any Lien at any time held by it as security for the Borrower Obligations or for the
guarantee contained in this Section 2 or any property subject thereto. 
 2.5 Guarantee Absolute and Unconditional.
Each Guarantor waives (to the extent not prohibited by applicable law) any and all notice of the creation, renewal, extension or accrual of any of the Borrower Obligations and notice of or proof of reliance by the Administrative Agent or any Lender
upon the guarantee contained in this Section 2 or acceptance of the guarantee contained in this Section 2; 

  
 6 

 the Borrower Obligations, and any of them, shall conclusively be deemed to have been created, contracted or
incurred, or renewed, extended, amended or waived, in reliance upon the guarantee contained in this Section 2; and all dealings between the Borrower and any of the Guarantors, on the one hand, and the Administrative Agent and the
Lenders, on the other hand, likewise shall be conclusively presumed to have been had or consummated in reliance upon the guarantee contained in this Section 2. Each Guarantor waives (to the extent not prohibited by applicable law) diligence,
presentment, protest, demand for payment and notice of default or nonpayment to or upon the Borrower or any of the Guarantors with respect to the Borrower Obligations. Each Guarantor understands and agrees that the guarantee of such Guarantor
contained in this Section 2 shall be construed as a continuing, absolute and unconditional guarantee of payment without regard to (a) the validity or enforceability of the Credit Agreement or any other Loan Document, any of the Borrower
Obligations or any other collateral security therefor or guarantee or right of offset with respect thereto at any time or from time to time held by the Administrative Agent or any Lender, (b) any defense, set-off or counterclaim (other than a
defense of payment or performance) which may at any time be available to or be asserted by the Borrower or any other Person against the Administrative Agent or any Lender, or (c) any other circumstance whatsoever (with or without notice to or
knowledge of the Borrower or such Guarantor) which constitutes, or might be construed to constitute, an equitable or legal discharge of the Borrower for the Borrower Obligations, or of such Guarantor under the guarantee contained in this
Section 2, in bankruptcy or in any other instance. When making any demand hereunder or otherwise pursuing its rights and remedies hereunder against any Guarantor, the Administrative Agent or any Lender may, but shall be under no obligation to,
make a similar demand on or otherwise pursue such rights and remedies as it may have against the Borrower, any other Guarantor or any other Person or against any collateral security or guarantee for the Borrower Obligations or any right of offset
with respect thereto, and any failure by the Administrative Agent or any Lender to make any such demand, to pursue such other rights or remedies or to collect any payments from the Borrower, any other Guarantor or any other Person or to realize upon
any such collateral security or guarantee or to exercise any such right of offset, or any release of the Borrower, any other Guarantor or any other Person or any such collateral security, guarantee or right of offset, shall not relieve any Guarantor
of any obligation or liability hereunder, and shall not impair or affect the rights and remedies, whether express, implied or available as a matter of law, of the Administrative Agent or any Lender against any Guarantor. For the purposes hereof
“demand” shall include the commencement and continuance of any legal proceedings. 
 2.6 Reinstatement. The
guarantee contained in this Section 2 shall continue to be effective, or be reinstated, as the case may be, if at any time payment, or any part thereof, of any of the Borrower Obligations is rescinded or must otherwise be restored or returned
by the Administrative Agent or any Lender upon the insolvency, bankruptcy, dissolution, liquidation or reorganization of the Borrower or any Guarantor, or upon or as a result of the appointment of a receiver, intervenor or conservator of, or trustee
or similar officer for, the Borrower or any Guarantor or any substantial part of its property, or otherwise, all as though such payments had not been made. 
 2.7 Payments. Each Guarantor hereby guarantees that payments hereunder will be paid to the Administrative Agent without set-off or counterclaim in Dollars at the Funding Office. 

SECTION 3. GRANT OF SECURITY INTEREST 
 Each Grantor hereby grants to the Administrative Agent, for the ratable benefit of the Secured Parties, a security interest in all of such Grantor’s right, title and interest in and to the following
property now owned or at any time hereafter acquired by such Grantor or in which such Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the “Collateral”), as collateral security for
the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of such Grantor’s Obligations: 

  
 7 

 (a) all Accounts; 
 (b) all Chattel Paper; 
 (c) all Contracts; 

(d) all Deposit Accounts; 
 (e) all Documents (other than title documents with respect to Vehicles, except as set forth in clause (n) below); 
 (f) all Equipment; 
 (g) all Fixtures; 

(h) all General Intangibles; 
 (i) all Instruments; 
 (j) all Intellectual Property; 

(k) all Inventory; 
 (l) all Investment Property; 
 (m) all Letter-of-Credit Rights;

 (n) upon the making of a request by the Administrative Agent pursuant to Section 5.11 hereof, all Vehicles and title
documents with respect to Vehicles; 
 (o) all Commercial Tort Claims specified on Schedule 3.1 (as such schedule may be amended
or supplemented from time to time); 
 (p) all other property not otherwise described above (except for any property
specifically excluded from any clause in this section above, and any property specifically excluded from any defined term used in any clause of this section above); 
 (q) all books and Records pertaining to the Collateral; and 
 (r) to the extent
not otherwise included, all Proceeds, Supporting Obligations and products of any and all of the foregoing and all collateral security and guarantees given by any Person with respect to any of the foregoing; 

provided, however, that notwithstanding any of the other provisions set forth herein or any other Loan Document to the contrary,
the term “Collateral” shall not include and this Agreement shall not constitute a grant of a security interest in (i) any property to the extent that such grant of a security interest (A) is prohibited by any Requirements of Law,
(B) requires a consent not obtained of any Governmental Authority pursuant to such Requirement of Law or is prohibited by, or constitutes a breach or default under or results in the termination (other than by Holdings or any of its
Subsidiaries) of or 

  
 8 

 requires any consent not obtained under, any contract, lease, license, agreement, instrument or other
document evidencing or giving rise to such property or, in the case of any Investment Property, Pledged Stock or Pledged Note, any applicable shareholder or similar agreement, except to the extent that such Requirement of Law or the term in such
contract, lease, license, agreement, instrument or other document or shareholder or similar agreement providing for such prohibition, breach, default or termination or requiring such consent is ineffective under applicable law; provided that
proceeds or receivables in respect of any property described in this clause (B) shall be “Collateral” to the extent not prohibited by any Requirement of Law, or (C) would result in the invalidation thereof with respect to any
intent-to-use Trademark application for which an amendment to allege use or statement of use has not been filed under 15 U.S.C. § 1051(d), respectively, or if filed, has not been deemed in conformance with 15 U.S.C. § 1051(a) or examined
and accepted, respectively, by the United States Patent and Trademark Office, solely to the extent that, and solely during the period in which, the grant of a security interest therein would impair the validity or enforceability of any registration
that issues from such intent-to-use application under applicable federal law, (ii) any Deposit Accounts and Securities Accounts in which funds are maintained and used, in the ordinary course of business, solely for the payment of salaries and
wages, workers’ compensation, 401K, health and welfare plans and similar expenses, (iii) any other asset for which the cost of obtaining or causing a Grantor to grant a security interest in such asset is excessive in relation to the
benefit or value of the security that would be afforded thereby to the Secured Parties as determined by the Administrative Agent in its sole discretion, (iv) stock of a (A) CFC, (B) Domestic Subsidiary of a CFC or (C) CFC Holdco
(except, in each case, non-voting stock and 66% of the total outstanding voting Capital Stock thereof held directly by a Grantor), (v) assets owned by any Grantor on the date hereof or hereafter acquired that are subject to a Lien permitted to
be incurred or outstanding pursuant to Section 7.3(g), (k) or (o) of the Credit Agreement if the contract or agreement in which such Lien is granted (or the documentation providing for such Lien) prohibits the creation by such Grantor
of a security interest or Lien thereon or requires the consent of any Person other than Holdings and its Subsidiaries as a condition to the creation of any other security interest or Lien on such assets or if such contract would be breached or give
any party other than Holdings and its Subsidiaries any right to terminate as a result of creation of such security interest or Lien and (vi) stock of any joint venture (or a holding company parent thereof), including any JV Subsidiary, to the
extent not required to be pledged pursuant to the Credit Agreement or to the extent such assignment, pledge or grant requires, pursuant to the constituent documents of such JV Subsidiary or joint venture, shareholder or like agreement binding on any
shareholder, partner or member of such Person, the consent of any governing body, shareholder, partner or member of such Person (other than Holdings or any of its Affiliates) and such consent shall not have been obtained after the use of
commercially reasonable efforts. 
 SECTION 4. REPRESENTATIONS AND WARRANTIES 

To induce the Administrative Agent and the Lenders to enter into the Credit Agreement and to induce the Lenders to make their respective
extensions of credit to the Borrower thereunder, each Grantor hereby represents and warrants to the Administrative Agent and each Lender that: 
 4.1 Title; No Other Liens. Except for the security interest granted to the Administrative Agent for the ratable benefit of the Secured Parties pursuant to this Agreement and the other Liens
permitted to exist on the Collateral by the Credit Agreement (“Permitted Liens”), such Grantor owns each item of the Collateral material to the operations of the Business free and clear of any and all Liens. For the avoidance of
doubt, it is understood and agreed that any Grantor may, as part of its business, grant licenses in the ordinary course of business to third parties to use Intellectual Property owned or developed by a Grantor. For purposes of this Agreement and the
other Loan Documents, such licensing activity shall not constitute a “Lien” on such Intellectual Property. Each of the Administrative Agent and each 

  
 9 

 Lender understands that any such licenses may be exclusive to the applicable licensees, and such exclusivity
provisions may limit the ability of the Administrative Agent to utilize, sell, lease or transfer the related Intellectual Property or otherwise realize value from such Intellectual Property pursuant hereto. 

4.2 Perfected First Priority Liens. The security interests granted pursuant to this Agreement, upon execution and delivery of this
Agreement by the parties hereto, will create in favor of the Administrative Agent, for the benefit of the Secured Parties, a valid and enforceable security interest in the Collateral and (a) when the Collateral constituting Instruments,
tangible Chattel Paper and certificated Pledged Stock and Pledged Notes is delivered to the Administrative Agent, together with instruments of transfer duly endorsed in blank, the security interest created under this Agreement will constitute a
perfected first priority security interest in all right, title and interest of the Grantors in such Collateral, subject only to Permitted Liens, (b) with respect to Collateral consisting of Registered United States Intellectual Property, when
filings substantially in the form of Annex 2 have been made at the United States Patent and Trademark Office and the United States Copyright Office, as applicable will constitute a perfected first priority security interest in all Registered United
States Intellectual Property to the extent perfection can be obtained by such filings and (c) upon the filing of all Uniform Commercial Code financing statements, naming each Grantor as “debtor” and the Administrative Agent as
“secured party” and describing the Collateral as “all property”, “all assets” or “all personal property”, in the appropriate filing offices for each such Grantor, the security interest created under this
Agreement will constitute a perfected first priority security interest in all right, title and interest of the Grantors in the remaining Collateral to the extent perfection can be obtained by filing Uniform Commercial Code financing statements,
except for rights secured by Permitted Liens and the exceptions set forth in the Credit Agreement, or the schedules thereto. 

4.3 Jurisdiction of Organization; Chief Executive Office. On the date hereof, such Grantor’s jurisdiction of organization,
identification number from the jurisdiction of organization (if any), and the location of such Grantor’s chief executive office or principal place of business as the case may be, are specified on Schedule 4. Such Grantor has furnished to the
Administrative Agent a certified charter, certificate of incorporation or other organization document and long-form good standing certificate as of a date which is recent to the date hereof. 

4.4 Inventory and Equipment. On the date hereof, the Inventory and the Equipment (other than mobile goods) are kept at the
locations listed on Schedule 5. 
 4.5 Farm Products. None of the Collateral constitutes, or is the Proceeds of, Farm
Products. 
 4.6 Investment Property. (a) The shares of Pledged Stock pledged by such Grantor hereunder constitute
all the issued and outstanding shares of all classes of the Capital Stock of each Issuer owned by such Grantor (except in the case of an Issuer that is a CFC, Domestic Subsidiary of a CFC or a CFC Holdco, in which case the Pledged Stock will only
consist of the non-voting stock and 66% of the outstanding voting Capital Stock thereof held directly by a Grantor). 
 (b) All
the shares of the Pledged Stock have been duly and validly issued and are fully paid and non-assessable. 
 (c) Each of the
Pledged Notes constitutes the legal, valid and binding obligation of the obligor with respect thereto, enforceable in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and
other similar laws relating to or affecting creditors’ rights generally, general equitable principles (whether considered in a proceeding in equity or at law) and an implied covenant of good faith and fair dealing. 

  
 10 

 (d) Such Grantor is the record and beneficial owner of, and has good and marketable title
to, the Pledged Notes and Pledged Stock pledged by it hereunder, free of any and all Liens or options in favor of, or claims of, any other Person, except the security interest created by this Agreement. 

4.7 Receivables. No amount in excess of $250,000 that is payable to such Grantor under or in connection with any Receivable is
evidenced by any Instrument or tangible Chattel Paper which has not been delivered to the Administrative Agent. 
 4.8
Material Government Contracts. (a) Schedule 7 lists all Material Government Contracts to which the Borrower or any of its Subsidiaries is a party on the date hereof. 

(b) No consent of any party (other than such Grantor) to any Material Government Contract is required, or purports to be required, in
connection with the execution, delivery and performance of this Agreement, except as has been obtained or will be obtained in connection with any Assignments of Claims submitted in accordance with Section 5.7(e) of this Agreement. 

(c) Each Material Government Contract is in full force and effect and constitutes a valid and legally enforceable obligation of the
parties thereto, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting creditors’ rights generally, general equitable principles (whether considered
in a proceeding in equity or at law) and an implied covenant of good faith and fair dealing. 
 (d) None of the Material
Government Contracts prohibit the novation of the contract in accordance with the Assignment of Claims Act, 31 U.S.C. 3727, 41 U.S.C. 15, and the Grantors will submit the documentation required under the Assignment of Claims Act to the U.S.
Government seeking approval of the novation of each such Material Government Contract. 
 (e) Neither such Grantor nor (to the
best of such Grantor’s knowledge) any of the other parties to the Material Government Contracts is in default in the performance or observance of any of the terms thereof. 

(f) To best of each such Grantor’s knowledge, the right, title and interest of such Grantor in, to and under the Material Government
Contracts are not subject to any defenses, offsets, counterclaims or claims. 
 (g) Subject to Section 6.12 of the Credit
Agreement, such Grantor has delivered to the Administrative Agent a complete and correct copy of each Material Government Contract, including all amendments, supplements and other modifications thereto to the extent permitted by law. 

(h) No amount in excess of $250,000 that is payable to such Grantor under or in connection with any Material Government Contract is
evidenced by any Instrument or Chattel Paper which has not been delivered to the Administrative Agent. 
 4.9 Intellectual
Property. (a) Schedule 4.9(a) lists (i) all Registered United States Patents and Trademarks owned by such Grantor in its own name on the date hereof, and (ii) Registered United States Copyrights, as set forth therein.

 (b) On the date hereof, to such Grantor’s Actual Knowledge, all material Intellectual Property owned by such Grantor is
valid, subsisting, and unexpired, and has not been abandoned and is not being infringed by any other Person. 

  
 11 

 (c) No holding, decision or judgment has been rendered by any Governmental Authority against
such Grantor which would limit or cancel the validity of, or such Grantor’s rights in, any Intellectual Property owned by such Grantor in any respect that could reasonably be expected to have a Material Adverse Effect. 

(d) No claim, action or proceeding is pending, or, to the knowledge of such Grantor, has been threatened in writing, on the date hereof
(i) seeking to limit or cancel the validity of any Intellectual Property that is material to the operation of the Business or such Grantor’s ownership interest therein, or (ii) which, if such claim, action or proceeding resulted in an
adverse decision, would reasonably be expected to have a material adverse effect on the value of any such Intellectual Property. 
 4.10 Commercial Tort Claims. 
 (a) On the date hereof, except to the extent
described on Schedule 3.1, no Grantor has rights in any Commercial Tort Claim with potential value in excess of $1,000,000. 
 (b) Upon the filing of a financing statement identifying the Commercial Tort Claim referred to in Section 5.9 hereof against such Grantor in the jurisdiction specified in Schedule 3 hereto, the
security interest granted in such Commercial Tort Claim will constitute a valid perfected security interest in favor of the Administrative Agent, for the ratable benefit of the Secured Parties, as collateral security for such Grantor’s
Obligations, enforceable in accordance with the terms hereof against all creditors of such Grantor and any Persons purporting to purchase such Collateral from Grantor, which security interest shall be prior to all other Liens on such Collateral
except for unrecorded liens permitted by the Credit Agreement which have priority over the Liens on such Collateral by operation of law. 
 SECTION 5. COVENANTS 
 Each Grantor covenants and agrees with the Administrative
Agent and the Lenders that, from and after the date of this Agreement until the Obligations shall have been paid in full: 
 5.1
Delivery of Instruments, Certificated Securities and Chattel Paper. If any amount in excess of $250,000 that is payable under or in connection with any of the Collateral shall be or become evidenced by any Instrument, Certificated Security or
tangible Chattel Paper, such Instrument, Certificated Security or Chattel Paper shall be immediately delivered to the Administrative Agent, duly indorsed in a manner satisfactory to the Administrative Agent, to be held as Collateral pursuant to this
Agreement. 
 5.2 Maintenance of Insurance. (a) Such Grantor will maintain, or cause to be maintained, insurance
coverage as required by Section 6.5 of the Credit Agreement, such policies to be in such form and amounts and having such coverage as may be reasonably satisfactory to the Administrative Agent. 

(b) All such insurance shall, except as otherwise reasonably determined by the Administrative Agent, (i) provide that no
cancellation, material reduction in amount or material change in coverage thereof shall be effective until at least 30 days after receipt by the Administrative Agent of written notice thereof, (ii) insure such Grantor and the Secured Parties
against liability for personal injury and property damage relating to the Collateral, (iii) name the Administrative Agent as insured party and loss payee and (iv) be reasonably satisfactory in all other respects to the Administrative
Agent. 
 5.3 Maintenance of Perfected Security Interest; Further Documentation. (a) Such Grantor shall maintain the
security interest created by this Agreement as a perfected security interest having at 

  
 12 

 
least the priority described in Section 4.2 and shall defend such security interest against the claims and demands of all Persons whomsoever, subject to the rights of such Grantor under the
Loan Documents to dispose of the Collateral or incur Liens permitted by the Credit Agreement. 
 (b) Such Grantor will furnish
to the Administrative Agent and the Lenders from time to time supplements to the schedules further updating or identifying and describing the assets and property of such Grantor as the Administrative Agent may reasonably request, all in reasonable
detail. 
 (c) Subject to Section 5.11, at any time and from time to time, upon the written request of the Administrative
Agent, and at the sole expense of such Grantor, such Grantor will promptly and duly execute and deliver, and have recorded, such further instruments and documents and take such further actions as the Administrative Agent may reasonably request for
the purpose of obtaining or preserving the full benefits of this Agreement and of the rights and powers herein granted, including, without limitation, (i) filing any financing or continuation statements under the Uniform Commercial Code (or
other similar laws) in effect in any jurisdiction with respect to the security interests created hereby, (ii) filing Intellectual Property Short Form Security Agreements substantially in the form of Annex 2 hereof and (iii) in the case of
Investment Property, Deposit Accounts, Letter-of-Credit Rights and any other relevant Collateral, taking any actions necessary to enable the Administrative Agent to obtain “control” (within the meaning of the applicable Uniform Commercial
Code) with respect thereto; provided that this clause (iii) shall not require any Grantor (x) to enter into any control agreement with respect to any Deposit Account or Securities Account or (y) to take any action (other than
the filing of a Uniform Commercial Code financing statement) with respect to any Letter-of-Credit Right with a value individually of less than $250,000. 
 5.4 Changes in Name, etc. Such Grantor will not, except upon 15 days’ prior written notice to the Administrative Agent and delivery to the Administrative. Agent of all additional executed
financing statements and other documents reasonably requested by the Administrative Agent to maintain the validity, perfection and priority of the security interests provided for herein, (i) change its jurisdiction of organization or the
location of its chief executive office or principal place of business from that referred to in Section 4.3 or (ii) change its name. 
 5.5 Notices. Such Grantor will advise the Administrative Agent and the Lenders promptly, in reasonable detail, of: 
 (a) any Lien (other than security interests created hereby or Permitted Liens) on any of the Collateral which would adversely affect the ability of the Administrative Agent to exercise any of its remedies
hereunder; and 
 (b) of the occurrence of any other event which could reasonably be expected to have a material adverse effect
on the aggregate value of all of the Collateral taken as a whole or on the security interests created hereby. 
 5.6
Investment Property. (a) If such Grantor shall become entitled to receive or shall receive any certificate (including, without limitation, any certificate representing a dividend or a distribution in connection with any reclassification,
increase or reduction of capital or any certificate issued in connection with any reorganization), option or rights in respect of the Capital Stock of any Issuer, whether in addition to, in substitution of, as a conversion of, or in exchange for,
any shares of the Pledged Stock, or otherwise in respect thereof, such Grantor shall accept the same as the agent of the Administrative Agent and the Secured Parties, hold the same in trust for the Administrative Agent and the Lenders and deliver
the same forthwith to the Administrative Agent in the exact form received, duly indorsed by such Grantor to the Administrative Agent, if required, together with an undated stock power 

  
 13 

 covering such certificate duly executed in blank by such Grantor and with, if the Administrative Agent so
requests, signature guaranteed, to be held by the Administrative Agent, subject to the terms hereof, as additional collateral security for the Obligations. At any time after the occurrence and during the continuation of an Event of Default, upon
request by the Administrative Agent any sums paid upon or in respect of the Investment Property upon the liquidation or dissolution of any Issuer shall be paid over to the Administrative Agent to be held by it hereunder as additional collateral
security for the Obligations, and in case any distribution of capital shall be made on or in respect of the Investment Property or any property shall be distributed upon or with respect to the Investment Property pursuant to the recapitalization or
reclassification of the capital of any Issuer or pursuant to the reorganization thereof, the property so distributed shall, unless otherwise subject to a perfected security interest in favor of the Administrative Agent, be delivered to the
Administrative Agent to be held by it hereunder as additional collateral security for the Obligations. If any sums of money or property so paid or distributed in respect of the Investment Property shall be received by such Grantor, such Grantor
shall, until such money or property is paid or delivered to the Administrative Agent, hold such money or property in trust for the Administrative Agent and the Secured Parties, segregated from other funds of such Grantor, as additional collateral
security for the Obligations. This Section 5.6(a) shall be subject in all respects to the limitations set forth in Section 4.6. 
 (b) Without the prior written consent of the Administrative Agent, such Grantor will not (i) vote to enable, or take any other action to permit, any Issuer to issue any Capital Stock of any nature or to
issue any other securities convertible into or granting the right to purchase or exchange for any Capital Stock of any nature of any Issuer, (ii) sell, assign, transfer, exchange, or otherwise dispose of, or grant any option with respect to,
the Investment Property or Proceeds thereof, (iii) create, incur or permit to exist any Lien (other than Permitted Liens) or option in favor of, or any claim of any Person with respect to, any of the Investment Property or Proceeds thereof, or
any interest therein, except for the security interests created by this Agreement or (iv) enter into any agreement or undertaking restricting the right or ability of such Grantor or the Administrative Agent to sell, assign or transfer any of
the Investment Property or Proceeds thereof, in each case, except pursuant to any transactions that would not violate the Credit Agreement, this Agreement or any other Loan Document. 

(c) In the case of each Grantor which is an Issuer, such Issuer agrees that (i) it will be bound by the terms of this Agreement
relating to the Investment Property issued by it and will comply with such terms insofar as such terms are applicable to it, (ii) it will notify the Administrative Agent promptly in writing of the occurrence of any of the events described in
Section 5.6(a) with respect to the Investment Property issued by it and (iii) the terms of Sections 6.3(c) and 6.7 shall apply to it, mutatis mutandis, with respect to all actions that may be required of it pursuant to
Section 6.3(c) or 6.7 with respect to the Investment Property issued by it. 
 5.7 Material Government Contracts.
(a) Such Grantor will perform and comply in all material respects with all its obligations under the Material Government Contracts. 
 (b) Such Grantor will not amend, modify, terminate (prior to the stated expiration date) or waive any provision of any Material Government Contract in any manner which could reasonably be expected to
materially adversely affect the aggregate value of all Material Government Contracts, taken as a whole, as Collateral. 
 (c)
Such Grantor will exercise promptly and diligently each material right which it may have under each Material Government Contract (other than any right of termination). 

  
 14 

 (d) Such Grantor will deliver to the Administrative Agent a copy of each material demand,
notice or document received by it from any party that owes obligations relating to any Material Government Contract that contests the validity or enforceability of such Contract to the extent that disclosure of such document is not prohibited by
law. 
 (e) Such Grantor shall (i) on each date that the Borrower is required to deliver financial statements pursuant to
Section 6.1(a) or (b) of the Credit Agreement, deliver to the Administrative Agent an update and supplement to Schedule 7, identifying any new Material Government Contracts entered into since the last date financial statements were
delivered pursuant to Section 6.1(a) and (b) of the Credit Agreement (or, with respect to the first such date financial statements are delivered pursuant to such Sections, since the date hereof), and (ii) within fifteen days of such
notice or, in the case of the Material Government Contracts existing on the Closing Date, within ninety days of the Closing Date, deliver to the Administrative Agent such documentation reasonably necessary to comply with the Assignment of Claims Act
of 1940 with respect to the assignment of the right of payment in respect of all Material Government Contracts. The Administrative Agent shall not submit such documentation to any applicable Governmental Authority unless an Event of Default has
occurred and is continuing. In such event, each such Grantor shall cooperate with the Administrative Agent to facilitate the submission of such documentation and use commercially reasonably efforts to obtain the consent of the applicable
Governmental Authority party to each such Material Government Contract in respect of the assignment of such claims, but any failure to receive such consent shall not constitute a Default. 

5.8 Intellectual Property. (a) Such Grantor (either itself or through licensees) will use commercially reasonable efforts to
(i) use any material Registered Trademark owned by such Grantor in a manner that would not result in abandonment of such Trademark, (ii) maintain as in the past the quality of products and services offered under such material Registered
Trademark, (iii) use such material Registered Trademark with all notices and legends required by applicable Requirements of Law, and (iv) not (and not permit any licensee or sublicensee thereof to) do any act or knowingly omit to do any
act whereby such material Trademark may become invalidated. 
 (b) Except as permitted pursuant to Section 5.8(i), such
Grantor will use commercially reasonable efforts not to do any act, or knowingly omit to do any act, whereby any material issued letter Patent may become forfeited, abandoned or dedicated to the public, except at the end of the life of such Patent.

 (c) Such Grantor will use commercially reasonable efforts not to (and will use commercially reasonable efforts not to permit
any licensee or sublicensee thereof to) do any act or knowingly omit to do any act whereby any material Copyright may become invalidated or abandoned. 
 (d) Such Grantor will not intentionally infringe the Intellectual Property of any other Person. 
 (e) Such Grantor has taken commercially reasonable steps to safeguard its Trade Secrets and, to its Actual Knowledge, none of the Trade Secrets owned by such Grantor has been used, divulged, or disclosed
to any other Person other than such Grantor or its employees, agents, licensees or customers who are bound by confidentiality obligations that reasonably protect the interest of such Grantor. 

(f) Such Grantor will notify the Administrative Agent and the Lenders immediately if it knows, or has reason to know, that any
application or registration relating to any material Intellectual Property may become forfeited, abandoned or dedicated to the public, or of any material adverse determination or development (including, without limitation, the institution of, or any
such determination or development in, any proceeding in the United States Patent and Trademark Office, the United States Copyright Office or any court or tribunal in any country) regarding such Grantor’s ownership of, or the validity of, any
material Intellectual Property or such Grantor’s right to register the same or to own and maintain the same. 

  
 15 

 (g) Whenever such Grantor, either by itself or through any agent, employee, licensee or
designee acquires or becomes an exclusive licensee of any United States Intellectual Property application or registration, or files an application for the registration of any Intellectual Property with the United States Patent and Trademark Office,
the United States Copyright Office or any similar office or agency in any other country or any political subdivision thereof, such Grantor shall report such filing to the Administrative Agent within thirty Business Days after the last day of the
fiscal quarter in which such filing occurs. Upon request of the Administrative Agent, such Grantor shall execute and deliver, and have recorded, an Intellectual Property Short Form Security Agreement substantially in the form of Annex 2 hereof and
any and all agreements, instruments, documents, and papers as the Administrative Agent may reasonably request to evidence the Administrative Agent’s and the Lenders’ security interest in the foregoing to the extent owned by or exclusively
licensed by such Grantor. 
 (h) Such Grantor will take reasonable and necessary steps, including, without limitation, in any
proceeding before the United States Patent and Trademark Office, the United States Copyright Office or any similar office or agency in any other country or any political subdivision thereof, to maintain and pursue each application (and to obtain the
relevant registration) and to maintain each registration of the material Intellectual Property owned by such Grantor, including, without limitation, filing, of applications for renewal, affidavits of use and affidavits of incontestability, and
payment of maintenance fees, unless such Grantor decides, in its reasonable business judgment, not to pursue or maintain any such application or registration. 
 (i) In the event that, to the Actual Knowledge of such Grantor, any material Intellectual Property owned by such Grantor is infringed, misappropriated or diluted by a third party, such Grantor shall
(i) take such actions as such Grantor shall reasonably deem appropriate under the circumstances to protect such material Intellectual Property and (ii) promptly notify the Administrative Agent after it learns thereof. 

5.9 Commercial Tort Claims. If such Grantor shall obtain an interest in any Commercial Tort Claim with a potential value in excess
of $1,000,000, such Grantor shall within 30 days of obtaining such interest sign and deliver documentation acceptable to the Administrative Agent granting a security interest under the terms and provisions of this Agreement in and to such Commercial
Tort Claim. 
 5.10 Receivables. To the extent permitted by applicable law, such Grantor will deliver to the
Administrative Agent a copy of each material demand, notice or document received by it from one or more parties that owe obligations in respect of Receivables to such Grantor contesting the validity or enforceability of more than 10% of the
aggregate amount of all then outstanding Receivables of all Grantors taken as a whole. 
 5.11 Perfection of Assets Covered
by Certificates of Title. Prior to the occurrence and continuance of any Event of Default, except to the extent perfection may be accomplished by the filing of financing statements under the Uniform Commercial Code, nothing herein shall obligate
any Grantor to take any actions to perfect the security interest granted pursuant to this Agreement in any Vehicles or equipment or other property of any Grantor constituting Collateral covered by certificates of title (except if the aggregate value
thereof for all Grantors is $500,000 or more, in which event, the applicable Grantors shall be required to notify the Administrative Agent promptly of their interest therein and to take the actions specified in the immediately succeeding sentence
promptly following the request of the Administrative Agent). During the continuance of an Event of Default, promptly following the request of the Administrative Agent, all applications for certificates of title/ownership indicating the
Administrative Agent’s security interest in any Vehicle or any other such property constituting Collateral covered by such certificate, and any other necessary documentation, shall be filed in each office in each jurisdiction which the
Administrative Agent shall deem necessary to perfect its security interests in any such Vehicles or other such property constituting Collateral covered by certificates of title. 

  
 16 

 SECTION 6. REMEDIAL PROVISIONS 

6.1 Certain Matters Relating to Receivables. (a) After the occurrence and during the continuance of an Event of Default, the
Administrative Agent shall have the right with notice to the Borrower to make test verifications of the Receivables in any manner and through any medium that it reasonably considers advisable, and each Grantor shall, to the extent permitted by
applicable law, furnish all such assistance and information as the Administrative Agent may reasonably require in connection with such test verifications. At any time and from time to time after the occurrence and during the continuance of an Event
of Default, upon the Administrative Agent’s request and at the expense of the relevant Grantor, such Grantor shall cause independent public accountants or others satisfactory to the Administrative Agent to furnish to the Administrative Agent
reports showing reconciliations, aging and test verifications of, and trial balances for, the Receivables. 
 (b) The
Administrative Agent hereby authorizes each Grantor to collect such Grantor’s Receivables, and the Administrative Agent may curtail or terminate said authority at any time after the occurrence and during the continuance of an Event of Default.
If required by the Administrative Agent at any time after the occurrence and during the continuance of an Event of Default, any payments of Receivables, when collected by any Grantor, (i) shall be forthwith (and, in any event, within two
Business Days) deposited by such Grantor in the exact form received, duly indorsed by such Grantor to the Administrative Agent if required, in a Collateral Account maintained under the sole dominion and control of the Administrative Agent, subject
to withdrawal by the Administrative Agent for the account of the Lenders only as provided in Section 6.5, and (ii) until so turned over, shall be held by such Grantor in trust for the Administrative Agent and the Secured Parties,
segregated from other funds of such Grantor. Each such deposit of Proceeds of Receivables shall be accompanied by a report identifying in reasonable detail the nature and source of the payments included in the deposit. 

(c) After the occurrence and during the continuance of an Event of Default, at the Administrative Agent’s request, each Grantor
shall deliver to the Administrative Agent all original and other documents in its possession and control evidencing, and relating to, the agreements and transactions which gave rise to the Receivables, as the Administrative Agent shall reasonably
request and to the extent permitted by applicable law. 
 6.2 Communications with Obligors; Grantors Remain Liable.
(a) The Administrative Agent in its own name or in the name of others may at any time after the occurrence and during the continuance of an Event of Default communicate with obligors under the Receivables and parties to the Contracts to verify
with them to the Administrative Agent’s satisfaction the existence, amount and terms of any Receivables or Contracts. 

(b) Upon the request of the Administrative Agent at any time after the occurrence and during the continuance of an Event of Default, each
Grantor shall notify obligors on the Receivables and parties to the Contracts that the Receivables and the Contracts have been assigned to the Administrative Agent for the ratable benefit of the Secured Parties and that payments in respect thereof
shall be made directly to the Administrative Agent. 

  
 17 

 (c) Anything herein to the contrary notwithstanding, each Grantor shall remain liable under
each of the Receivables and Contracts to observe and perform all the conditions and obligations to be observed and performed by it thereunder, all in accordance with the terms of any agreement giving rise thereto. Neither the Administrative Agent
nor any Lender shall have any obligation or liability under any Receivable (or any agreement giving rise thereto) or Contract by reason of or arising out of this Agreement or the receipt by the Administrative Agent or any Lender of any payment
relating thereto, nor shall the Administrative Agent or any Lender be obligated in any manner to perform any of the obligations of any Grantor under or pursuant to any Receivable (or any agreement giving rise thereto) or Contract, to make any
payment, to make any inquiry as to the nature or the sufficiency of any payment received by it or as to the sufficiency of any performance by any party thereunder, to present or file any claim, to take any action to enforce any performance or to
collect the payment of any amounts which may have been assigned to it or to which it may be entitled at any time or times. 

6.3 Pledged Stock and Pledged Notes. (a) Unless an Event of Default shall have occurred and be continuing and the
Administrative Agent shall have given notice to the Borrower of the Administrative Agent’s intent to exercise its corresponding rights pursuant to Section 6.3(b), each Grantor shall be permitted to receive all cash dividends paid in
respect of the Pledged Stock and all payments made in respect of the Pledged Notes to the extent permitted in the Credit Agreement, and to exercise all voting and corporate or other organizational rights with respect to the Investment Property;
provided, however, that no vote shall be cast or corporate or other organizational right exercised or other action taken which would be inconsistent with or result in any violation of any provision of the Credit Agreement, this Agreement or
any other Loan Document. 
 (b) If an Event of Default shall occur and be continuing and the Administrative Agent shall give
notice of its intent to exercise such rights to the Borrower (i) the Administrative Agent shall have the right to receive any and all cash dividends, payments or other Proceeds paid in respect of the Investment Property and make application
thereof to the Obligations in the order set forth in Section 6.5, and (ii) the Administrative Agent shall have the right to require that any or all of the Investment Property shall be registered in the name of the Administrative Agent or
its nominee, and the Administrative Agent or its nominee may thereafter exercise (x) all voting, corporate and other rights pertaining to such Investment Property at any meeting of shareholders of the relevant Issuer or Issuers or otherwise and
(y) any and all rights of conversion, exchange and subscription and any other rights, privileges or options pertaining to such Investment Property as if it were the absolute owner thereof (including, without limitation, the right to exchange at
its discretion any and all of the Investment Property upon the merger, consolidation, reorganization, recapitalization or other fundamental change in the corporate or other organizational structure of any Issuer, or upon the exercise by any Grantor
or the Administrative Agent of any right, privilege or option pertaining to such Investment Property, and in connection therewith, the right to deposit and deliver any and all of the Investment Property with any committee, depositary, transfer
agent, registrar or other designated agency upon such terms and conditions as the Administrative Agent may determine), all without liability except to account for property actually received by it, but the Administrative Agent shall have no duty to
any Grantor to exercise any such right, privilege or option and shall not be responsible for any failure to do so or delay in so doing. 
 (c) Each Grantor hereby authorizes and instructs each Issuer of any Investment Property pledged by such Grantor hereunder to (i) comply with any instruction received by it from the Administrative
Agent in writing that (x) states that an Event of Default has occurred and is continuing and (y) is otherwise in accordance with the terms of this Agreement, without any other or further instructions from such Grantor, and each Grantor
agrees that each Issuer shall be fully protected in so complying, and (ii) unless otherwise expressly permitted hereby, pay any dividends or other payments with respect to the Investment Property directly to the Administrative Agent after it
has received written notice of the occurrence and continuance of an Event of Default from the Administrative Agent. 
 6.4
Proceeds to be Turned Over To Administrative Agent. In addition to the rights of the Administrative Agent and the Lenders specified in Section 6.1 with respect to payments of Receivables, if

  
 18 

 
an Event of Default shall occur and be continuing, all Proceeds received by any Grantor consisting of cash, checks and other near-cash items shall be held by such Grantor in trust for the
Administrative Agent and the Lenders, segregated from other funds of such Grantor, and shall, forthwith upon receipt by such Grantor, be turned over to the Administrative Agent in the exact form received by such Grantor (duly indorsed by such
Grantor to the Administrative Agent, if required). All Proceeds received by the Administrative Agent hereunder shall be held by the Administrative Agent in a Collateral Account maintained under its sole dominion and control. All Proceeds while held
by the Administrative Agent in a Collateral Account (or by such Grantor in trust for the Administrative Agent and the Secured Parties) shall continue to be held as collateral security for all the Obligations and shall not constitute payment thereof
until applied as provided in Section 6.5. 
 6.5 Application of Proceeds. If an Event of Default shall have occurred
and be continuing the Administrative Agent shall apply all or any part of Proceeds constituting Collateral, whether or not held in any Collateral Account, and any proceeds of the guarantee set forth in Section 2, in payment of the Obligations
in the following order: 
 First, to pay incurred and unpaid fees and expenses of the Administrative Agent
under the Loan Documents; 
 Second, to the Administrative Agent, for application by it towards payment of
amounts then due and owing and remaining unpaid in respect of the Obligations, pro rata among the Secured Parties according to the amounts of the Obligations then due and owing and remaining unpaid to the Secured Parties; 

Third, to the Administrative Agent, for application by it towards prepayment of the Obligations until the
Obligations have been paid in full, pro rata among the Secured Parties according to the amounts of the Obligations then held by the Secured Parties; and 

Fourth, to the Borrower or to whomsoever may be lawfully entitled to receive the same, if any balance is remaining
after the Obligations shall have been paid in full. 
 6.6 Code and Other Remedies. If an Event of Default shall occur
and be continuing, the Administrative Agent, on behalf of the Secured Parties, may exercise, in addition to all other rights and remedies granted to them in this Agreement and in any other instrument or agreement securing, evidencing or relating to
the Obligations, all rights and remedies of a secured party under the New York UCC or any other applicable law. Without limiting the generality of the foregoing, the Administrative Agent, without demand of performance or other demand, presentment,
protest, advertisement or notice of any kind (except any notice required by law referred to below) to or upon any Grantor or any other Person (all and each of which demands, defenses, advertisements and notices are hereby waived to the extent not
prohibited by law), may in such circumstances forthwith collect, receive, appropriate and realize upon the Collateral, or any part thereof, and/or may forthwith sell, lease, assign, give option or options to purchase, or otherwise dispose of and
deliver the Collateral or any part thereof (or contract to do any of the foregoing), in one or more parcels at public or private sale or sales, at any exchange, broker’s board or office of the Administrative Agent or any Lender or elsewhere
upon such terms and conditions as it may deem advisable and at such prices as it may deem best, for cash or on credit or for future delivery without assumption of any credit risk. The Administrative Agent or any Lender shall have the right upon any
such public sale or sales, and, to the extent permitted by law, upon any such private sale or sales, to purchase the whole or any part of the Collateral so sold, free of any right or equity of redemption in any Grantor, which right or equity is
hereby waived and released to the extent not prohibited by law. Each Grantor further agrees, at the Administrative Agent’s request, to assemble the Collateral and make it available to the Administrative Agent at places which the Administrative
Agent shall reasonably select, 

  
 19 

 whether at such Grantor’s premises or elsewhere. The Administrative Agent shall apply the net proceeds
of any action taken by it pursuant to this Section 6.6, after deducting all reasonable costs and expenses of every kind incurred in connection therewith or incidental to the care or safekeeping of any of the Collateral or in any way relating to
the Collateral or the rights of the Administrative Agent and the Lenders hereunder, including, without limitation, reasonable and documented attorneys’ fees and disbursements, to the payment in whole or in part of the Obligations, in the order
set forth in Section 6.5, and only after such application and after the payment by the Administrative Agent of any other amount required by any provision of law, including, without limitation, Section 9-615(a)(3) of the New York UCC, need
the Administrative Agent account for the surplus, if any, to any Grantor. To the extent permitted by applicable law, each Grantor waives all claims, damages and demands it may acquire against the Administrative Agent or any Lender arising out of the
exercise by them of any rights hereunder. If any notice of a proposed sale or other disposition of Collateral shall be required by law, such notice shall be deemed reasonable and proper if given at least 10 days before such sale or other
disposition. 
 6.7 Registration Rights. (a) If the Administrative Agent shall determine to exercise its right to
sell any or all of the Pledged Stock pursuant to Section 6.6, and if in the opinion of the Administrative Agent it is necessary or advisable to have the Pledged Stock, or that portion thereof to be sold, registered under the provisions of the
Securities Act, the relevant Grantor will use commercially reasonable efforts to cause the Issuer thereof to (i) execute and deliver, and cause the directors and officers of such Issuer to execute and deliver, all such instruments and
documents, and do or cause to be done all such other acts as may be, in the opinion of the Administrative Agent, necessary or advisable to register the Pledged Stock, or that portion thereof to be sold, under the provisions of the Securities Act,
(ii) use its commercially reasonable efforts to cause the registration statement relating thereto to become effective and to remain effective for a period of one year from the date of the first public offering of the Pledged Stock, or that
portion thereof to be sold, and (iii) make all amendments thereto and/or to the related prospectus which, in the opinion of the Administrative Agent, are reasonably necessary or advisable, all in conformity with the requirements of the
Securities Act and the rules and regulations of the Securities and Exchange Commission applicable thereto. Each Grantor agrees to cause such Issuer to comply with the provisions of the securities or “Blue Sky” laws of any and all
jurisdictions which the Administrative Agent shall designate and to make available to its security holders, as soon as practicable, an earnings statement (which need not be audited) which will satisfy the provisions of Section 11(a) of the
Securities Act. 
 (b) Each Grantor recognizes that the Administrative Agent may be unable to effect a public sale of any or all
the Pledged Stock, by reason of certain prohibitions contained in the Securities Act and applicable state securities laws or otherwise, and may be compelled to resort to one or more private sales thereof to a restricted group of purchasers which
will be obliged to agree, among other things, to acquire such securities for their own account for investment and not with a view to the distribution or resale thereof. Each Grantor acknowledges and agrees that any such private sale may result in
prices and other terms less favorable than if such sale were a public sale and, notwithstanding such circumstances, agrees that any such private sale shall be deemed to have been made in a commercially reasonable manner. The Administrative Agent
shall be under no obligation to delay a sale of any of the Pledged Stock for the period of time necessary to permit the Issuer thereof to register such securities for public sale under the Securities Act, or under applicable state securities laws,
even if such Issuer would agree to do so. 
 (c) Each Grantor agrees to use its commercially reasonable efforts to do or cause
to be done all such other acts as may be necessary to make such sale or sales of all or any portion of the Pledged Stock pursuant to this Section 6.7 valid and binding and in compliance with any and all other applicable Requirements of Law.
Each Grantor further agrees that a breach of any of the covenants contained in this Section 6.7 will cause irreparable injury to the Administrative Agent and the Lenders, that the . Administrative Agent and the Lenders have no adequate remedy
at law in respect of such breach and, as a consequence, that each and every covenant contained in this Section 6.7 shall be specifically enforceable against such Grantor, and such Grantor hereby waives and (to the extent not prohibited by law)
agrees not to assert any defenses against an action for specific performance of such covenants except for a defense that no Event of Default has occurred under the Credit Agreement. 

  
 20 

 6.8 Subordination. Each Grantor hereby agrees that, upon the occurrence and during
the continuance of an Event of Default, unless otherwise agreed by the Administrative Agent, all Indebtedness owing by it to any Subsidiary of the Borrower shall be fully subordinated to the indefeasible payment in full in cash of such
Grantor’s Obligations. 
 6.9 Deficiency. Each Grantor shall remain liable for any deficiency if the proceeds of any
sale or other disposition of the Collateral are insufficient to pay its Obligations and the reasonable fees and disbursements of any attorneys employed by the Administrative Agent to collect such deficiency. 

6.10 Grant of Intellectual Property License. For the purpose of enabling the Administrative Agent to exercise the rights and
remedies under this Agreement at such time as the Administrative Agent shall be lawfully entitled to exercise such rights and remedies, and for no other purpose, each Grantor hereby (a) grants to the Administrative Agent, for the benefit of the
Administrative Agent and the Secured Parties, an irrevocable, nonexclusive license (exercisable without payment of royalty or other compensation to any Grantor) to use, license or sublicense any Intellectual Property now owned or hereafter acquired
by such Grantor, and wherever the same may be located, and including in such license access to all media in which any of the licensed items may be recorded or stored and to all computer software and programs used for the compilation or printout
thereof, the right to prosecute and maintain all Intellectual Property and the right to sue for past infringement of the Intellectual Property; and (b) irrevocably agrees that the Administrative Agent may sell any of such Grantor’s
inventory directly to any person, including without limitation persons who have previously purchased the Grantor’s inventory from such Grantor and in connection with any such sale or other enforcement of the Administrative Agent’s rights
under this Agreement, may sell inventory which bears any Trademark owned by or licensed to such Grantor and any inventory that is covered by any Copyright owned by or licensed to such Grantor and the Administrative Agent may finish any work in
process and affix any Trademark owned by or licensed to such Grantor and sell such inventory as provided herein. Anything in this Section 6.10 to the contrary notwithstanding, the Administrative Agent agrees that it will not exercise any rights
hereunder unless an Event of Default shall have occurred and be continuing. 
 SECTION 7. THE ADMINISTRATIVE AGENT 

7.1 Administrative Agent’s Appointment as Attorney-in-Fact, etc. (a) Each Grantor hereby irrevocably constitutes and
appoints the Administrative Agent and any officer or agent thereof, with full power of substitution, as its true and lawful attorney-in-fact with full irrevocable power and authority in the place and stead of such Grantor and in the name of such
Grantor or in its own name, for the purpose of carrying out the terms of this Agreement, to take any and all appropriate action and to execute any and all documents and instruments which may be necessary or desirable to accomplish the purposes of
this Agreement, and, without limiting the generality of the foregoing, each Grantor hereby gives the Administrative Agent the power and right, on behalf of such Grantor, without notice to or assent by such Grantor, to do any or all of the following:

 (i) in the name of such Grantor or its own name, or otherwise, take possession of and indorse and collect any
checks, drafts, notes, acceptances or other instruments for the payment of moneys due under any Receivable or Contract or with respect to any other Collateral and file any claim or take any other action or proceeding in any court of law or equity or
otherwise deemed appropriate by the Administrative Agent for the purpose of collecting any and all such moneys due under any Receivable or Contract or with respect to any other Collateral whenever payable; 

  
 21 

 (ii) in the case of any Registered United States Intellectual Property owned
by such Grantor and any written license of Registered United States Intellectual Property to which any Grantor is an exclusive licensee, execute and deliver, and have recorded, Intellectual Property Short Form Security Agreements substantially in
the form of Annex 2 hereof and any and all agreements, instruments, documents and papers as the Administrative Agent may reasonably request to evidence the Administrative Agent’s and the Lenders’ security interest in such Intellectual
Property and the goodwill and general intangibles of such Grantor relating thereto or represented thereby; 

(iii) pay or discharge taxes and Liens levied or placed on or threatened against the Collateral, effect any repairs or any
insurance called for by the terms of this Agreement and pay all or any part of the premiums therefor and the costs thereof; 
 (iv) execute, in connection with any sale provided for in Section 6.6 or 6.7, any indorsements, assignments or other instruments of conveyance or transfer with respect to the Collateral; and

 (v) (1) direct any party liable for any payment under any of the Collateral to make payment of any and all
moneys due or to become due thereunder directly to the Administrative Agent or as the Administrative Agent shall direct; (2) ask or demand for, collect, and receive payment of and receipt for, any and all moneys, claims and other amounts due or
to become due at any time in respect of or arising out of any Collateral; (3) sign and indorse any invoices, freight or express bills, bills of lading, storage or warehouse receipts, drafts against debtors, assignments, verifications, notices
and other documents in connection with any of the Collateral; (4) commence and prosecute any suits, actions or proceedings at law or in equity in any court of competent jurisdiction to collect the Collateral or any portion thereof and to
enforce any other right in respect of any Collateral; (5) defend any suit, action or proceeding brought against such Grantor with respect to any Collateral; (6) settle, compromise or adjust any such suit, action or proceeding and, in
connection therewith, give such discharges or releases as the Administrative Agent may deem appropriate; (7) assign any Copyright, Patent or Trademark (along with the goodwill of the business to which any such Copyright, Patent or Trademark
pertains), throughout the world for such term or terms, on such conditions, and in such manner, as the Administrative Agent shall in its sole discretion determine; and (8) generally, sell, transfer, pledge and make any agreement with respect to
or otherwise deal with any of the Collateral as fully and completely as though the Administrative Agent were the absolute owner thereof for all purposes, and do, at the Administrative Agent’s option and such Grantor’s expense, at any time,
or from time to time, all acts and things which the Administrative Agent deems necessary to protect, preserve or realize upon the Collateral and the Administrative Agent’s and the Lenders’ security interests therein and to effect the
intent of this Agreement, all as fully and effectively as such Grantor might do. 
 Anything in this Section 7.1(a) to the
contrary notwithstanding, the Administrative Agent agrees that it will not exercise any rights under the power of attorney provided for in this Section 7.1(a) unless an Event of Default shall have occurred and be continuing. 

(b) If any Grantor fails to perform or comply with any of its agreements contained herein, the Administrative Agent, at its option, but
without any obligation so to do, may perform or comply, or otherwise cause performance or compliance, with such agreement. 

  
 22 

 (c) The expenses of the Administrative Agent incurred in connection with actions undertaken
as provided in this Section 7.1, together with interest thereon at a rate per annum equal to the highest rate per annum at which interest would then be payable on any category of past due ABR Loans under the Credit Agreement, from the date of
payment by the Administrative Agent to the date reimbursed by the relevant Grantor, shall be payable by such Grantor to the Administrative Agent on demand. 
 (d) Each Grantor hereby ratifies all that said attorneys shall lawfully do or cause to be done by virtue hereof. All powers, authorizations and agencies contained in this Agreement are coupled with an
interest and are irrevocable until this Agreement is terminated and the security interests created hereby are released. 
 7.2
Duty of Administrative Agent. The Administrative Agent’s sole duty with respect to the custody, safekeeping and physical preservation of the Collateral in its possession, under Section 9-207 of the New York UCC or otherwise, shall
be to deal with it in the same manner as the Administrative Agent deals with similar property for its own account. Neither the Administrative Agent, any Lender nor any of their respective officers, directors, employees or agents shall be liable for
failure to demand, collect or realize upon any of the Collateral or for any delay in doing so or shall be under any obligation to sell or otherwise dispose of any Collateral upon the request of any Grantor or any other Person or to take any other
action whatsoever with regard to the Collateral or any part thereof. The powers conferred on the Administrative Agent and the Lenders hereunder are solely to protect the Administrative Agent’s and the Lenders’ interests in the Collateral
and shall not impose any duty upon the Administrative Agent or any Lender to exercise any such powers. The Administrative Agent and the Lenders shall be accountable only for amounts that they actually receive as a result of the exercise of such
powers, and neither they nor any of their officers, directors, employees or agents shall be responsible to any Grantor for any act or failure to act hereunder, except for their own gross negligence or willful misconduct. 

7.3 Execution of Financing Statements. Pursuant to any applicable law, each Grantor authorizes the Administrative Agent to file or
record financing statements and other filing or recording documents or instruments with respect to the Collateral without the signature of such Grantor in such form and in such offices as the Administrative Agent determines appropriate to perfect
the security interests of the Administrative Agent under this Agreement. Each Grantor authorizes the Administrative Agent to use the collateral description “all personal property” in any such financing statements. Each Grantor hereby
ratifies and authorizes the filing by the Administrative Agent of any financing statement with respect to the Collateral made prior to the date hereof. 
 7.4 Authority of Administrative Agent. Each Grantor acknowledges that the rights and responsibilities of the Administrative Agent under this Agreement with respect to any action taken by the
Administrative Agent or the exercise or non-exercise by the Administrative Agent of any option, voting right, request, judgment or other right or remedy provided for herein or resulting or arising out of this Agreement shall, as between the
Administrative Agent and the Secured Parties, be governed by the Credit Agreement and by such other agreements with respect thereto as may exist from time to time among them, but, as between the Administrative Agent and the Grantors, the
Administrative Agent shall be conclusively presumed to be acting as agent for the Secured Parties with full and valid authority so to act or refrain from acting, and no Grantor shall be under any obligation, or entitlement, to make any inquiry
respecting such authority. 

  
 23 

 SECTION 8. MISCELLANEOUS 

8.1 Amendments in Writing. None of the terms or provisions of this Agreement may be waived, amended, supplemented or otherwise
modified except in accordance with Section 10.1 of the Credit Agreement. 
 8.2 Notices. All notices, requests and
demands to or upon the Administrative Agent or any Grantor hereunder shall be effected in the manner provided for in Section 10.2 of the Credit Agreement; provided that any such notice, request or demand to or upon any Guarantor shall be
addressed to such Guarantor at its notice address set forth on Schedule 1. 
 8.3 No Waiver by Course of Conduct; Cumulative
Remedies. Neither the Administrative Agent nor any Lender shall by any act (except by a written instrument pursuant to Section 8.1), delay, indulgence, omission or otherwise be deemed to have waived any right or remedy hereunder or to have
acquiesced in any Default or Event of Default. No failure to exercise, nor any delay in exercising, on the part of the Administrative Agent or any Lender, any right, power or privilege hereunder shall operate as a waiver thereof. No single or
partial exercise of any right, power or privilege hereunder shall preclude any other or further exercise thereof or the exercise of any other right, power or privilege. A waiver by the Administrative Agent or any Lender of any right or remedy
hereunder on any one occasion shall not be construed as a bar to any right or remedy which the Administrative Agent or such Lender would otherwise have on any future occasion. The rights and remedies herein provided are cumulative, may be exercised
singly or concurrently and are not exclusive of any other rights or remedies provided by law. 
 8.4 Enforcement Expenses;
Indemnification. (a) Each Guarantor agrees to pay, and to save the Administrative Agent and the Lenders harmless from, any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or
disbursements of any kind or nature whatsoever with respect to the execution, delivery, enforcement, performance and administration of this Agreement to the extent the Borrower would be required to do so pursuant to Section 10.5 of the Credit
Agreement. 
 (b) The agreements in this Section 8.4 shall survive repayment of the Obligations and all other amounts
payable under the Credit Agreement and the other Loan Documents. 
 8.5 Successors and Assigns. This Agreement shall be
binding upon the successors and assigns of each Grantor and shall inure to the benefit of the Administrative Agent and the Lenders and their successors and assigns; provided that no Grantor may assign, transfer or delegate any of its rights or
obligations under this Agreement without the prior written consent of the Administrative Agent. 
 8.6 Set-Off. In
addition to any rights and remedies of the Lenders provided by law, each Lender shall have the right following the occurrence and during the continuance of an Event of Default, without notice to any Grantor, any such notice being expressly waived by
each Grantor to the extent permitted by applicable law, upon any Obligations becoming due and payable by any Grantor (whether at the stated maturity, by acceleration or otherwise), to apply to the payment of such Obligations, by setoff or otherwise,
any and all deposits (general or special, time or demand, provisional or final), in any currency, and any other credits, indebtedness or claims, in any currency, in each case whether direct or indirect, absolute or contingent, matured or unmatured,
at any time held or owing by such Lender, any Affiliate thereof or any of their respective branches or agencies to or for the credit or the account of such Grantor. Each Lender agrees promptly to notify the relevant Grantor and the Administrative
Agent after any such application made by such Lender, provided that the failure to give such notice shall not affect the validity of such application. 

  
 24 

 8.7 Counterparts. This Agreement may be executed by one or more of the parties to
this Agreement on any number of separate counterparts (including by telecopy), and all of said counterparts taken together shall be deemed to constitute one and the same instrument. 

8.8 Severability. Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such
jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable
such provision in any other jurisdiction. 
 8.9 Section Headings. The Section headings used in this Agreement are for
convenience of reference only and are not to affect the construction hereof or be taken into consideration in the interpretation hereof. 
 8.10 Integration. This Agreement and the other Loan Documents represent the agreement of the Grantors, the Administrative Agent and the Secured Parties with respect to the subject matter hereof and
thereof, and there are no promises, undertakings, representations or warranties by the Administrative Agent or any Secured Party relative to subject matter hereof and thereof not expressly set forth or referred to herein or in the other Loan
Documents. 
 8.11 GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE
WITH, THE LAW OF THE STATE OF NEW YORK. 
 8.12 Submission To Jurisdiction; Waivers. Each Grantor hereby irrevocably
and unconditionally: 
 (a) submits for itself and its property in any legal action or proceeding relating to this Agreement and
the other Loan Documents to which it is a party, or for recognition and enforcement of any judgment in respect thereof, to the non-exclusive general jurisdiction of the courts of the State of New York, the courts of the United States of America for
the Southern District of New York, and appellate courts from any thereof; 
 (b) consents that any such action or proceeding may
be brought in such courts and waives any objection that it may now or hereafter have to the venue of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees not to plead or
claim the same; 
 (c) agrees that service of process in any such action or proceeding may be effected by mailing a copy thereof
by registered or certified mail (or any substantially similar form of mail), postage prepaid, to such Grantor at its address referred to in Section 8.2 or at such other address of which the Administrative Agent shall have been notified pursuant
thereto; 
 (d) agrees that nothing herein shall affect the right to effect service of process in any other manner permitted by
law or shall limit the right to sue in any other jurisdiction; and 
 (e) waives, to the maximum extent not prohibited by law,
any right it may have to claim or recover in any legal action or proceeding referred to in this Section any special, exemplary, punitive or consequential damages; 
 8.13 Acknowledgements. Each Grantor hereby acknowledges that: 

  
 25 

 (a) it has been advised by counsel in the negotiation, execution and delivery of this
Agreement and the other Loan Documents to which it is a party; 
 (b) neither the Administrative Agent nor any Lender has any
fiduciary relationship with or duty to any Grantor arising out of or in connection with this Agreement or any of the other Loan Documents, and the relationship between the Grantors, on the one hand, and the Administrative Agent and Lenders, on the
other hand, in connection herewith or therewith is solely that of debtor and creditor; and 
 (c) no joint venture is created
hereby or by the other Loan Documents or otherwise exists by virtue of the transactions contemplated hereby among the Lenders or among the Grantors and the Lenders. 
 8.14 Additional Grantors. Each Subsidiary of the Borrower that is required to become, or that the Borrower desires to become, a party to this Agreement pursuant to Section 6.10 of the Credit
Agreement shall become a Grantor for all purposes of this Agreement upon execution and delivery by such Subsidiary of an Assumption Agreement in the form of Annex 1 hereto. 
 8.15 Rights Relating to the Collateral. Notwithstanding the security interests created and to be created pursuant to the Security Documents, unless otherwise provided in the Security Documents, the
Grantors shall retain and be entitled to exercise all their respective rights relating to the Collateral subject to the terms and conditions of the Security Documents. 
 8.16 Releases. (a) At such time as the Loans, the Reimbursement Obligations and the other Obligations (other than Obligations in respect of Specified Swap Agreements and Specified Cash
Management Agreements that are not then due and payable) shall have been paid in full, the Collateral shall be released from the Liens created hereby, and this Agreement and all obligations (other than those expressly stated to survive such
termination) of the Administrative Agent and each Grantor hereunder shall terminate, all without delivery of any instrument or performance of any act by any party, and all rights to the Collateral shall revert to the Grantors. At the request and
sole expense of any Grantor following any such termination, the Administrative Agent shall promptly deliver to such Grantor any Collateral held by the Administrative Agent hereunder, and promptly execute and deliver to such Grantor such documents as
such Grantor shall reasonably request to evidence such termination. 
 (b) If any of the Collateral shall be sold, transferred
or otherwise disposed of by any Grantor in a transaction permitted by the Credit Agreement, then the Administrative Agent, at the request and sole expense of such Grantor, shall execute and deliver to such Grantor all releases or other documents
reasonably necessary or desirable for the release of the Liens created hereby on such Collateral. At the request and sole expense of the Borrower, a Subsidiary Guarantor shall be released from its obligations hereunder in the event that all the
Capital Stock of such Subsidiary Guarantor shall be sold, transferred or otherwise disposed of in a transaction permitted by the Credit Agreement; provided that the Borrower shall have delivered to the Administrative Agent, at least five
Business Days prior to the date of the proposed release, a written request for release identifying the relevant Subsidiary Guarantor and the terms of the sale or other disposition in reasonable detail, including the price thereof and any expenses in
connection therewith, together with a certification by the Borrower stating that such transaction is in compliance with the Credit Agreement and the other Loan Documents. 
 8.17 WAIVER OF JURY TRIAL. EACH GRANTOR HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT AND
FOR ANY COUNTERCLAIM THEREIN. 

  
 26 

 IN WITNESS WHEREOF, each of the undersigned has caused this Guarantee and Collateral
Agreement to be duly executed and delivered as of the date first above written. 
  

			
	VCPH HOLDING CORP.
		
	By:	 	/s/ Ramzi M. Musallam
		 	Name: Ramzi M. Musallam
		 	Title: Secretary

 [Signature Page to Guarantee and Collateral Agreement] 

 
			
	WOLVERINE HEALTHCARE ANALYTICS, INC.
		
	By:	 	/s/ Ramzi M. Musallam
		 	Name: Ramzi M. Musallam
		 	Title: Secretary

 [Signature Page to Guarantee and Collateral Agreement] 

 
			
	 JPMORGAN CHASE BANK, N.A., as
 Administrative Agent

		
	By:	 	/s/ Vanessa Chiu
		 	Name: Vanessa Chiu
		 	Title: Executive Director

 [Signature Page to Guarantee and Collateral Agreement] 

 SCHEDULE 1 

Notice Addresses 
 Before the consummation of the Merger: 
  

			
	 Entity
	  	 Notice Address

	Wolverine Healthcare Analytics, Inc.	  	 Wolverine Healthcare Analytics, Inc.
 777 E. Eisenhower Parkway
 Ann Arbor, MI 48108

		
		  	with copies to
		
		  	 VCPH Holdings LLC
 c/o The
Veritas Capital Fund IV, L.P.
 590 Madison Avenue
 New York, NY 10022
 Attn: Robert B. McKeon

		
	VCPH Holding Corp.	  	 VCPH Holding Corp.
 777 E.
Eisenhower Parkway
 Ann Arbor, MI 48108

		
		  	with copies to
		
		  	 VCPH Holdings LLC
 c/o The
Veritas Capital Fund IV, L.P.
 590 Madison Avenue
 New York, NY 10022
 Attn: Robert B. McKeon

 After the consummation of the Merger: 

 

			
	 Entity
	  	 Notice Address

	Thomson Reuters (Healthcare) Inc.1	  	 Thomson Reuters (Healthcare) Inc.
 777 E. Eisenhower Parkway
 Ann Arbor, MI 48108

		
		  	with copies to
		
		  	 VCPH Holdings LLC
 c/o The
Veritas Capital Fund IV, L.P.
 590 Madison Avenue
 New York, NY 10022
 Attn: Robert B. McKeon

		
	VCPH Holding Corp.2	  	 VCPH Holding Corp.
 777 E.
Eisenhower Parkway
 Ann Arbor, MI 48108

		
		  	with copies to
		
		  	 VCPH Holdings LLC
 c/o The
Veritas Capital Fund IV, L.P.
 590 Madison Avenue
 New York, NY 10022
 Attn: Robert B. McKeon

  

	1 	 Name of entity to be changed to Truven Health Analytics Inc. on the Closing Date after consummation of the Merger. 

	2 	 Name of entity to be changed to Truven Holding Corp. on the Closing Date after consummation of the Merger. 

 SCHEDULE 2 

Description Of Investment Property 
 Pledged Stock before the consummation of the Merger: 
  

															
	 Issuer
	  	Number of
Authorized
Shares	  	Class of
Stock	  	Number of
Shares
Outstanding	  	Whether
Certificated	  	Share
Certificate
Nos.	  	Record and
Beneficial
Owner	  	Par
Value
Per
Share
	 Wolverine Healthcare Analytics, Inc.
	  	1,000	  	Common
Stock	  	8	  	Yes	  	1	  	VCPH
Holding Corp.	  	$0.01

 Pledged Stock after the consummation of the Merger: 

 

															
	 Issuer
	  	Number of
Authorized
Shares	  	Class of
Stock	  	Number of
Shares
Outstanding	  	Whether
Certificated	  	Share
Certificate
Nos.	  	Record and
Beneficial
Owner	  	Par
Value
Per
Share
	 Thomson Reuters (Healthcare) Inc.3
	  	1,000	  	Common
Stock	  	8	  	Yes	  	1	  	VCPH
Holding Corp.	  	$1.00

 Pledged Notes before and after the consummation of the Merger: 

None. 
  

	3	 Upon this
entity’s change of name to Truven Health Analytics Inc., the share certificates described herein will be exchanged for share certificates reflecting Truven Health Analytics Inc. as issuer. The other information regarding the entity’s
Equity Interests will not change from the description of such information herein (other than the name of the record and beneficial owner, which will be Truven Holding Corp. upon the change of name of VCPH Holding Corp. to Truven Holding Corp.).

 SCHEDULE 3 

Filings And Other Actions Required To Perfect Security Interests 

Uniform Commercial Code Filings 
 Before the consummation of the Merger: 
  

			
	 Grantor
	  	 Filing and Filing Office

	Wolverine Healthcare Analytics, Inc.	  	UCC-1, Secretary of State of the State of Delaware
	VCPH Holding Corp.	  	UCC-1, Secretary of State of the State of Delaware

 After the consummation of the Merger: 

 

			
	 Grantor
	  	 Filing and Filing Office

	Thomson Reuters (Healthcare)
Inc.4	  	UCC-1, Secretary of State of the State of Delaware
	VCPH Holding Corp.5	  	UCC-1, Secretary of State of the State of Delaware

 Copyright, Patent and Trademark Filings 

Before the consummation of the Merger: 
  

			
	 Grantor
	  	 Filing Office

	Wolverine Healthcare Analytics, Inc.	  	 United States Patent and Trademark Office and

United States Copyright Office

	VCPH Holding Corp.	  	 United States Patent and Trademark Office and

United States Copyright Office

 After the consummation of the Merger: 

 

			
	 Grantor
	  	 Filing Office

	Thomson Reuters (Healthcare)
Inc.6	  	United States Patent and Trademark Office and United States Copyright Office
	VCPH Holding Corp.7	  	 United States Patent and Trademark Office and

United States Copyright Office

  

	4 	 Following the change of name from Thomson Reuters (Healthcare) Inc. to Truven Health Analytics Inc., a UCC-1 will be filed with the Secretary of State
of the State of Delaware against Truven Health Analytics Inc. 

	5 	 Following the change of name from VCPH Holding Corp. to Truven Holding Corp., a UCC-1 will be filed with the Secretary of State of the State of
Delaware against Truven Holding Corp. 

	6 	 Following the change of name from Thomson Reuters (Healthcare) Inc. to Truven Health Analytics Inc., name change filings will be filed with the United
States Patent and Trademark Office and the United States Copyright Office to reflect the change of name. 

	7 	 Following the change of name from VCPH Holding Corp. to Truven Holding Corp., name change filings will be filed with the United States Patent and
Trademark Office and the United States Copyright Office to reflect the change of name. 

 Actions with respect to Pledged Stock 

Delivery of the Pledged Stock, to the extent certificated, to the Administrative Agent pursuant to Section 5.6 of the Guarantee and Collateral
Agreement. 
 Other Actions 
 None. 

 SCHEDULE 4 

Location Of Jurisdiction Of Organization And Chief Executive Office 

Before the consummation of the Merger: 
  

					
	 Grantor
	  	 Jurisdiction of

Organization
	  	 Location of Chief

Executive Office

	VCPH Holding Corp.	  	Delaware	  	 777 E. Eisenhower Parkway,
 Ann Arbor, MI 48108

	Wolverine Healthcare Analytics, Inc.	  	Delaware	  	 777 E. Eisenhower Parkway,
 Ann Arbor, MI 48108

 After the consummation of the Merger: 

 

					
	 Grantor
	  	 Jurisdiction of

Organization
	  	 Location of Chief

Executive Office

	 VCPH Holding Corp.8
	  	Delaware	  	 777 E. Eisenhower Parkway,
 Ann Arbor, MI 48108

	 Thomson Reuters (Healthcare) Inc.9
	  	Delaware	  	 777 E. Eisenhower Parkway,
 Ann Arbor, MI 48108

  

	8 	 Name of entity to be changed to Truven Holding Corp. on the Closing Date after consummation of the Merger. 

	9 	 Name of entity to be changed to Truven Health Analytics Inc. on the Closing Date after consummation of the Merger. 

 SCHEDULE 5 

Locations Of Inventory And Equipment 
 Before the consummation of the Merger: 
 None. 

After the consummation of the Merger: 
  

	1.	Data center located at 5400 Data Court, Ann Arbor, Michigan, 48108. 

  

	2.	Data center located at 201 Mentor Drive, Santa Barbara, California, 93111. 

 

	3.	Data center located at 777 Eisenhower Parkway, Ann Arbor, Michigan, 48108. 

 

	4.	Data center located at 6200 South Syracuse Way, Suite 300, Greenwood Village, Colorado, 80112. 

 

	5.	Windstream Charlotte Metro Data Center located at 111 Corning Rd, Suite 150, Cary, North Carolina, 27518. 

 

	6.	Windstream Charlotte Metro Data Center located at 4021 Rose Lake Drive, Suite 200, Charlotte, North Carolina, 28217. 

 

	7.	Windstream Hosted Solutions located at 5301 Departure Drive, Suite 111, Raleigh, North Carolina, 27616. 

 SCHEDULE 6 

Intellectual Property 
 Before the consummation of the Merger: 
 Trademark Registrations and
Applications 
 None.  
 Patents and Patent Applications 
 None. 

Copyrights and Copyright Applications 
 None. 
 After the consummation of the Merger:  

Trademark Registrations and Applications 
  

									
	 Owner
	  	 Trademark
	  	 Application Number
	  	 Registration Number (for
registered trademarks
only)
	  	 Country

	 Thomson Reuters (Healthcare) Inc.
	  	100 TOP HOSPITALS	  	75803008	  	2421001	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	1-SECOND HELP	  	76331686	  	2776436	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	 1ST MEDICAL

RESPONSE
	  	78972554	  	3300387	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	ACTION O-I	  	78147386	  	2987976	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	ALTCAREDEX	  	75896203	  	2408813	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	ALTCAREDEX	  	75896212	  	2425103	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	ALTMEDDEX	  	75552794	  	2451458	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	ALTMEDDEX POINTS	  	75939900	  	2518614	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	ASCENT	  	74607628	  	1972471	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	AUTO-AUDIT	  	74132906	  	1674087	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	AUTO-AUDIT	  	74132906	  	1674087	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	CAREDISCOVERY	  	77324586	  	3886650	  	United States of America

									
	 Owner
	  	 Trademark
	  	 Application Number
	  	 Registration Number

(for registered trademarks only)
	  	 Country

	 Thomson Reuters (Healthcare) Inc.
	  	CARENOTES	  	78962117	  	3307347	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	CLINICAL CHECKLIST	  	78609754	  	3209684	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	CLINICAL KNOWLEDGE OBJECTS	  	75255176	  	2165513	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	CLINICAL XPERT	  	77793638	  	3836333	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	CLINICALPOINTS	  	75326205	  	2251884	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	DATABRIDGE	  	74708000	  	2265199	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	DATAPROBE	  	74600563	  	2036013	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	DATASCAN	  	74242353	  	1717821	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	DISEASEDEX	  	76508891	  	3006885	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	587330	  	587330	  	Australia
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	784779	  	520164	  	Benelux
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	816632057	  	816632057	  	Brazil
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	825258561	  	825258561	  	Brazil
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	825258570	  	825258570	  	Brazil
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	1002561	  	525893	  	Canada
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	61198	  	61198	  	Egypt
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	1062611	  	1062611	  	European Community
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	92/431912	  	92431912	  	France
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	M 73111	  	2040696	  	Germany
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	125444	  	125444	  	Israel
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	125445	  	125445	  	Israel
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	644123	  	644123	  	Italy
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	24482/1982	  	1712396	  	Japan
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	227126	  	490001	  	Mexico

									
	 Owner
	  	 Trademark
	  	 Application Number
	  	 Registration Number (for
registered trademarks
only)
	  	 Country

	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	1734	  	1734	  	Oman
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	14485	  	30341	  	Peru
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	S111194	  	T94/11111F	  	Singapore
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	327974	  	Kor79692	  	Thailand
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	327975	  	Bor6684	  	Thailand
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	2120730	  	2120730	  	United Kingdom
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	2005987	  	2005987	  	United Kingdom
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGDEX	  	85018060	  	3889616	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGKNOWLEDGE	  	75543369	  	2414796	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGPOINTS	  	730129	  	730129	  	Australia
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGPOINTS	  	845536	  	490079	  	Canada
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGPOINTS	  	274343	  	274343	  	New Zealand
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGPOINTS	  	2127408	  	2127408	  	United Kingdom
	 Thomson Reuters (Healthcare) Inc.
	  	DRUGPOINTS	  	85270365	  	 	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	DRUG-REAX	  	733764	  	733764	  	Australia
	 Thomson Reuters (Healthcare) Inc.
	  	DRUG-REAX	  	394062248	  	39406224	  	Germany
	 Thomson Reuters (Healthcare) Inc.
	  	DRUG-REAX	  	RM97C002068	  	781756	  	Italy
	 Thomson Reuters (Healthcare) Inc.
	  	DRUG-REAX	  	327976	  	Kor79691	  	Thailand
	 Thomson Reuters (Healthcare) Inc.
	  	DRUG-REAX	  	327977	  	Bor6715	  	Thailand
	 Thomson Reuters (Healthcare) Inc.
	  	DRUG-REAX	  	74594849	  	1928170	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	EMERGINDEX	  	649350	  	649350	  	Australia
	 Thomson Reuters (Healthcare) Inc.
	  	EMERGINDEX	  	723469	  	723469	  	Australia
	 Thomson Reuters (Healthcare) Inc.
	  	EMERGINDEX	  	816632014	  	816632014	  	Brazil
	 Thomson Reuters (Healthcare) Inc.
	  	EMERGINDEX	  	826095054	  	826095054	  	Brazil

									
	 Owner
	  	 Trademark
	  	 Application Number
	  	 Registration Number (for
registered trademarks
only)
	  	 Country

	 Thomson Reuters (Healthcare) Inc.
	  	EMERGINDEX	  	61199	  	61199	  	Egypt
	 Thomson Reuters (Healthcare) Inc.
	  	EMERGINDEX	  	394062221	  	39406222	  	Germany
	 Thomson Reuters (Healthcare) Inc.
	  	EMERGINDEX	  	1735	  	1735	  	Oman
	 Thomson Reuters (Healthcare) Inc.
	  	EMERGINDEX	  	14488	  	30344	  	Peru
	 Thomson Reuters (Healthcare) Inc.
	  	EXECUTIVE OUTLOOK	  	76023032	  	2574370	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	FORMULARY ADVISOR	  	76446993	  	2875762	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	HEALTHVIEW PLUS	  	78151187	  	3011930	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	HOUSEHOLDVIEW	  	78151182	  	2833168	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	IDENTIDEX	  	6-130224	  	3350068	  	Japan
	 Thomson Reuters (Healthcare) Inc.
	  	IDENTIDEX	  	327981	  	Bor6504	  	Thailand
	 Thomson Reuters (Healthcare) Inc.
	  	IDENTIDEX	  	327980	  	Kor77516	  	Thailand
	 Thomson Reuters (Healthcare) Inc.
	  	IDENTIDEX	  	74089775	  	1655390	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	INFECTION XPERT	  	85366219	  	 	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	INFOBUTTON ACCESS	  	78563867	  	3138098	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	INFOQUICK	  	77689506	  	3708079	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	INFORMATION RESOURCES GROUP	  	78691635	  	3172697	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	INFOTEXT	  	78763657	  	3158563	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	INTEGRATED INDEX	  	75317307	  	2291932	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	IV INDEX	  	78763693	  	3278163	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	LAB ADVISOR	  	77586927	  	3645198	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	MARKET EXPERT	  	76025381	  	2626819	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	MARKET OUTLOOK	  	76022848	  	2762152	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	MARKETDISCOVERY	  	85405553	  	 	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	MARKETSCAN	  	74528792	  	1913950	  	United States of America

									
	 Owner
	  	 Trademark
	  	 Application Number
	  	 Registration Number (for
registered trademarks
only)
	  	 Country

	 Thomson Reuters (Healthcare) Inc.
	  	MEDITEXT	  	78763808	  	3239123	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	MEDSTAT	  	826798	  	826798	  	Australia
	 Thomson Reuters (Healthcare) Inc.
	  	MEDSTAT	  	74104856	  	1722309	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	MEDSTAT	  	75902685	  	2417589	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	MEDSTAT ADVANTAGE SUITE	  	75531210	  	2423803	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	 MEDSTAT DECISION

ANALYST
	  	75531305	  	2423804	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	MEDSTAT MODELER	  	75062524	  	2168017	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	MEDSTAT PERFORMANCE EXPERT	  	78744256	  	3249049	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	MERCURYMD	  	76385020	  	2672051	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	MICROMEDEX	  	2171527	  	1765309	  	Argentina
	 Thomson Reuters (Healthcare) Inc.
	  	MICROMEDEX	  	2171528	  	1765310	  	Argentina
	 Thomson Reuters (Healthcare) Inc.
	  	MICROMEDEX	  	767444	  	767444	  	Australia
	 Thomson Reuters (Healthcare) Inc.
	  	MICROMEDEX	  	893484	  	616607	  	Benelux
	 Thomson Reuters (Healthcare) Inc.
	  	MICROMEDEX	  	910224	  	628980	  	Benelux
	 Thomson Reuters (Healthcare) Inc.
	  	MICROMEDEX	  	821148729	  	821148729	  	Brazil
	 Thomson Reuters (Healthcare) Inc.
	  	MICROMEDEX	  	821148745	  	821148745	  	Brazil
	 Thomson Reuters (Healthcare) Inc.
	  	MICROMEDEX	  	874899	  	523683	  	Canada
	 Thomson Reuters (Healthcare) Inc.
	  	MICROMEDEX	  	63791	  	63791	  	Egypt
	 Thomson Reuters (Healthcare) Inc.
	  	MICROMEDEX	  	1062462	  	1062462	  	European Community
	 Thomson Reuters (Healthcare) Inc.
	  	MICROMEDEX	  	39709628	  	39709628	  	Germany
	 Thomson Reuters (Healthcare) Inc.
	  	MICROMEDEX	  	125440	  	125440	  	Israel
	 Thomson Reuters (Healthcare) Inc.
	  	MICROMEDEX	  	125441	  	125441	  	Israel
	 Thomson Reuters (Healthcare) Inc.
	  	MICROMEDEX	  	RM98C004377	  	844480	  	Italy
	 Thomson Reuters (Healthcare) Inc.
	  	MICROMEDEX	  	2007-37713	  	5100491	  	Japan

									
	 Owner
	  	 Trademark
	  	 Application Number
	  	 Registration Number (for
registered trademarks
only)
	  	 Country

	 Thomson Reuters (Healthcare) Inc.
	  	MICROMEDEX	  	344920	  	595021	  	Mexico
	 Thomson Reuters (Healthcare) Inc.
	  	MICROMEDEX	  	344921	  	595022	  	Mexico
	 Thomson Reuters (Healthcare) Inc.
	  	MICROMEDEX	  	73806226	  	1718993	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	MICROMEDEX	  	73806225	  	1694270	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	MICROMEDEX	  	73805977	  	1715081	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	MOBILEMICROMEDEX	  	76226680	  	2707703	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	NEOFAX	  	76349383	  	2749481	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	NEOFAX ESSENTIALS	  	85405838	  	 	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	NEOFAX-PC	  	74640908	  	2021367	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	NURSING XPERT	  	85182172	  	 	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	OUTCOMES ANALYST	  	74430762	  	1899481	  	 United States of

America

	 Thomson Reuters (Healthcare) Inc.
	  	OUTPATIENT FORECASTER	  	78607550	  	3252952	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	P & T QUIK	  	327983	  	Bor6503	  	Thailand
	 Thomson Reuters (Healthcare) Inc.
	  	P & T QUIK	  	74008458	  	1648504	  	 United States of

America

	 Thomson Reuters (Healthcare) Inc.
	  	P & T QUIK (stylized)	  	327982	  	Kor79700	  	Thailand
	 Thomson Reuters (Healthcare) Inc.
	  	PATIENT SAFETY EXPERT	  	78861782	  	3175742	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	PEDIATRICS ESSENTIALS	  	85405825	  	 	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	PEER-A-MED	  	74293198	  	1806540	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	PHARMACY XPERT	  	85182153	  	 	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	2171525	  	1765307	  	Argentina
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	2171526	  	1765308	  	Argentina
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	587331	  	A587331	  	Australia
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	841381	  	566036	  	Benelux
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	816632022	  	816632022	  	Brazil

									
	 Owner
	  	 Trademark
	  	 Application Number
	  	 Registration Number (for
registered trademarks
only)
	  	 Country

	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	1002562	  	525946	  	Canada
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	61200	  	61200	  	Egypt
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	1062504	  	1062504	  	European Community
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	M 73110	  	2040695	  	Germany
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	125443	  	125443	  	Israel
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	125442	  	125442	  	Israel
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	RM97C002069	  	781757	  	Italy
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	S57-024481	  	1715855	  	Japan
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	344922	  	595023	  	Mexico
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	344923	  	595024	  	Mexico
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	1733	  	1733	  	Oman
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	14487	  	30343	  	Peru
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	12336/96	  	T96/12336G	  	Singapore
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	327984	  	Kor77206	  	Thailand
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	327985	  	Bor10855	  	Thailand
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	2120241	  	2120241	  	United Kingdom
	 Thomson Reuters (Healthcare) Inc.
	  	POISINDEX	  	73617702	  	1466214	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	PROFSOFT	  	78342042	  	2983004	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	PROVIDER VIEW	  	75577818	  	2594640	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	PULSE	  	77735750	  	 	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	READYPRICE	  	74708948	  	2038268	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	RED BOOK	  	72385153	  	942000	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	RED BOOK UPDATE	  	73478971	  	1325745	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	REPRORISK	  	6-130225	  	3350069	  	Japan

									
	 Owner
	  	 Trademark
	  	 Application Number
	  	 Registration Number (for
registered trademarks
only)
	  	 Country

	 Thomson Reuters (Healthcare) Inc.
	  	REPRORISK	  	327986	  	Kor77207	  	Thailand
	 Thomson Reuters (Healthcare) Inc.
	  	REPRORISK	  	327987	  	Bor6428	  	Thailand
	 Thomson Reuters (Healthcare) Inc.
	  	REPRORISK	  	74054918	  	1682347	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	REPROTEXT	  	74054917	  	1685755	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	SOLESOURCE	  	74659005	  	1994898	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	SOLUCIENT	  	76207343	  	2711891	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	SOLUCIENT	  	76207342	  	2650431	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	SOLUCIENT	  	76207341	  	2640723	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	SOLUCIENT (& Design)	  	76207344	  	2633028	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	STCS	  	75711006	  	2598453	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	TOMES	  	649351	  	649351	  	Australia
	 Thomson Reuters (Healthcare) Inc.
	  	TOMES	  	14486	  	30342	  	Peru
	 Thomson Reuters (Healthcare) Inc.
	  	TOMES	  	327988	  	Kor77208	  	Thailand
	 Thomson Reuters (Healthcare) Inc.
	  	TOMES	  	327989	  	Bor6502	  	Thailand
	 Thomson Reuters (Healthcare) Inc.
	  	TOMES	  	73805975	  	1598304	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	TOMES	  	73806234	  	1604127	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	TOMES PLUS	  	841382	  	569175	  	Benelux
	 Thomson Reuters (Healthcare) Inc.
	  	TOMES PLUS	  	9-116463	  	4204165	  	Japan
	 Thomson Reuters (Healthcare) Inc.
	  	TOMES PLUS	  	327990	  	Kor79699	  	Thailand
	 Thomson Reuters (Healthcare) Inc.
	  	TOMES PLUS	  	327991	  	Bor6427	  	Thailand
	 Thomson Reuters (Healthcare) Inc.
	  	TOMES PLUS	  	74103461	  	1655861	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	TOMES PLUS	  	74100917	  	1655456	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	TOXPOINTS	  	75326076	  	2298625	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	TRANSLATION ENGINE	  	76345014	  	2701558	  	United States of America

									
	 Owner
	  	 Trademark
	  	 Application Number
	  	 Registration Number (for
registered trademarks
only)
	  	 Country

	 Thomson Reuters (Healthcare) Inc.
	  	ULTIMEDEX	  	77452065	  	3536921	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	CONSUMER ADVANTAGE	  	77330249	  	3673757	  	United States of America
	 Thomson Reuters (Healthcare) Inc.
	  	INTERCEPT	  	85344612	  	 	  	United States of America

 Patents and Patent Applications 

 

											
	 	  	 	  	 	  	 	  	Patent No.	  	 
	 	  	 	  	 	  	 	  	(with respect	  	Grant Date
	 	  	 	  	 	  	Application	  	to issued	  	(Issued
	 Owner
	  	 Patent
	  	 Country
	  	 No.
	  	 patents only)
	  	 Patents Only)

	 Thomson Reuters (Healthcare) Inc.
	  	Systems, Methods, and Software for Forecasting Medical Treatment Risks and Costs Based on Illness Severity and Patient
Illness Burden	  	US	  	11/520,847	  	 	  	 
	 Thomson Reuters (Healthcare) Inc.
	  	Docking Station	  	US	  	29/142,926	  	D454,880	  	03/26/2002
	 Thomson Reuters (Healthcare) Inc.
	  	Method and System for Extracting Medical Information for Presentation to Medical Providers on Mobile Terminals	  	Canada	  	2,434,714	  	 	  	 
	 Thomson Reuters (Healthcare) Inc.
	  	Method and System for Extracting Medical Information for Presentation to Medical Providers on Mobile Terminals	  	US	  	09/776,484	  	7,831,449	  	11/09/2010
	 Thomson Reuters (Healthcare) Inc.
	  	Method and System for Extracting Medical Information for Presentation to Medical Providers on Mobile Terminals	  	US	  	12/942,532	  	 	  	 

											
	 Owner
	  	 Patent
	  	 Country
	  	 Application

No.
	  	 Patent No.

(with respect

to issued

patents only)
	  	 Grant Date

(Issued

Patents Only)

	 Thomson Reuters

(Healthcare) Inc.
	  	 Handheld Device

Graphical User

Interfaces for Displaying
 Patient Medical Records
	  	US	  	10/101,577	  	7,343,565	  	03/11/2008
	 Thomson Reuters

(Healthcare) Inc.
	  	 Handheld Device

Graphical User

Interfaces for Displaying
 Patient Medical Records
	  	US	  	11/970,177	  	 	  	 
	 Thomson Reuters

(Healthcare) Inc.
	  	 Docking Statons for

Transferring Data

Between Handheld

Electronic Devices and
 Other Devices Via
 Infarred

Communications
	  	US	  	10/156,475	  	6,895,445	  	05/17/2005
	 Thomson Reuters

(Healthcare) Inc.
	  	Docking Station	  	US	  	29/161,351	  	D476,659	  	07/01/2003
	 Thomson Reuters

(Healthcare) Inc.
	  	 System, Methods, and

Software for Clinical
 Order Sets
	  	US	  	12/545,714	  	 	  	 
	 Thomson Reuters

(Healthcare) Inc.
	  	 Systems, Methods, and

Software for Supporting
 Consumer Healthcare
 Decisions
	  	US	  	12/321,129	  	 	  	 
	 Thomson Reuters

(Healthcare) Inc.
	  	 Network-Based Method And System For

Managing And

Providing Access To
 A Formulary
	  	US	  	10/675,236	  	 	  	 
	 Thomson Reuters

(Healthcare) Inc.
	  	Internet Delivery	  	US	  	10/675,235	  	7,747,644	  	06/29/2010
	 Thomson Reuters

(Healthcare) Inc.
	  	Internet Delivery	  	US	  	12/773,603	  	 	  	 
	 Thomson Reuters

(Healthcare) Inc.
	  	 System and Method for

Managing Mobile HIE
 Information
	  	US	  	13/112,151	  	 	  	 

 Copyrights and Copyright Applications 

 

					
	 Owner
	  	 Title
	  	 Copyright

Number

	 Thomson Reuters

(Healthcare) Inc.
	  	Advice for the Patient: drug information in lay language.	  	TX0005489274

					
	 Owner
	  	 Title
	  	Copyright
Number
	 Thomson Reuters

(Healthcare) Inc.
	  	Advice for the patient : drug information in lay language / by authority of the United States Pharmacopeial Convention,
Inc.	  	CSN0023890
	 Thomson Reuters

(Healthcare) Inc.
	  	Advice for the patient : drug information in lay language / by authority of the United States Pharmacopeial Convention,
Inc.	  	CSN0023890
	 Thomson Reuters

(Healthcare) Inc.
	  	CareNotes system.	  	TX0004085538
	 Thomson Reuters

(Healthcare) Inc.
	  	Computerized clinical information system (CCIS) database.	  	TX0002704465
	 Thomson Reuters

(Healthcare) Inc.
	  	[Computerized clinical information system (CCIS) database : v. 64, expires May 31, 1990]	  	TX0002809683
	 Thomson Reuters

(Healthcare) Inc.
	  	Computerized clinical information system (CCIS) software.	  	TX0002737659
	 Thomson Reuters

(Healthcare) Inc.
	  	[Computerized clinical information system (CCIS) software : v. 64, expires May 31, 1990]	  	TX0002809682
	 Thomson Reuters

(Healthcare) Inc.
	  	Drug information for the health care professional.	  	TX0005489273
	 Thomson Reuters

(Healthcare) Inc.
	  	Drug information for the health care professional / by authority of the United States Pharmacopeial Convention, Inc.	  	CSN0076344
	 Thomson Reuters

(Healthcare) Inc.
	  	Drug information for the health care professional / by authority of the United States Pharmacopeial Convention, Inc.	  	CSN0076344
	 Thomson Reuters

(Healthcare) Inc.
	  	Drugdex.	  	CSN0020663
	 Thomson Reuters

(Healthcare) Inc.
	  	Drugdex.	  	CSN0020663
	 Thomson Reuters

(Healthcare) Inc.
	  	Drugdex.	  	CSN0020663
	 Thomson Reuters

(Healthcare) Inc.
	  	Drugdex.	  	CSN0020663
	 Thomson Reuters

(Healthcare) Inc.
	  	Drugdex.	  	CSN0020663
	 Thomson Reuters

(Healthcare) Inc.
	  	Drugdex.	  	CSN0020663
	 Thomson Reuters

(Healthcare) Inc.
	  	Drugdex.	  	CSN0020663
	 Thomson Reuters

(Healthcare) Inc.
	  	Drugdex.	  	CSN0020663
	 Thomson Reuters

(Healthcare) Inc.
	  	Drugdex.	  	CSN0020663
	 Thomson Reuters

(Healthcare) Inc.
	  	Drugdex.	  	CSN0020663
	 Thomson Reuters

(Healthcare) Inc.
	  	Drugdex.	  	CSN0020663
	 Thomson Reuters

(Healthcare) Inc.
	  	DRUGDEX : February 1992, 72nd update, exp. 5/31/92.	  	TX0003294862
	 Thomson Reuters

(Healthcare) Inc.
	  	Drugdex medical information system / TX 1-069-254 (1983) et al.	  	V2027P343
	 Thomson Reuters

(Healthcare) Inc.
	  	Emergindex.	  	CSN0037100

					
	 Owner
	  	 Title
	  	Copyright
Number
	 Thomson Reuters

(Healthcare) Inc.
	  	Emergindex.	  	CSN0037100
	 Thomson Reuters

(Healthcare) Inc.
	  	Emergindex medical information system / TX 1-072-322 (1983) et al.	  	V2027P345
	 Thomson Reuters

(Healthcare) Inc.
	  	Hip fracture & 203 other titles.	  	V3483D858
	 Thomson Reuters

(Healthcare) Inc.
	  	Hip fracture & 203 other titles.	  	V3475D260
	 Thomson Reuters

(Healthcare) Inc.
	  	IDENTIDEX : expires Nov, 1993.	  	TX0003752358
	 Thomson Reuters

(Healthcare) Inc.
	  	Identidex : table & capsule I.D.	  	CSN0059256
	 Thomson Reuters

(Healthcare) Inc.
	  	Identidex : table & capsule I.D.	  	CSN0059256
	 Thomson Reuters

(Healthcare) Inc.
	  	Identidex : tablet & capsule I.D.	  	CSN0059256
	 Thomson Reuters

(Healthcare) Inc.
	  	Identidex : tablet & capsule I.D.	  	CSN0059256
	 Thomson Reuters

(Healthcare) Inc.
	  	Identidex : tablet & capsule I.D.	  	CSN0059256
	 Thomson Reuters

(Healthcare) Inc.
	  	Identidex : tablet & capsule I.D.	  	CSN0059256
	 Thomson Reuters

(Healthcare) Inc.
	  	Identidex : tablet & capsule I.D.	  	CSN0059256
	 Thomson Reuters

(Healthcare) Inc.
	  	Identidex : tablet & capsule I.D.	  	CSN0059256
	 Thomson Reuters

(Healthcare) Inc.
	  	Identidex : tablet & capsule I.D.	  	CSN0059256
	 Thomson Reuters

(Healthcare) Inc.
	  	Identidex : tablet & capsule I.D.	  	CSN0059256
	 Thomson Reuters

(Healthcare) Inc.
	  	[KINETIDEX system]	  	TX0004125285
	 Thomson Reuters

(Healthcare) Inc.
	  	Micromedex international healthcare series : vol. 86, expires 31 December 1995.	  	TX0004131554
	 Thomson Reuters

(Healthcare) Inc.
	  	Poisindex.	  	CSN0018014
	 Thomson Reuters

(Healthcare) Inc.
	  	Poisindex.	  	CSN0018014
	 Thomson Reuters

(Healthcare) Inc.
	  	Poisindex.	  	CSN0018014
	 Thomson Reuters

(Healthcare) Inc.
	  	Poisindex.	  	CSN0018014
	 Thomson Reuters

(Healthcare) Inc.
	  	Poisindex.	  	CSN0018014
	 Thomson Reuters

(Healthcare) Inc.
	  	Poisindex.	  	CSN0018014
	 Thomson Reuters

(Healthcare) Inc.
	  	Poisindex.	  	CSN0018014
	 Thomson Reuters

(Healthcare) Inc.
	  	Poisindex.	  	CSN0018014
	 Thomson Reuters

(Healthcare) Inc.
	  	Poisindex.	  	CSN0018014

					
	 Owner
	  	 Title
	  	Copyright
Number
	 Thomson Reuters

(Healthcare) Inc.
	  	Poisindex : exp. 11/30/93.	  	TX0003728450
	 Thomson Reuters

(Healthcare) Inc.
	  	Poisindex medical information system / TX 1-106-903 et al.	  	V2027P344
	 Thomson Reuters

(Healthcare) Inc.
	  	TOXICALL system.	  	TXu000702889
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen Drugs in Prospect, 1978 : set no. 1, cards 1-62.	  	TX0000199113
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen Drugs in Prospect, 1978 : set no. 2, cards 63-123.	  	TX0000199115
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen Drugs in Prospect, 1978 : set no. 3, cards 124-185.	  	TX0000199117
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen Drugs in Prospect, 1978 : set no. 4, cards 186-244.	  	TX0000199118
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen Drugs in Prospect, 1978 : set no. 5, cards 245-307.	  	TX0000199114
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen Drugs in Prospect, 1978 : set no. 6, cards 308-364.	  	TX0000199112
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen Drugs in prospect : set 10 : acc. no. 78-546-78-608 : 63 entries.	  	TX0000241757
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in prospect : set 11 : acc. no. 78-609-78-668 : 63 entries.	  	TX0000241758
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in prospect : set 12 : acc. no. 78-669-78-731 : 63 entries.	  	TX0000241759
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen Drugs in Prospect : set no. 7, acc. no. 78-365-78-419.	  	TX0000199116
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in prospect : [set no. 8] : acc. no. 78-420-78-482.	  	TX0000241756

					
	 Owner
	  	 Title
	  	Copyright
Number
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in prospect : [set no.] 9 : acc. no. 78-483-78-545.	  	TX0000241760
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in research, 1978 : set no. 1 : cards 1-199.	  	TX0000241761
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in research, 1978 : set no. 2 : cards 1-199.	  	TX0000241754
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in research, 1978 : set no. 3 : cards 1-199.	  	TX0000241749
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in research, 1978 : [set no. 4] : acc. no. 478-001-478-199 : 199 reports.	  	TX0000241748
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in research : set 10 : 199 entries.	  	TX0000241752
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in research : set 6 : acc. no. 786-001-786-141 : 199 entries.	  	TX0000241753
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in research : set 9 : 199 entries.	  	TX0000241755
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in research : set [no. 5] : acc. no. 785-001-785-154 : 199 entries.	  	TX0000241750
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in research : set no. 8 : 199 entries.	  	TX0000241751
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in use, 1978 : acc. no. 3796-4066.	  	TX0000199110
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in use, 1978 : set no. 1, acc. no. 1-271, 271 reports.	  	TX0000172350
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in use, 1978 : set no. 10, acc. no. 2440-2711.	  	TX0000197382

					
	 Owner
	  	 Title
	  	Copyright
Number
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in use, 1978 : set no. 11, acc. no. 2712-2982.	  	TX0000199105
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in use, 1978 : set no. 12, acc. no. 2983-3253.	  	TX0000199102
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in use, 1978 : set no. 2, acc. no. 272-542.	  	TX0000197381
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in use, 1978 : set no. 3, acc. no. 543-814.	  	TX0000197387
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in use, 1978 : set no. 4, acc. no. 815-1084.	  	TX0000197389
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in use, 1978 : set no. 5, acc. no. 1085-1354.	  	TX0000197383
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in use, 1978 : set no. 6, acc. no. 1355-1625.	  	TX0000197386
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in use, 1978 : set no. 7, acc. no. 1626-1897.	  	TX0000197390
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in use, 1978 : set no. 8, acc. no. 1898-2168.	  	TX0000197384
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in use, 1978 : set no. 9, acc. no. 2169-2439.	  	TX0000197385
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in use : acc. no. 4067-4337.	  	TX0000294041
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in use : acc. no. 4609-4879.	  	TX0000199109
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in use : set no. 19, acc. no. 78-4880-78-5150.	  	TX0000197388

					
	 Owner
	  	 Title
	  	Copyright
Number
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in use : set no. 20, acc. no. 78-5151[-]78-5421.	  	TX0000199108
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in use : set no. 21, acc. no. 78-5422-78-5692.	  	TX0000199106
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen drugs in use : set no. 22, acc. no. 78-5693-78-5963.	  	TX0000199111
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen Information Systems drugs in research : acc. no. 787-001, 787-139, [set no. 7].	  	TX0000295957
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen Information Systems drugs in use : acc. no. 4338-4608.	  	TX0000199107
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen new product survey : new pharmaceutical specialties.	  	CSN0015979
	 Thomson Reuters

(Healthcare) Inc.
	  	DeHaen new product survey : new pharmaceutical specialties.	  	CSN0015979
	 Thomson Reuters

(Healthcare) Inc.
	  	New product survey : new pharmaceutical specialties / Paul DeHaen Information Systems, a division of Micromedex, Inc.	  	CSN0017724
	 Thomson Reuters

(Healthcare) Inc.
	  	New product survey : new pharmaceutical specialties / Paul DeHaen Information Systems, a division of Micromedex, Inc.	  	CSN0017725
	 Thomson Reuters

(Healthcare) Inc.
	  	Paul DeHaen Information Systems drugs in use, 1978 : acc. no. 3254-3524.	  	TX0000199104
	 Thomson Reuters

(Healthcare) Inc.
	  	Paul DeHaen Information Systems drugs in use, 1978 : acc. no. 3525-3795.	  	TX0000199103

  

					
	 Owner
	  	 Title
	  	Copyright
Number
	 Thomson Reuters

(Healthcare) Inc.
	  	Advances in B2-agonist therapy : making a difference in acute and chronic asthma treatment.	  	TX0005545160
	 Thomson Reuters

(Healthcare) Inc.
	  	Advice for the patient: drug information in lay language / by authority of the United States Pharmacopeial Convention,
Inc.	  	CSN0023890

					
	 Owner
	  	 Title
	  	Copyright
Number
	 Thomson Reuters

(Healthcare) Inc.
	  	Approved drug products and legal requirements / by authority of the United States Pharmacopeial Convention, Inc.	  	CSN0086579
	 Thomson Reuters

(Healthcare) Inc.
	  	Approved drug products and legal requirements / by authority of the United States Pharmacopeial Convention, Inc.	  	CSN0086579
	 Thomson Reuters

(Healthcare) Inc.
	  	Approved drug products and legal requirements / by authority of the United States Pharmacopeial Convention, Inc.	  	CSN0086579
	 Thomson Reuters

(Healthcare) Inc.
	  	Arthritis & rheumatology : an Internet resource guide.	  	CSN0140926
	 Thomson Reuters

(Healthcare) Inc.
	  	Arthritis & rheumatology : an Internet resource guide.	  	CSN0140926
	 Thomson Reuters

(Healthcare) Inc.
	  	Attention deficit hyperactivity disorder: a health economic perspective : an audio program from the symposium held during the AMCP 13th
annual meeting and showcase.	  	SR0000303788
	 Thomson Reuters

(Healthcare) Inc.
	  	Cardiology : an Internet resource guide.	  	CSN0141087
	 Thomson Reuters

(Healthcare) Inc.
	  	Cardiology : an Internet resource guide.	  	CSN0141087
	 Thomson Reuters

(Healthcare) Inc.
	  	Diccionario de especialidades farmaceuticas.	  	CSN0137943
	 Thomson Reuters

(Healthcare) Inc.
	  	Drug information for the health care professional / by authority of the United States Pharmacopeial Convention, Inc.	  	CSN0076344
	 Thomson Reuters

(Healthcare) Inc.
	  	Drug information for the health care professional / by authority of the United States Pharmacopeial Convention, Inc.	  	CSN0076344
	 Thomson Reuters

(Healthcare) Inc.
	  	Drug information for the health care professional / by authority of the United States Pharmacopeial Convention, Inc.	  	CSN0076344
	 Thomson Reuters

(Healthcare) Inc.
	  	Drug Topics Red Book, : [the pharmacist’s guide to products and prices / Eugene Prinz, compilation editor... et
all.].	  	CSN0016132
	 Thomson Reuters

(Healthcare) Inc.
	  	Endocrinology & metabolism : an Internet resource guide.	  	CSN0141389
	 Thomson Reuters

(Healthcare) Inc.
	  	Endocrinology & metabolism : an Internet resource guide.	  	CSN0141389
	 Thomson Reuters

(Healthcare) Inc.
	  	Infectious diseases & immunology : an Internet resource guide.	  	CSN0141769
	 Thomson Reuters

(Healthcare) Inc.
	  	Infectious diseases & immunology : an Internet resource guide.	  	CSN0141769
	 Thomson Reuters

(Healthcare) Inc.
	  	It isn’t just sugar anymore : the insulin resistance syndrome and cardiovascular disease.	  	TX0005985431
	 Thomson Reuters

(Healthcare) Inc.
	  	Management of chronic HCV : health economic considerations for managed care : an audio program from the symposium held during the AMCP
13th annual meeting and showcase.	  	SR0000303786
	 Thomson Reuters

(Healthcare) Inc.
	  	Management of spasticity in children with cerebral palsy : an integrated approach.	  	PA0001233780

					
	 Owner
	  	 Title
	  	Copyright
Number
	Thomson Reuters (Healthcare) Inc.	  	Multi-symptom management of PMS/PMDD : a new innovation in hormonal therapy : an audio program from the symposium held during the AMCP
13th annual meeting and showcase.	  	SR0000303787
	Thomson Reuters (Healthcare) Inc.	  	PDR Drug Guide for Mental Health Professionals : with a foreword by Ronald J. Comer.	  	CSN0142351
	Thomson Reuters (Healthcare) Inc.	  	PDR Drug Guide for Mental Health Professionals : with a foreword by Ronald J. Comer.	  	CSN0142351
	Thomson Reuters (Healthcare) Inc.	  	PDR Drug Guide for Mental Health Professionals : with a foreword by Ronald J. Comer.	  	CSN0142351
	Thomson Reuters (Healthcare) Inc.	  	PDR Drug Guide for Mental Health Professionals : with a foreword by Ronald J. Comer.	  	CSN0142351
	Thomson Reuters (Healthcare) Inc.	  	PDR Electronic Library.	  	CSN0138536
	Thomson Reuters (Healthcare) Inc.	  	PDR Electronic Library.	  	CSN0138536
	Thomson Reuters (Healthcare) Inc.	  	PDR Nurse’s Drug Handbook : the information standard for prescription drugs and nursing considerations / George R. Spratt, Adrienne
L. Woods.	  	CSN0135693
	Thomson Reuters (Healthcare) Inc.	  	PDR Pharmacopoeia : pocket dosing guide.	  	CSN0138537
	Thomson Reuters (Healthcare) Inc.	  	PDR Pocket Guide to Prescription Drugs.	  	TX0006958798
	Thomson Reuters (Healthcare) Inc.	  	Physicians’ Desk Reference Companion Guide.	  	CSN0123437
	Thomson Reuters (Healthcare) Inc.	  	Physicians’ Desk Reference for Nonprescription Drugs and Dietary Supplements.	  	CSN0138558
	Thomson Reuters (Healthcare) Inc.	  	Physicians’ Desk Reference for Ophthalmic Medicines.	  	CSN0137218
	Thomson Reuters (Healthcare) Inc.	  	Physicians’ Desk Reference / managing editor, Barbara B. Huff [et al.].	  	CSN0017979
	Thomson Reuters (Healthcare) Inc.	  	Pocket PDR: Pocket Physicians’ Desk Reference.	  	CSN0142408
	Thomson Reuters (Healthcare) Inc.	  	Psychiatry : an Internet resource guide.	  	CSN0142467
	Thomson Reuters (Healthcare) Inc.	  	Psychiatry : an Internet resource guide.	  	CSN0142467
	Thomson Reuters (Healthcare) Inc.	  	Slide selections from spectrum of insulin resistance : clinical implications.	  	TX0005363507
	Thomson Reuters (Healthcare) Inc.	  	Type 2 diabetes is a cardiovascular disease.	  	TX0005985437
	Thomson Reuters (Healthcare) Inc.	  	Urology & nephrology : an Internet resource guide.	  	CSN0142912
	Thomson Reuters (Healthcare) Inc.	  	Urology & nephrology : an Internet resource guide.	  	CSN0142912
	Thomson Reuters (Healthcare) Inc.	  	USP DI desktop series.	  	CSN0137552
	Thomson Reuters (Healthcare) Inc.	  	Advice for the Patient : drug information in lay language / by authority of the United States Pharmacopeial Convention,
Inc.	  	CSN0023890

					
	 Owner
	  	 Title
	  	Copyright
Number
	 Thomson Reuters

(Healthcare) Inc.
	  	Advice for the patient: drug information in lay language / by authority of the United States Pharmacopeial Convention,
Inc.	  	CSN0023890
	 Thomson Reuters

(Healthcare) Inc.
	  	Lipid management: report from the National Lipid Education Council—vol. 7, no. 1, spring02 & 61 other titles.	  	V355ID559
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide.	  	CSN0150051
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide.	  	CSN0150050
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide.	  	CSN0150051
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide. Dermatology.	  	CSN0152972
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : endocrinology.	  	CSN0144909
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : endocrinology.	  	CSN0144909
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : endocrinology.	  	CSN0144909
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : gastroenterology.	  	CSN0150052
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : gastroenterology.	  	CSN0150052
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : HIV/AIDS.	  	CSN0150053
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : HIV/AIDS.	  	CSN0150053
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : nephrology.	  	CSN0151872
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : oncology.	  	CSN0150055
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : oncology.	  	CSN0150055
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : prescribing information for over 1500 products.	  	CSN0152358
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : prescribing information for over 1500 products.	  	CSN0152358
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : prescribing information for over... products.	  	CSN0150054
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : prescribing information for over... products.	  	CSN0150054
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : psychiatry.	  	CSN0146733
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : psychiatry.	  	CSN0146733
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : psychiatry.	  	CSN0146733
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : psychiatry.	  	CSN0146733
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : respiratory medicine.	  	CSN0150056

					
	 Owner
	  	 Title
	  	Copyright
Number
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : respiratory medicine.	  	CSN0150056
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : urology.	  	CSN0150057
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Concise Prescribing Guide : urology.	  	CSN0150057
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Monthly Prescribing Guide : concise prescribing information for over ... products.	  	CSN0144910
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Monthly Prescribing Guide : concise prescribing information for over ... products.	  	CSN0144910
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Monthly Prescribing Guide : concise prescribing information for over ... products.	  	CSN0144910
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Monthly Prescribing Guide : concise prescribing information for over ... products.	  	CSN0144910
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR monthly prescribing guide, Oncology.	  	CSN0144911
	 Thomson Reuters

(Healthcare) Inc.
	  	PDR Nurse’s Drug Handbook : the information standard for prescription drugs and nursing considerations / George R. Spratto, Adrienne
L. Woods.	  	CSN0135693
	 Thomson Reuters

(Healthcare) Inc.
	  	Physicians’ Desk Reference for Nonprescription Drugs and Dietary Supplements.	  	CSN0138558
	 Thomson Reuters

(Healthcare) Inc.
	  	Physicians’ Desk Reference for Nonprescription Drugs and Dietary Supplements.	  	CSN0138558
	 Thomson Reuters

(Healthcare) Inc.
	  	Red Book : Pharmacy’s Fundamental Reference.	  	CSN0145067
	 Thomson Reuters

(Healthcare) Inc.
	  	Red Book : Pharmacy’s Fundamental Reference.	  	CSN0145067
	 Thomson Reuters

(Healthcare) Inc.
	  	Red Book update : [pricing, merchandising, deals, drug topics] / Margot Theis Raven, merchandising editor... [et al.].	  	CSN0066206
	 Thomson Reuters

(Healthcare) Inc.
	  	Red Book update : [pricing, merchandising, deals, drug topics] / Margot Theis Raven, merchandising editor... [et al.].	  	CSN0066206
	 Thomson Reuters

(Healthcare) Inc.
	  	Red Book update : [pricing. merchandising, deals, drug topics] / Margot Theis Raven, merchandising editor ... [et al.].	  	CSN0066206
	 Thomson Reuters

(Healthcare) Inc.
	  	Red Book update : [pricing, merchandising, deals, drug topics] / Margot Theis Raven, merchandising editor... [et al.].	  	CSN0066206
	 Thomson Reuters

(Healthcare) Inc.
	  	Red Book update : [pricing, merchandising, deals, drug topics] / Margot Theis Raven, merchandising editor... [et al.].	  	CSN0066206
	 Thomson Reuters

(Healthcare) Inc.
	  	Toxicall system : computer program /DCR 1995. TXu 702-889 (1995)	  	V3524D036
	 Thomson Reuters

(Healthcare) Inc.
	  	Management of chronic HCV : health economic considerations for managed care.	  	TX0005562851
	 Thomson Reuters

(Healthcare) Inc.
	  	New hepatitis C virus therapeutic landscape : implications for patient management : symposium.	  	TX0005704352

					
	 Owner
	  	 Title
	  	Copyright
Number
	 Thomson Reuters

(Healthcare) Inc.
	  	HBSI explore standard & 4 other titles.	  	V3544D166
	 Thomson Reuters

(Healthcare) Inc.
	  	HBSI explore standard transaction code database & 1 other title.	  	V3522D307
	 Thomson Reuters

(Healthcare) Inc.
	  	HBSI explore standard transaction code database & 1 other title.	  	V3474D954
	 Thomson Reuters

(Healthcare) Inc.
	  	HBSI explore standard transaction code (STC database & 1 other title.	  	V3522D545
	 Thomson Reuters

(Healthcare) Inc.
	  	Source code for the physician planner & 2 other titles.	  	V3542D366

  

					
	 Owner
	  	 Title
	  	Copyright
Number
	 Thomson Reuters

(Healthcare) Inc.
	  	Advanced JavaScript programming.	  	TX0004742552
	 Thomson Reuters

(Healthcare) Inc.
	  	AutocCAD 2002 & 18 other titles.	  	V3493D454
	 Thomson Reuters

(Healthcare) Inc.
	  	AutocCAD 2002 & 18 other titles.	  	V3493D455
	 Thomson Reuters

(Healthcare) Inc.
	  	AutocCAD 2002 & 18 other titles.	  	V3493D456
	 Thomson Reuters

(Healthcare) Inc.
	  	AutocCAD 2002 & 18 other titles.	  	V3493D457
	 Thomson Reuters

(Healthcare) Inc.
	  	AutocCAD 2002 & 18 other titles. (Part 005 of 005)	  	V3493D458
	 Thomson Reuters

(Healthcare) Inc.
	  	Microstation fundamentals : exercise workbook.	  	TX0004976996
	 Thomson Reuters

(Healthcare) Inc.
	  	MicroStation/J for architecture and facilities : exercise workbook.	  	TX0005195754
	 Thomson Reuters

(Healthcare) Inc.
	  	MicroStation/J for civil engineering : exercise workbook.	  	TX0005195756
	 Thomson Reuters

(Healthcare) Inc.
	  	MicroStation/J for civil engineering : exercise workbook.	  	TX0005031906
	 Thomson Reuters

(Healthcare) Inc.
	  	MicroStation/J for multiple disciplines : exercise workbook.	  	TX0005195757
	 Thomson Reuters

(Healthcare) Inc.
	  	MicroStation/J fundamentals : reference manual.	  	TX0005195755
	 Thomson Reuters

(Healthcare) Inc.
	  	MicroStation/J fundamentals : reference manual.	  	TX0005031907
	 Thomson Reuters

(Healthcare) Inc.
	  	Chemlab reporter / by ProSoft Development.	  	TXu000481007
	 Thomson Reuters

(Healthcare) Inc.
	  	ProSoft summer/fall 1996 course catalogue.	  	TX0004344963
	 Thomson Reuters

(Healthcare) Inc.
	  	Advanced HTML authoring.	  	TX0004791490

					
	 Owner
	  	 Title
	  	Copyright
Number
	 Thomson Reuters

(Healthcare) Inc.
	  	Basic Internet business skills : 1BIBS.	  	TX0004743938
	 Thomson Reuters

(Healthcare) Inc.
	  	Internet/intranet publishing using Microsoft FrontPage 97 : bk. 1-2.	  	TX0004744948
	 Thomson Reuters

(Healthcare) Inc.
	  	Pro-trader.	  	TX0001646541
	 Thomson Reuters

(Healthcare) Inc.
	  	Law Office Administrator.	  	TXu001194498
	 Thomson Reuters

(Healthcare) Inc.
	  	MicroStation V8 for civil engineering : exercise workbook.	  	TX0005897938
	 Thomson Reuters

(Healthcare) Inc.
	  	MicroStation V8 for multiple disciplines : exercise workbook.	  	TX0005897939
	 Thomson Reuters

(Healthcare) Inc.
	  	MicroStation V8 fundamentals : exercise workbook.	  	TX0005897935
	 Thomson Reuters

(Healthcare) Inc.
	  	MicroStation V8 fundamentals: reference manual.	  	TX0005898019
	 Thomson Reuters

(Healthcare) Inc.
	  	NetSPEX designer: CAD standards management for the enterprise.	  	TX0006249780
	 Thomson Reuters

(Healthcare) Inc.
	  	IBM Profit complex planning function, version 1.0.42.	  	TX0005985163
	 Thomson Reuters

(Healthcare) Inc.
	  	IBM profit core planning function, version 2.0.14.	  	TX0005985176
	 Thomson Reuters

(Healthcare) Inc.
	  	IBM profit customer commit function.	  	TX0005993843
	 Thomson Reuters

(Healthcare) Inc.
	  	420/site designer examination-PROMETRIC : 1D0-420-P03-P-June 2001.	  	TX0005446559
	 Thomson Reuters

(Healthcare) Inc.
	  	420/site designer examination-VUE 1D0-420 P03-V-June 2001.	  	TX0005446560
	 Thomson Reuters

(Healthcare) Inc.
	  	Advanced internet system management.	  	TX0005596706
	 Thomson Reuters

(Healthcare) Inc.
	  	CIW Application Developer exam : 1D0-430-P01.	  	TX0005542176
	 Thomson Reuters

(Healthcare) Inc.
	  	CIW certified Internet webmaster : version 107.	  	TX0005787649
	 Thomson Reuters

(Healthcare) Inc.
	  	CIW Database Specialist exam : 1D0-410-P01.	  	TX0005542181
	 Thomson Reuters

(Healthcare) Inc.
	  	CIW E-Commerce Designer exam : 1D0-425-P05.	  	TX0005542178
	 Thomson Reuters

(Healthcare) Inc.
	  	CIW Enterprise Specialist exam : 1D0-442-P01.	  	TX0005542179
	 Thomson Reuters

(Healthcare) Inc.
	  	CIW Foundations exam : 1D0-410-P05.	  	TX0005542177
	 Thomson Reuters

(Healthcare) Inc.
	  	CIW foundations exam 410-PO3 : version 3.	  	TX0005610484
	 Thomson Reuters

(Healthcare) Inc.
	  	CIW foundations exam 410-PO4 : version 4.	  	TX0005610485
	 Thomson Reuters

(Healthcare) Inc.
	  	CIW I-Accelerate exam : 1D0-475-P02.	  	TX0005542184

					
	 Owner
	  	 Title
	  	Copyright
Number
	 Thomson Reuters

(Healthcare) Inc.
	  	CIW Internetworking Professional exam : 1D0-460-P02.	  	TX0005542175
	 Thomson Reuters

(Healthcare) Inc.
	  	CIW JavaScript fundamentals exam : 1D0-435-P01.	  	TX0005542180
	 Thomson Reuters

(Healthcare) Inc.
	  	CIW Perl Fundamentals exam : 1D0-437-P02.	  	TX0005542185
	 Thomson Reuters

(Healthcare) Inc.
	  	CIW Security Professional exam : 1D0-470-P02.	  	TX0005542183
	 Thomson Reuters

(Healthcare) Inc.
	  	CIW Server Administrator exam : 1D0-450-P03.	  	TX0005542182
	 Thomson Reuters

(Healthcare) Inc.
	  	CIW site designer exam : 1D0-420-P04.	  	TX0005542174
	 Thomson Reuters

(Healthcare) Inc.
	  	E-commerce strategies and practices : vol. 1-2.	  	TX0005596704
	 Thomson Reuters

(Healthcare) Inc.
	  	Enterprise JavaBeans : version 1.17 : official Certified Internet Webmaster curriculum.	  	TX0005596688
	 Thomson Reuters

(Healthcare) Inc.
	  	Fundamentals of CGI using Perl.	  	TX0005596711
	 Thomson Reuters

(Healthcare) Inc.
	  	Internetworking fundamentals.	  	TX0005596707
	 Thomson Reuters

(Healthcare) Inc.
	  	JavaScript fundamentals.	  	TX0005596705
	 Thomson Reuters

(Healthcare) Inc.
	  	Object-oriented analysis and design.	  	TX0005596708
	 Thomson Reuters

(Healthcare) Inc.
	  	Sun certified Java programmer : exam preparation guide.	  	TX0005596709
	 Thomson Reuters

(Healthcare) Inc.
	  	Web page authoring fundamentals.	  	TX0005596710
	 Thomson Reuters

(Healthcare) Inc.
	  	JavaScript fundamentals : bks. 1 & 2.	  	TX0005048002
	 Thomson Reuters

(Healthcare) Inc.
	  	Security auditing, attacks, and threat analysis.	  	TX0004966328
	 Thomson Reuters

(Healthcare) Inc.
	  	Visual Java for visualage : bk. 1 -2 / developer, Paul Strack : editor, Jill McKenna.	  	TX0004971093
	 Thomson Reuters

(Healthcare) Inc.
	  	Windows NT network security.	  	TX0004966327
	 Thomson Reuters

(Healthcare) Inc.
	  	Advanced TCP/IP concents and practices : version 5.07 : official Certified Internet Webmaster curriculum.	  	TX0005596701
	 Thomson Reuters

(Healthcare) Inc.
	  	Building database client applications using JDBC 2.0 : version 1.17: official Certified Internet Webmaster curriculum.	  	TX0005596689
	 Thomson Reuters

(Healthcare) Inc.
	  	Database design methodology : version 1.17 : official Certified Internet Webmaster curriculum.	  	TX0005596695
	 Thomson Reuters

(Healthcare) Inc.
	  	Design methodology and technology : version 5.27 : vol. 1- 3 : official Certified Internet Webmaster curriculum.	  	TX0005596696

					
	 Owner
	  	 Title
	  	Copyright
Number
	 Thomson Reuters

(Healthcare) Inc.
	  	Distributed object computing using Java and CORBA : version 1.17 : official Certified Internet Webmaster curriculum.	  	TX0005596700
	 Thomson Reuters

(Healthcare) Inc.
	  	Dynamic server pages : version 1.17 : vol. 1-2 : official Certified Internet Webmaster curriculum.	  	TX0005596693
	 Thomson Reuters

(Healthcare) Inc.
	  	Internet fundamentals : version 4.17 : official Certified Internet Webmaster curriculum.	  	TX0005596694
	 Thomson Reuters

(Healthcare) Inc.
	  	Internet system management: version 4.07 : official Certified Internet Webmaster curriculum.	  	TX0005596703
	 Thomson Reuters

(Healthcare) Inc.
	  	Java programming fundamentals : version 5.07 : official Certified Internet Webmaster curriculum.	  	TX0005596698
	 Thomson Reuters

(Healthcare) Inc.
	  	Network security and firewalls : version 5.07 : official Certified Internet Webmaster curriculum.	  	TX0005596699
	 Thomson Reuters

(Healthcare) Inc.
	  	Networking fundamentals : version 5.17 : official Certified Internet Webmaster curriculum.	  	TX0005596702
	 Thomson Reuters

(Healthcare) Inc.
	  	Operating system security : version 2.07 : official Certified Internet Webmaster curriculum.	  	TX0005596691
	 Thomson Reuters

(Healthcare) Inc.
	  	Perl fundamentals : version 1.17 : official Certified Internet Webmaster curriculum.	  	TX0005596697
	 Thomson Reuters

(Healthcare) Inc.
	  	Security auditing, attacks, and threat analysis : version 5.07 : official Certified Internet Webmaster curriculum.	  	TX0005596692
	 Thomson Reuters

(Healthcare) Inc.
	  	TCP/IP Internetworking : version 4.07 : official Certified Internet Webmaster curriculum.	  	TX0005596690
	 Thomson Reuters

(Healthcare) Inc.
	  	Advanced Internet system management.	  	TX0005032684
	 Thomson Reuters

(Healthcare) Inc.
	  	Advanced TCP/IP concepts and practices : bk. 1-2.	  	TX0005036951
	 Thomson Reuters

(Healthcare) Inc.
	  	Application developer : Prosoft exam 330.	  	TX0005199911
	 Thomson Reuters

(Healthcare) Inc.
	  	Basic Internet business fundamentals.	  	TX0005032683
	 Thomson Reuters

(Healthcare) Inc.
	  	E-Commerce concepts and practices.	  	TX0005032687
	 Thomson Reuters

(Healthcare) Inc.
	  	Enterprise development using CORBA and Java.	  	TX0005032685
	 Thomson Reuters

(Healthcare) Inc.
	  	Enterprise development with JFC swing / developer, Nazmul Bin Idris.	  	TX0004957085
	 Thomson Reuters

(Healthcare) Inc.
	  	Internet system management.	  	TX0005032686
	 Thomson Reuters

(Healthcare) Inc.
	  	Internetworking professional : Prosoft exam 360.	  	TX0005199910
	 Thomson Reuters

(Healthcare) Inc.
	  	Linux certified administrator : Prosoft exam 601.	  	TX0005199913

					
	 Owner
	  	 Title
	  	Copyright
Number
	 Thomson Reuters

(Healthcare) Inc.
	  	 Network security and firewalls / developers. Tim Crothers and James
Stanger.
	  	TX0004957084
	 Thomson Reuters

(Healthcare) Inc.
	  	Networking fundamentals : bk. 1-2	  	TX0004916295
	 Thomson Reuters

(Healthcare) Inc.
	  	Prosoft exam 310 : foundations.	  	TX00051363S6
	 Thomson Reuters

(Healthcare) Inc.
	  	Prosoft exam 320 : site designer.	  	TX0005136384
	 Thomson Reuters

(Healthcare) Inc.
	  	Prosoft exam 340 : enterprise developer.	  	TX0005136387
	 Thomson Reuters

(Healthcare) Inc.
	  	Prosoft exam 380 : e-commerce professional.	  	TX0005136385
	 Thomson Reuters

(Healthcare) Inc.
	  	Security professional : Prosoft exam 370.	  	TX0005199912
	 Thomson Reuters

(Healthcare) Inc.
	  	Server administrator : Prosoft exam 350.	  	TX0005199909
	 Thomson Reuters

(Healthcare) Inc.
	  	SNMP network management : bk. 1-2.	  	TX0005021719
	 Thomson Reuters

(Healthcare) Inc.
	  	TCP/IP Internetworking.	  	TX0004916296
	 Thomson Reuters

(Healthcare) Inc.
	  	UNIX and TCP/IP network security. / developer: Sharon Kalwani.	  	TX0004957078
	 Thomson Reuters

(Healthcare) Inc.
	  	UNIX fundamentals / developer, Jerry Teitelbaum ; editor, Jill McKenna.	  	TX0004916300
	 Thomson Reuters

(Healthcare) Inc.
	  	UNIX system & network administration : bk. 1-2.	  	TX0005021718
	 Thomson Reuters

(Healthcare) Inc.
	  	Visual Java for Visual Cafe : book 1-2	  	TX0004916294
	 Thomson Reuters

(Healthcare) Inc.
	  	Syncronize backup.	  	TX0006371434
	 Thomson Reuters

(Healthcare) Inc.
	  	Is paperwork overwhelming your practice?	  	TX0003554305
	 Thomson Reuters

(Healthcare) Inc.
	  	Is paperwork overwhelming your practice? TX 3-554-305.	  	V3593D922

 SCHEDULE 7 

Material Government Contracts 
 Before the consummation of the Merger: 
 None. 

After the consummation of the Merger: 
  

	1.	Agency for Healthcare Research and Quality: Contract No. HHSA290200600009C, dated as of September 26, 2006, between Agency for Healthcare Research and
Quality and The MEDSTAT Group. 

 Annex 1 to 
 Guarantee and Collateral Agreement 
 ASSUMPTION AGREEMENT, dated as of
[    ], made by
                                         
                (the “Additional Grantor”), in favor of JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “Administrative
Agent”) for the banks and other financial institutions or entities (the “Secured Parties”) in connection with the Guarantee and Collateral Agreement referred to below. All capitalized terms not defined herein shall have the
meaning ascribed to them in such Guarantee and Collateral Agreement. 
 W I T N E S
S E T H: 
 WHEREAS, VCPH Holding Corp., (“Holdings”). Wolverine Healthcare
Analytics, Inc., (as further defined in the Credit Agreement, the “Borrower”), the Lenders and the Administrative Agent have entered into a Credit Agreement, dated as of June 6, 2012 (as amended, replaced, restated,
supplemented or otherwise modified from time to time, the “Credit Agreement”); 
 WHEREAS, in connection with
the Credit Agreement, the Borrower and certain of its Affiliates (other than the Additional Grantor) have entered into the Guarantee and Collateral Agreement, dated as of June 6, 2012 (as amended, restated, replaced, supplemented or otherwise
modified from time to time, the “Guarantee and Collateral Agreement”) in favor of the Administrative Agent for the ratable benefit of the Secured Parties; 
 WHEREAS, the Credit Agreement requires the Additional Grantor to become a party to the Guarantee and Collateral Agreement; and 
 WHEREAS, the Additional Grantor has agreed to execute and deliver this Assumption Agreement in order to become a party to the Guarantee and Collateral Agreement; 

NOW, THEREFORE, IT IS AGREED: 
 1. Guarantee and Collateral Agreement. By executing and delivering this Assumption Agreement, the Additional Grantor, as provided in Section 8.14 of the Guarantee and Collateral Agreement,
hereby becomes a party to the Guarantee and Collateral Agreement as a Grantor and a Guarantor thereunder with the same force and effect as if originally named therein as a Grantor and a Guarantor and, without limiting the generality of the
foregoing, hereby expressly assumes all obligations and liabilities of a Grantor and a Guarantor thereunder and hereby grants to the Administrative Agent, for the benefit of the Secured Parties, as collateral security for the payment when due of the
Obligations of the Additional Grantor, a security interest in the Collateral. The information set forth in Annex 1-A hereto is hereby added to the information set forth in the Schedules to the Guarantee and Collateral Agreement. The Additional
Grantor hereby represents and warrants that each of the representations and warranties contained in Section 4 of the Guarantee and Collateral Agreement as they relate to the Additional Grantor and the Collateral owned by it is true and correct
on and as the date hereof (after giving effect to this Assumption Agreement) as if made on and as of such date. 

  
 1 

 2. Governing Law. THIS ASSUMPTION AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED
AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. 
 IN WITNESS WHEREOF, the undersigned has caused this
Assumption Agreement to be duly executed and delivered as of the date first above written. 
  

							
		 		 	[ADDITIONAL GRANTOR]
				
		 		 	By:	 	 
		 		 		 	Name:
		 		 		 	Title:

  
 2 

 Annex 1-A to 
 Assumption Agreement 
 Supplement to Schedule 1 

Supplement to Schedule 2 
 Supplement to Schedule 3 
 Supplement to Schedule 4 

Supplement to Schedule 5 
 Supplement to Schedule 6 
 Supplement to Schedule 7 

 Annex 2 
 GRANT OF 
 SECURITY INTEREST IN [TRADEMARK/PATENT/COPYRIGHT] RIGHTS 

This GRANT OF SECURITY INTEREST IN [TRADEMARK/ PATENT/ COPYRIGHT] RIGHTS (“Agreement”), effective as of
                     , 2012 is made by [Grantor], a [state] [form of entity], located at [address] (the “Grantor”), in favor of
JPMorgan Chase Bank, N.A., as Administrative Agent (in such capacity, the “Administrative Agent”) for the banks and other financial institutions or entities (the “Lenders”) from time to time parties to the Credit
Agreement, dated as of June 6, 2012 (as amended, restated, replaced, supplemented or otherwise modified from time to time, the “Credit Agreement”), among VCPH Holding Corp., (“Holdings”), Wolverine Healthcare
Analytics, Inc. (as further defined in the Credit Agreement, the “Borrower”), the Lenders and the Administrative Agent. 
 W I T N E S S E T H: 
 WHEREAS, pursuant to the Credit Agreement, the Lenders have
severally agreed to make extensions of credit to the Borrower upon the terms and subject to the conditions set forth therein; and 
 WHEREAS, in connection with the Credit Agreement, the Grantors have executed and delivered the Guarantee and Collateral Agreement, dated as of June 6, 2012, in favor of the Administrative Agent
(together with all amendments and modifications, if any, from time to time thereafter made thereto, the “Security Agreement”); 
 WHEREAS, pursuant to the Security Agreement, the Grantor pledged and granted to the Administrative Agent for the benefit of the Secured Parties a continuing security interest in all of Grantor’s
right, title and interest in and to intellectual property owned by such Grantor, including the Trademarks/Patents/Copyrights set forth on Schedule A hereto; and 
 WHEREAS, the Grantor has duly authorized the execution, delivery and performance of this Agreement; 
 NOW THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, and in order to induce the Lenders to make extensions of credit to the Borrower pursuant to the Credit
Agreement, the Grantor agrees, for the benefit of the Agent and the Secured Parties, as follows: 
 SECTION 1.
Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided or provided by reference in the Credit Agreement and the Security
Agreement. 
 SECTION 2. Grant of Security Interest. The Grantor hereby pledges and grants a continuing security interest
in, and a right of setoff against, and agrees to assign, transfer and convey, upon demand made upon the occurrence and during the continuance of an Event of Default without requiring further action by either party and to be effective upon such
demand, all of the Grantor’s right, title and interest in, to and under the Trademarks/Patents/Copyrights set forth on Schedule A hereto (collectively, the “Collateral”), to the Administrative Agent for the benefit of the
Administrative Agent and the Secured Parties to secure payment, performance and observance of the Obligations. 

 SECTION 3. Purpose. This Agreement has been executed and delivered by the Grantor for
the purpose of recording the grant of security interest herein with the [United States / other jurisdiction] [Patent and Trademark][Copyright] Office. The security interest granted hereby has been granted to the Secured Parties in connection with
the Security Agreement and is expressly subject to the terms and conditions thereof. The Security Agreement (and all rights and remedies of the Secured Parties thereunder) shall remain in full force and effect in accordance with its terms.

 SECTION 4. Acknowledgment. Grantor does hereby further acknowledge and affirm that the rights and remedies of the
Secured Parties with respect to the security interest in the Collateral granted hereby are more fully set forth in the Credit Agreement and the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are
incorporated by reference herein as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the terms of the Security Agreement, the terms of the Security Agreement shall govern. 

SECTION 5. Counterparts. This Agreement may be executed in counterparts, each of which will be deemed an original, but all of
which together constitute one and the same original. 
 (Remainder of the page intentionally left blank) 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and
delivered by their respective officers thereunto duly authorized as of the day and year first above written. 
  

			
	 [GRANTOR]

		
	 By:
	 	 
	 Name:
	 	
	 Title:
	 	
	 Date:
	 	
	
	JPMORGAN CHASE BANK, N.A., as Administrative Agent for the Secured Parties
		
	 By:
	 	 
	 Name:
	 	
	 Title:
	 	
	 Date:
	 	

 Schedule A 
 U.S. [Patent/Trademark/Copyright] Registrations and Applications and Exclusive Inbound Licenses of Same

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}]]